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Abstract 
Das Krankheitsbild der Sepsis geht im Zusammenhang mit Sekundärinfektionen häufig mit 
hoher Morbidität und Mortalität einher und ist daher ein wichtiges Themengebiet der 
angewandten biomedizinischen Forschung. Dr. Theo Sterns hat 2005 in seiner Doktorarbeit 
beschrieben, dass die Abwesenheit von TNF-Rezeptor Typ-2 (TNFR2) im Mausmodell für 
Sepsis, der CLP-induzierten Peritonitis, einen Schutz vor einer folgenden Zweitinfektion bewirkt. 
Ziel dieser Arbeit war es, diesen in vivo Befund auf myeloide Zellen zu übertragen, um 
nachvollziehen zu können, ob in diesem zellulären System TNFR2-vermittelte Mechanismen 
einen Einfluss auf die Pathogenese der Sepsis haben.  
Es stellte sich heraus, dass CD11b+ CD11c- Zellen aus der Milz nach Restimulation mit LPS 
und IFN-ү erst dann in der Lage sind, Stickoxid (NO) zu produzieren, wenn die Maus mit einer 
CLP vorbehandelt wurde, und, dass die Zellen aus TNFR2-/- Tieren bedeutend weniger NO 
produzieren. Das NO-Produktionsdefizit zeigte sich auch in weiteren myeloiden Zellen sogar 
aus naiven TNFR2-/- Tieren, wie z.B. in peritonealen Exsudatzellen (PEC) und Dendritischen 
Zellen, welche in vitro aus knochenmarkständigen Vorläuferzellen generiert wurden (BMDC).  
Am Modell der BMDC wurde das Fehlen von TNFR2 detailliert untersucht. Es zeigte sich, dass 
BMDC von TNFR2-/- Mäusen eine reduzierte IL-6-Produktion nach Restimulation mit LPS und 
IFN-ү aufweisen. Die Zellausbeute und Proliferation von TNFR2-/- BMDC ist jedoch bei gleicher 
Sterblichkeitsrate reduziert. In Zusammenhang mit erhöhten Proliferationsraten bei TNFR1-/- 
BMDC, welche von der Arbeitsgruppe um Lutz auch als „unsterblich“ beschrieben wurden, ist 
dies ein starkes Indiz für ein TNFR2-vermitteltes Proliferationssignal. BMDC von TNFR2-/- 
Tieren zeigten in der späten Phase der Differenzierung zu BMDC einen höheren Anteil an 
Zellen, welche die Aktivierungsmarker MHCII, CD80 und CD86 trugen. Der Anteil der myeloiden 
Suppressorzellen (MDSC) hingegen war während der ganzen Differenzierung erniedrigt. Dies 
ist ein Indiz dafür, dass in TNFR2-/- Zellsystemen die T-Zell-Antwort verbessert abläuft, da 
einerseits die Antigen präsentierenden Zellen eine bessere Antigenpräsentation aufweisen und 
zusätzlich eine reduzierte Suppressivität vorherrscht. TNFR2 scheint somit eine suppressive 
Funktion für T-Zellen zu vermitteln. 
Da löslicher TNFR2 große Mengen an löslichem TNF biologisch inaktiveren kann, wurde die 
Frage geklärt, ob die beschriebenen Effekte auf intrinsischen TNFR2-Signalen beruhen, oder 
ob sie über veränderte TNF-Konzentrationen TNFR2 vermittelt sind. BMDC aus Knochenmark-
chimären Wildtyp Mäusen, welche mit TNFR2-/- Knochenmark rekonstituiert wurden, zeigten 
weiterhin reduzierte NO-Produktion und einen erhöhten Anteil an Aktivierungsmarkern. 
BMDC-Kulturen, welche zu Beginn der Differenzierung aus 50% Wildtyp und 50% TNFR2-/- 
Knochenmarkszellen zusammengesetzt wurden, gewährleisteten identische Konzentrationen 
an löslichem TNF und löslichem TNFR2 für beide Populationen. Die TNFR2-/- BMDC aus diesen 
Kulturen wiesen alle Phänotypen auf, die auch für TNFR2-/- Reinkulturen gezeigt wurden: 
reduzierte NO und IL-6 Produktion, sowie ein erhöhter Anteil an Aktivierungsmarkern bei einem 
erniedrigten Prozentsatz an MDSC. Dies ist ein starkes Indiz dafür, dass das Fehlen 
intrinsischer Signale in TNFR2-/- BMDC für diese Befunde verantwortlich ist und 
Umgebungseffekte über lösliches TNF während der Kultur eine untergeordnete Rolle spielen. 
Epigenetische Modifikationen in TNFR2-/- Systemen, welche womöglich bereits sehr früh in der 
Ontogenese über das Fehlen intrinsischer TNFR2- oder auch über verstärkte TNFR1- Signale 
induziert werden, können in diesen Modellen letztendlich als Ursache für die erwähnten 
Phänotypen nicht ausgeschlossen werden. Um eine Klärung dieser Frage zu ermöglichen, 
wurden monoklonale Antikörper gegen TNFR2 generiert, um mittels möglicherweise 
blockierender Antikörper den TNFR2-/- Phänotyp in vitro nachahmen zu können und somit einen 
endgültigen Beweis für das Fehlen intrinsischer TNFR2-Signale zu erbringen. Es konnte jedoch 
weder agonistische noch antagonistische Funktionalität in einem speziell entwickelten 
zelluläreren Assay basierend auf Fusionsproteinen aus den Extrazellulardomänen von TNFR1 
und TNFR2 und der Intrazellulardomäne von humanem Fas nachgewiesen werden. 
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1 Introduction 
1.1 Preamble 
Fundamental research on the effects of tumor necrosis factor (TNF) and tumor necrosis factor 
receptor type 2 (TNFR2) performed in this research group was the basis of this thesis. Dr. Theo 
Sterns reported that TNFR2 deficient mice were protected from a secondary infection during the 
phase of sepsis that is usually characterized as sepsis-induced immunosuppression (Sterns, 
Pollak et al. 2005).  
 
1.2 The TNF / TNF receptor superfamily 
The TNF / TNF receptor superfamily consists of 19 ligands and 29 receptors. The signals 
generated within this group of molecules take part in the regulation of immune response, 
haematopoiesis, and morphogenesis but are also implicated in tumorigenesis, transplant 
rejection, septic shock, viral replication, bone resorption, rheumatoid arthritis, and diabetes. In 
addition to specific functional effects on the target cells, members of the TNF / TNF receptor 
superfamily deliver general signals such as signals for proliferation, survival, differentiation, or 
apoptosis (Aggarwal 2003). 
The ligands and the receptors of the TNF / TNF receptor superfamily are membrane-bound and 
soluble and mostly restricted to cells and tissues of the immune system. Ligands often are pluri-
specific as they can interact with more than one receptor. Interestingly, redundancy within the 
different effects caused by the different ligand-receptor pairs has not been found so far 
indicating very unique and focused functions. Ligands of the TNF superfamily are biologically 
active type 2 transmembrane proteins with intracellular N-termini that trigger the respective 
receptors as self-assembling, non-covalent bound trimers (Peschon, Slack et al. 1998). The 
ligands of the TNF superfamily show a structural homology of 20 – 30%. The homologue 
sequences are essential for the assembly of the trimeric structure. The non-homologue areas 
guarantee specific receptor recognition and activation (Loetscher, Stueber et al. 1993; Fesik 
2000). Various ligands are biologically active in both the membrane-bound and the 
proteolytically cleaved soluble form (Idriss and Naismith 2000).  
Receptors of the TNF receptor superfamily are type 1 transmembrane proteins featuring 
cystein-rich domains (CRD). Highly conservated cystein residues within the protein generate 
intrachain disulfide bridges that are responsible for the typical pseudo-repeats of these 
I Introduction 
 
2
receptors (Smith, Farrah et al. 1994). The number of CRD within the receptors of the TNF 
receptor superfamily varies from 1 to 6 (Hehlgans and Pfeffer 2005). 
 
1.2.1 Structure of TNF 
Tumor necrosis factor (TNF) is a member of the cytokine family. Cytokines comprise numerous 
small molecules that are mainly secreted by cells of the immune system and act as 
messengers. They are proteins, peptides, or glycoproteins and are extensively used in cellular 
communication. Cytokines regulate differentiation, proliferation, and apoptosis of cells and 
influence the cytokine production of the target cells in many cases (Burke, Naylor et al. 1993).  
TNF is one of the most prominent members of the TNF / TNF receptor superfamily and was one 
of the main research targets in this study. The molecule was described first in 1975 as an 
endotoxin-induced glycoprotein with antitumor effects on transplanted sarcomas in mice as it 
caused haemorrhagic necrosis (Carswell, Old et al. 1975).  
Many TNF-related and TNF receptor-related molecules were discovered since the initial 
description of TNF and its receptors as the first cloned members of this familiy in both human 
and mouse (Loetscher, Pan et al. 1990; Lewis, Tartaglia et al. 1991). 
TNF is a type 2 membrane protein that stays membrane-bound as a pre-protein and is cleaved 
off by metalloproteinases to be released from the producer cells as mature soluble TNF 
(Gearing, Beckett et al. 1994; Black 2002). The receptor binding site of TNF is formed by the 
groove between two adjoining ligand chains and, hence, TNF trimers exhibit three receptor 
binding sites. Trimerization of soluble TNF is necessary for efficient activation of TNF receptors. 
Membrane-associated as well as soluble forms of TNF are biologically active. Mouse TNF is 
glycosylated and shows 80% sequence homology compared to human TNF. TNF does not 
undergo posttranscriptional modification (Pennica, Hayflick et al. 1985). 
TNF is expressed at the transcriptional level with an unusually long and uncommon leader 
sequence in multiple cell types like macrophages, monocytes, T and B cells, granulocytes, and 
even mast cells (Echtenacher, Mannel et al. 1996). During inflammation those cells initially 
produce a transmembrane form of TNF (pre-TNF) of 26 kDa stored in the Golgi apparatus 
(Shurety, Merino-Trigo et al. 2000) or at the cell membrane. As a consequence of long-lasting 
stimulation, metalloproteinases cleave the extracellular domain of TNF, releasing a soluble TNF 
homotrimer of three mature 17 kDa TNF molecules (Black, Rauch et al. 1997; Moss, Jin et al. 
1997). The most prominent member of these metalloproteinases is the membrane-bound TNFα 
converting enzyme (TACE).  
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1.2.2 Functions of TNF 
Both 26 kDa pre-TNF and the 17 kDa soluble TNF homotrimer provide biological activity via two 
identified membrane TNF receptors, tumor necrosis factor receptor type 1 (TNFR1) of an 
apparent molceluar weight of 50 kDa and tumor necrosis factor receptor type 2 (TNFR2) of 
about 75 kDa (Smith, Davis et al. 1990). Many of the proinflammatory properties of TNF can be 
explained by their effects on vascular endothelium and endothelial leukocyte interactions. When 
exposed to TNF, endothelial cells support the inflammatory response by expressing different 
adhesion molecules such as E-selectin, intercellular adhesion molecule-1 (ICAM-1), and 
vascular cell adhesion molecule-1 (VCAM-1) as well as chemokines like interleukin-8 (IL-8), 
monocyte chemotactic protein-1 (MCP-1), and interferon-inducible protein 10 (IP-10). The 
binding to adhesion molecules enables leukocytes to invade the tissue by crossing the vascular 
endothelium. Chemokines guide the migration to the center of inflammation independent of 
antigen recognition (Pober, Bevilacqua et al. 1986; Munro, Pober et al. 1989; Rollins, 
Yoshimura et al. 1990). The TNF-mediated expression of adhesion molecules and chemokines 
is regulated in distinct temporal, spatial, and anatomical patterns (Messadi, Pober et al. 1987; 
Petzelbauer, Pober et al. 1994; Bradley and Pober 1996). Additionally, TNF is able to cause 
vasodilation via inducing the expression of cyclo-oxygenase 2 (COX2) and the associated 
production of the vasodilator prostacyclin 2 (PGl2) (Mark, Trickler et al. 2001). This explains 
“rubor” (erythema) and “calor” (heat), two of the four classical signs of inflammation. “Tumor” 
(swelling), the third indicator in this row, results among others from TNF-mediated increased 
vascular permeability and subsequent trans-endothelial passage of fluid and macromolecules 
that create edema. TNF increases the risk of intravascular thrombosis as it induces the 
expression of pro-coagulant proteins like tissue factor and down-regulates anti-coagulant 
proteins such as thrombomodulin (Bevilacqua, Pober et al. 1986). One of the most prominent 
roles of TNF in normal inflammation consists in the orchestration of the host defense to 
bacterial, viral, and parasitic infections. Nevertheless, exact control of TNF is essential as 
unregulated exposure to TNF can be harmful to the organism.  
 
1.2.3 Regulation of TNF receptors 
Expression of TNFR1 and TNFR2 can be observed in most cell lines and in normal and 
diseased tissues (Al-Lamki, Wang et al. 2001). TNFR2 is mainly expressed on hematopoietic 
cells and, in contrast to TNFR1, highly regulated (Hehlgans and Pfeffer 2005). The extracellular 
ligand binding domains of the two TNF receptors are structurally similar and contain cystein-rich 
subdomains. The intracellular portions of the two receptors exhibit no sequence homology and 
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do not signal via intrinsic enzyme activity. Signal transduction is generated through the 
acquisition of cytosolic proteins to specific protein-protein interaction domains (Ledgerwood, 
Pober et al. 1999). The ability of TNFR1 and TNFR2 to signal via both identical and unrelated 
proteins depicts the common and independent function of both receptors. Membrane-bound 
TNF is able to activate both TNFRs whereas soluble TNF activates TNFR1 more efficiently than 
TNFR2 (Grell 1995). 
 
1.2.3.1 Signaling of TNFR1 
TNFR1 is a 50 – 55 kDa type I transmembrane protein. In resting cells it is predominantly stored 
in the Golgi apparatus from where it can be carried over onto the cell surface. The relevance of 
the intracellular storage of TNFR1 is only vaguely understood. The most probable hypothesis 
describes the possibility of increasing cell membrane TNFR1 density very fast and without new 
protein synthesis. This would lead to enhanced susceptibility of the cell to TNF (Bradley, Thiru 
et al. 1995). TNFR1, expressed on the surface, is trimerized in the membrane through pre-
ligand assembly domains (PLADs) located at the distal end of the cystein-rich domain (Bennett, 
Macdonald et al. 1998). Silencer of death domain (SODD) prevents constitutive signaling as it is 
associated to the cytoplasmatic domains of non-stimulated TNFR1 (Lanford, Lan et al. 1999). 
After binding of TNF to TNFR1 receptor the resulting receptor-ligand complex is internalized 
(Schutze, Machleidt et al. 1999) and the death domain containing signal transduction adapter 
molecule TNF receptor associated death domain (TRADD) is recruited. From that point, two 
possible signaling pathways can be activated either inducing apoptosis or proinflammatory gene 
expression. 
In the case of apoptosis additional death domain-containing proteins, i.e. FADD and also the 
procaspases 8 and 10, are recruited to the TNFR1-TRADD complex. The successful activation 
leads to DNA degradation and cell death (Hsu, Xiong et al. 1995; Ashkenazi and Dixit 1998). 
TNFR1-bound TRADD can also recruit cellular inhibitor of apoptosis protein (cIAP) (Rothe, Pan 
et al. 1995) and receptor-interacting protein (RIP) (Kelliher, Grimm et al. 1998). Those 
molecules enable TNFR-associated factor 2 (TRAF2) to join the TNFR1-signaling complex (Liu, 
Hsu et al. 1996). This complex formation results in the activation of different kinases, e.g. NIK 
(NF-κB inducing kinase), IKKα and β (IκB kinase α and β), mitogen-activated protein (MAP) 
kinases, c-Jun N-terminal (JNK) kinase, and p38 kinase (Liu, Hsu et al. 1996; Eder 1997; 
Kelliher, Grimm et al. 1998; Mercurio and Manning 1999). The activation of these kinases 
further mediates the activation of transcription factors and, thus, induces the expression of 
proinflammatory and antiapoptotic genes. For the induction of apoptosis the internalization of 
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the TNF-TNFR1 complex is required whereas the activation of the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) pathway can be seen after ligand binding even if 
the internalization of TNFR1 is prevented (Schutze, Machleidt et al. 1999). 
 
1.2.3.2 Signaling of TNFR2  
TNFR2 is a 75 – 80 kDa membrane-bound protein with immanent structural similarities to 
TNFR1 in the extracellular domains mainly consisting of cysteine-rich repeats (Beutler and van 
Huffel 1994). The intracellular domains of TNFR1 and TNFR2 exhibit no homology. 
Consequently, the functions of both receptors are different. Due to a missing death domain, the 
main function of TNFR2 is the recruitment of TRAF2 and the activation of the NF-κB pathway. 
The cellular effects can be manifold: cytokines are produced as well as intracellular regulatory 
proteins with potential anti-apoptotic features such as TRAF1 and TRAF2 and the inhibitors of 
apoptosis inducing proteins (c-IAP1 and c-IAP2) (Wang, Mayo et al. 1998). Furthermore, 
alternative intracellular signaling architectures are known to employ activation of p38 kinase and 
N-terminal JNK kinase (Liu, Hsu et al. 1996; Kelliher, Grimm et al. 1998). In contrast to TNFR1, 
which is found on almost all tissues and cells, the expression of TNFR2 seems to be more 
restricted and precisely regulated especially in lymphoid tissues and cells (Grell, Douni et al. 
1995). As TNFR2 has no death domain, direct induction of apoptosis is not possible and, 
therefore, induction of anti-apoptotic processes via NF-κB can be assumed. Nevertheless, 
enhanced apoptosis was reported when TNFR1 and TNFR2 were triggered together with TNF. 
TNFR1 and TNFR2 have similar affinities to their ligand TNF at room temperature, but 
TNF-TNFR2 complexes are formed only transiently (Grell, Wajant et al. 1998). 
TNFR2 is required for antigen-mediated T cell differentiation and survival (Kim, Priatel et al. 
2006) and induces the expression of intracellular adhesion molecule (ICAM-1), E-selectin, and 
MCP-1/JE on endothelial cells (Chandrasekharan, Siemionow et al. 2007). Furthermore, TNFR2 
influences the migration of intestinal epithelial cells as well as Langerhans cells (Takayama, 
Yokozeki et al. 1999; Corredor, Yan et al. 2003) and is known to induce proliferation in various 
types of cells and angiogenesis (Theiss, Simmons et al. 2005).  
 
1.2.4 Reverse signaling of TNFR2 via membrane-bound TNF 
Reverse signaling, employing the intracellular domains of the whole membrane-bound TNF as 
signaling domains and TNF receptors as possible ligands, has been discussed by many 
authors. It has been shown that CD3-mediated activation of transcription of interferon-γ (IFN-γ) 
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and IL-4 can be influenced in a costimulatory way when T cells were incubated with anti-TNF 
antibodies (Ferran, Dautry et al. 1994). Reverse signaling in human monocytes and 
macrophages was suggested to generate resistance to lipopolysaccharide (LPS) (Eissner, 
Kirchner et al. 2000). E-selectin expression in activated human CD4 T cells has been reported 
to depend on reverse signaling via membrane-bound TNF (Harashima, Horiuchi et al. 2001). 
When the membrane-bound form of TNF is highly expressed on tumor cells it can promote 
NF-κB activation through reverse signaling and supporting tumor cell survival. In contrast, there 
is also evidence that membrane-bound TNF, when acting as a ligand, inhibits NF-κB signaling 
and, thus, induces tumor cell death (Zhang, Yan et al. 2008).  
Currently, it is widely accepted that TNF, being a factor that strongly regulates growth, 
differentiation, and death of both hematopoietic and non-hematopoietic cell types, is one of the 
key players in pathophysiology. By directing its two transmembrane receptors to deliver signals 
of cellular proliferation, differentiation, or apoptosis, TNF seems not only to orchestrate acute 
responses to infection and immunological injury, but also to act as a balancing factor required 
for the re-establishment of physiological homeostasis and immune regulation. The level, timing, 
and duration of TNF activity are of critical regulatory significance. 
 
1.2.5 TNF inhibitor function of soluble TNFR2 
Both TNFR1 and TNFR2 can be proteolytically cleaved and released from the cell membrane. 
The soluble forms of those receptors remain biologically active as they can still bind TNF 
(Bazzoni and Beutler 1995). The soluble forms of TNFRs represent biological markers for 
inflammatory processes as they are very efficient in neutralizing soluble TNF (Wallach, 
Engelmann et al. 1991). Increased levels of TNFRs can be found in cancer, rheumatoid arthritis, 
lupus erythematodes, HIV, and sepsis (Aderka, Englemann et al. 1991; Cope, Aderka et al. 
1992; Aderka, Wysenbeek et al. 1993; Schroder, Stuber et al. 1995; Hober, Benyoucef et al. 
1996). In the mouse model of cecal ligation puncture (CLP), which causes septic peritonitis, 
high serum levels of soluble TNFR2 can be detected. The occurrence of soluble TNFR2 in this 
experimental setup is about 100 times higher than that of soluble TNFR1 (Villa, Sartor et al. 
1995). This might be explained by the induced expression of TNFR2 during inflammation. 
Interestingly, high levels of soluble TNFR2 can also be found in the urine of naïve mice (Eva 
Pfeifer, personal communication). 
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1.2.6 Anti-TNF therapy 
The overproduction of TNF can be causal, maybe as intermediate mediator, for a number of 
autoimmune diseases like rheumatoid arthritis, ankylosing spondylitis, and psoriasis (Sacca, 
Cuff et al. 1998; Bradley 2008). There are several ways to abrogate the harmful influence of 
excessive levels of TNF. On the one hand there are neutralizing anti-TNF antibodies like 
Infliximab and Adalimumab. On the other hand recombinant fusion proteins consisting of human 
TNFR2 and the Fc portion of human IgG1 (Etanercept) bind and deactivate TNF. Both 
strategies reduce the concentrations of biologically active TNF and, consequently, alleviate the 
disease patterns caused by chronic TNFR-signaling (Feldmann and Maini 2001; Victor, Gottlieb 
et al. 2003). However, 25% to 38% of rheumatoid arthritis patients treated with Eternacept do 
not respond to the medication compared to 21% to 42% of non-responders treated with 
Infliximab. This is not due to general unresponsiveness to anti-TNF therapy as it can be 
overcome by the administration of Infliximab to patients that do not respond to Eternacept, and 
reciprocally (Alonso-Ruiz, Pijoan et al. 2008).  
 
1.2.7 Affinity of human and mouse TNF for mouse TNF receptors 
Similar to the human system, soluble mouse TNF preferentially binds to mouse TNFR1 while 
membrane-bound mouse TNF is capable of efficient binding to both mouse TNFR1 and mouse 
TNFR2 (Grell, Douni et al. 1995; Papadakis and Targan 2000). Human TNF is only able to 
activate mouse TNFR1 but not mouse TNFR2 while mouse TNF triggers both human TNFR1 
and human TNFR2 (Tartaglia, Weber et al. 1991). 
 
1.2.8 TNFR2-/- systems 
Cellular TNFR2-/- systems, both in vivo and in vitro, are characterized by impaired TNF-
signaling. In such case, intrinsic TNFR2-signaling is abrogated and at the same time soluble 
bioactive TNF concentrations are not diminished via soluble TNFR2. Furthermore, reverse 
signaling can be excluded as the ligand for membrane-bound TNF, namely the soluble or 
membrane-bound TNFR2, is missing. However, reverse signaling via TNFR1 might occur. 
Nevertheless, not only TNFR2-related functions are impaired. Higher levels of soluble TNF 
might lead to higher TNFR1-signaling. This has to be taken into consideration when data 
generated from TNFR2-/- mice or cells are to be interpreted. Figure 1 illustrates the possible 
interactions of TNF receptors with TNF in the mice used for this thesis. 
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Figure 1: The TNF / TNFR system in cellular systems of wt and TNFR2-/- mice  
(A) In C57BL/6 wt mice and cell cultures TNF can signal via TNFR1 and TNFR2. Additionally, reverse 
signaling via TNFR2 as ligand and membrane-bound TNF as receptor is possible and TNFR2 might act 
as a regulator for soluble and biologically active TNF. (B) If TNFR2 is missing, TNFR2 intrinsic signaling 
and reverse signaling via TNFR2 as ligand and membrane-bound TNF as receptor are prevented. Higher 
concentrations of soluble TNF might trigger TNFR1 as the modulatory function of soluble TNFR2 is 
missing.  
A 
B 
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1.2.9 Phenotype of TNFR2 knockout mice (TNFR2-/-) 
The use of knockout mice is the best choice to investigate the functional role of the respective 
protein in vivo and in vitro. In this work TNFR2-/- mice were used. These mice were generated 
by Dr. Mark Moore (Deltagen). TNFR2-/- mice exhibit several phenotypic characteristics. Sterns 
et al. found that TNFR2-/- mice are protected from a secondary infection in a phase of sepsis 
that is usually characterized as sepsis-induced immunosuppression. Further, TNFR2-/- mice 
show decreased numbers of regulatory T cells (Treg) after CLP (Chen, Baumel et al. 2007), 
they are fully protected from experimental cerebral malaria (Lucas, Juillard et al. 1997), and 
they cannot be protected from lethal septic peritonitis by prior LPS treatment (Echtenacher and 
Mannel 2002). Mice without functional TNFR2 show exacerbated myelin oligodendrocyte 
glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis (Suvannavejh, 
Lee et al. 2000), and are more susceptible to dextran sodium sulfate-induced colitis (Stillie and 
Stadnyk 2009). Furthermore, it has been reported that TNFR2 is involved in the development of 
proteinuria in severe glomerulonephritis (Vielhauer, Stavrakis et al. 2005) and that TNFR2-/- 
mice are protected from the pathology of glomerulonephritis induced by antibodies against the 
glomerular basement membrane. 
 
1.2.10 Anti-mouse TNFR2 monoclonal antibodies (mAB) 
Usually, knock-out (-/-) mice allow to analyze the function of the respective missing protein by 
studying the effects of its lack. In the case of TNFR2, however, there is one ligand, two 
receptors, and, in addition, the possibility of reverse signaling. In TNFR2-/- mice not only forward 
and reverses signaling via TNFR2 are abrogated as TNFR1-signaling could also be strongly 
influenced by changes in the available concentrations of soluble TNF. In order to exclude side 
effects of TNFR1-signaling in TNFR2-/- mice, the observed effects should be reproduced in cells 
of wildtype mice treated with antagonistic reagents that specifically block the TNFR2. Vice 
versa, in cells of wildtype mice treated with selective agonistic substances, the distinct role of 
TNFR2 could be examined. Functional agonistic or antagonistic anti-mouse TNFR2 antibodies 
are the means of choice for selective activation or blockade of TNFR2. In order to facilitate the 
application of such antibodies in vivo over longer periods of time without the induction of an 
immune reaction against these substances, mouse anti-mouse antibodies are ideally suited. 
Unfortunately, neither agonistic nor antagonistic anti-mouse TNFR2 are available nor other 
reagents that selectively activate or block TNFR2.  
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1.3 Sepsis and immunoparalysis 
The term sepsis originally defined a disease state based on a bacterial infection that spreads all 
over the organism via the blood and develops systemic impacts. Sepsis is a serious medical 
condition that is characterized by a whole-body inflammatory state and the presence of a known 
or suspected infection (Ayres 1985; Balk and Bone 1989). Sepsis is increasingly considered as 
a common cause of morbidity and mortality, particularly in elderly, immunocompromised, and 
critically ill patients (Manship, McMillin et al. 1984).  
The characteristic mechanisms and processes caused by sepsis are subdivided in a biphasic 
model: the initial phase is characterized by a hyper-inflammatory state followed by a hypo-
inflammatory state as the second phase (Hoflich and Volk 2002). The hyper-inflammatory phase 
is also called “systemic inflammatory response syndrome” (SIRS) and results from a strong 
reaction of the immune system to infections, traumata, pancreatitis, inflammation of tissue and 
organs, burns, or intensive surgical intervention (Balk and Parrillo 1992). SIRS comprises the 
interactions of bacterial components such as toll-like receptor (TLR) ligands and endogenous 
mediators of the immune system with their specific targets or receptors. This phase is 
characterized by the release of pro-inflammatory cytokines like TNF, IL-1β, IFN-γ, granulocyte 
colony-stimulating factor (G-CSF), IL-6, and IL-12 (Goldie, Fearon et al. 1995). This cytokine 
profile resembles a type 1 helper T cell (TH1) immune response. Additionally, acute phase 
proteins are released from the liver. Furthermore, granulocytes and monocytes are activated 
and exhibit high metabolic activity. These cells emigrate from the bone marrow and migrate into 
the infected and inflamed tissue. As part of the innate immune system these cells initiate and 
increase the expression of multiple pro-inflammatory mediators and cytokines. Together, these 
reactions cause fever, hypotension, vasodilation, an increase of vascular permeability, and, 
finally, organ dysfunction and multi-organ failure. 
Overt nitric oxide (NO) production by the inducible form of NO-synthases (iNOS) is assumed to 
play an important role in early sepsis-related vasoregulative failure. In response to inflammatory 
stimuli, NO levels increase rapidly within minutes to hours (Vincent 2001). This leads to 
hypotension (Rees 1995; Rosselet, Feihl et al. 1998; Scott, Mehta et al. 2002) and 
refractoriness to the vasopressor catecholamines (Gray, Schott et al. 1991). Animals treated 
with selective iNOS-inhibitors or transgenic mice deficient in iNOS showed less hypotension 
and increased microvascular reactivity under septic conditions (MacMicking, Nathan et al. 1995; 
Wei, Charles et al. 1995; Hollenberg 2002). 
In response to the overwhelming cytokine storm and pro-inflammatory effects caused by SIRS, 
the organism reacts with a backlash called “compensatory anti-inflammatory response 
syndrome” (CARS) (Bone, Grodzin et al. 1997). This counter-regulation is meant to restore the 
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homeostasis and is mediated by both the innate and the adaptive immune system (Guillou 
1993). In particular, T cells orchestrate the regulatory effects as they change their specific 
cytokine profile. The initial TH1-typical cytokine profile changes into a type 2 helper T cell (TH2) 
type expressing high amounts of IL-4, IL-5, IL-10, and IL-13 (Di Santo, Meazza et al. 1997). 
Additionally, very potent pro-inflammatory acting cells like lymphocytes and dendritic cells are 
eliminated by apoptosis (Ding, Chung et al. 2004). Furthermore, high concentrations of 
molecules antagonizing the proinflammatory cytokines are produced. The biological activity of 
TNF, one of the most potent inflammatory cytokines during sepsis, is reduced by the expression 
of high amounts of soluble TNFR2 (Goldie, Fearon et al. 1995; Mannel and Echtenacher 2000). 
This anti-inflammatory response rapidly develops during sepsis and aims to dampen the initial 
pro-inflammatory event. It seems to predominate in some patients and to induce a state of 
“immunoparalysis”. In this case the immune system is not able to react to a second infection in 
an adequate way leading to organ failure and death.  
It has been shown that monocytes of septic patients with immune suppression express lower 
amounts of major histocompatibility complex II (MHCII) (Docke, Randow et al. 1997) 
Furthermore, the endotoxin-induced TNF expression was reduced. These two phenomena 
could be restored by ex vivo treatment of peripheral blood mononuclear cells with IFN-γ. The 
in vivo treatment of a small number of immunosuppressed septic patients with IFN-γ supported 
these findings. Additionally, the clearance of infections was ameliorated and the mortality was 
slightly reduced by IFN-ү treatment. 
In this work CLP was used to induce septic peritonitis in mice, as it is a clinically relevant and 
widely used animal model for sepsis (Buras, Holzmann et al. 2005; Deitch 2005; Rittirsch, 
Hoesel et al. 2007). The CLP surgery is performed so that ligation distal to the ileocecal valve 
and needle puncture of the ligated cecum cause leakage of fecal contents into the peritoneum, 
with subsequent development of polymicrobial bacteremia and sepsis (Rittirsch, Huber-Lang et 
al. 2009). Various species of bacteria become detectable in the blood followed by progressive 
SIRS, septic shock, and multiorgan injury (Alexander, Sheppard et al. 1991; Yasuda, 
Leelahavanichkul et al. 2008). Mice treated with CLP generally develop severe hypotension but 
no apparent hyperdynamic phase (Ganopolsky and Castellino 2004). The cytokine profile 
induced by CLP is comparable with the one observed in human sepsis. Anti-TNF treatment in 
sepsis does not lead to better prognosis neither in mice and nor in humans (Echtenacher, Falk 
et al. 1990; Eskandari, Bolgos et al. 1992; Remick, Newcomb et al. 2000; Miyaji, Hu et al. 2003; 
Yasuda, Yuen et al. 2006). Furthermore, CLP-induced sepsis leads to increased lymphocyte 
apoptosis resembling the immunosuppression in the later phase of human sepsis (Ayala and 
Chaudry 1996; Hotchkiss, Tinsley et al. 2003). CLP-induced shock differs clearly from LPS-
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induced sepsis and is more closely related to human sepsis. The clinical features and drug 
responses caused by CLP are more similar to the human etiopathology than the LPS model. 
Nevertheless, some key features of humans sepsis like kidney and lung injury cannot be 
induced by CLP. The CLP model is illustrated in Figure 2. 
 
 
Figure 2: Inflammatory state after CLP 
 
1.4 Myeloid cells 
Hematopoietic stem cells (HSCs) are multipotent stem cells located in the bone marrow. These 
cells can differentiate into three different lineages: the myeloid lineage, the lymphoid lineage, 
and the erythroid-megakaryocyte lineage. The myeloid lineage comprises monocytes and 
macrophages, granulocytes, and polymorphonuclear cells - neutrophils, basophiles, and 
eosinophils. Different from this, T and B cells constitute the lymphoid lineage whereas 
erythrocytes and platelets derived from megakaryocytes form the erythroid-megakaryocyte 
lineage (Katsura 2002). 
Myeloid cells are characterized by the expression of cluster of differentiation 11b (CD11b), one 
subunit of the CD11b / CD18 heterodimer (Arnaout, Gupta et al. 1988). CD11b is an integrin cell 
surface receptor, strongly regulated depending on the differentiation status, and tissue specific. 
The CD11b / CD18 heterodimer is expressed exclusively on the surface of mature monocytes, 
macrophages, neutrophils, and natural killer cells (Todd, Nadler et al. 1981). 
I Introduction 
 
13
1.4.1 Macrophages 
1.4.1.1 Historical background 
Macrophages are cells that functionally react early in the host defense as part of the innate 
immune system. In the year 1905 Ilya Mechnikov revealed the importance of phagocytes for the 
development and homeostasis of the immune system as well as for the host defense from 
infections. These processes were termed “innate immune reactions”. Parallel to this, Paul 
Ehrlich started to work on a phenomenon which is today known as “adaptive immunity”. Both 
researchers were awarded the Nobel Prize in physiology and medicine in the year 1908. 
Macrophages link innate and adaptive immunity and remain an important area of immunological 
research (Nathan 2008). 
 
1.4.1.2 Monocyte-derived macrophages 
Monocytes circulate in the peripheral blood and have the capacity to differentiate into 
tissue-resident macrophages as well as into more specialized cells like dendritic cells and 
osteoclasts. Monocytes are generated in the bone marrow and represent a direct descendant 
from a common myeloid progenitor that is shared with neutrophils. After circulating for several 
days these peripheral blood monocytes enter tissues and replenish the tissue macrophage 
populations (Volkman and Gowans 1965). The monocyte development in the bone marrow 
starting from the hematopoietic stem cell comprises the stages of granulocyte / macrophage 
colony-forming units (GM-CFU), macrophage colony-forming units (M-CFU), monoblasts, pro-
monocytes, and finally lymphocyte antigen 6 C+ (Ly6C+) “inflammatory” monocytes which are 
released into the peripheral blood. Inflammatory monocytes are the source of macrophages, 
dendritic cells, and osteoclasts in tissues. This is illustrated in Figure 3. Macrophages can be 
subdivided into different populations depending on the tissue they migrate to and on their 
function. For instance, osteoclasts are found in bone, microglia cells in the central nervous 
system, alveolar macrophages in the lung, kupfer cells in the liver, histiocytes in connective 
tissue, and white-pulp-, red-pulp-, marginal-zone-, and metallophilic-macrophages in the spleen 
(Mosser and Edwards 2008). The specific roles of these macrophages are the maintenance of 
homeostasis and the immune reaction in the respective organs. Furthermore, they immigrate 
and initiate immune reactions at the place of the infection. 
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Figure 3: Monocyte differentiation and macrophage development  
(Gordon and Taylor 2005) 
 
In the human system macrophages can be generated by in vitro culture of peripheral blood 
monocytes with M-CSF for 4 days (Lutter, Ugocsai et al. 2008). Mouse macrophages cannot be 
generated in an adequate amount as the yield of peripheral blood monocytes is limited. Mouse 
macrophages used in this work were either isolated from the spleen (spleen macrophages) or 
as a main part of peritoneal exudate cells 18 hours after phosphate buffered saline (PBS) 
injection into the peritoneal cavities. 
Additionally, bone marrow-derived dendritic cells (BMDC) were used as another source of 
myeloid cells (Lutz, Kukutsch et al. 1999). Bone marrow cells were grown in 
granulocyte / macrophage colony-stimulating factor (GM-CSF)-supplemented medium for 10 
days. This led to the differentiation of the cells into CD11c+ dendritic cells. Nevertheless, almost 
all of these cells kept the CD11b marker for myeloid cells (Nikolic, de Bruijn et al. 2003). 
 
1.4.2 Biological relevance of macrophages 
Macrophages are part of the mononuclear phagocyte family and exhibit broad phenotypic 
heterogeneity as a consequence of varying cellular differentiation, widespread tissue 
distribution, and different reactivity to many endogenous and exogenous stimuli. Constitutive 
and induced migration into the tissues is one characteristic attribute of macrophages. 
Additionally, interactions with altered host cells, modified molecules, and exogenous agents 
contribute to the differentiation of macrophages. Macrophages are resident phagocytic cells in 
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lymphoid and nonlymphoid tissues and believed to be involved in steady-state tissue 
homeostasis via clearance of apoptotic cells and the production of growth factors. Macrophages 
are equipped with a broad range of pathogen-recognition receptors that make them efficient at 
phagocytosis and induce production of inflammatory cytokines (Gordon 2002). These mediators 
are recognized by a multitude of both plasma-membrane associated and intracellular receptors. 
Consequently, the respective substances are taken up by phagocytosis or endocytosis, are 
processed, and presented on MHCII molecules. In addition, intracellular signaling occurs and 
gene expression patterns are activated or repressed. This leads to altered adhesion and 
migration and causes the secretion of various cytokines and cellular mediators as well as the 
activation of effector functions. Ligands on pathogenic host cells are recognized by a range of 
scavenger-type receptors resulting in the specific induction or suppression of macrophage 
inflammatory responses, depending on mechanisms not fully understood (Fadok, Bratton et al. 
1998; Gordon 2003). The recognition of foreign ligands is mediated either indirectly by a 
multitude of receptors that use opsonins like antibodies, complement, collectins, and LPS-
binding protein or in a direct way employing TLR and lectins for the recognition of 
carbohydrates, proteins, lipids, and nucleic acids. One of the most prominent intracellular 
signaling molecules that is activated after recognition of these substances is NF- B (Gordon 
2003). 
Macrophage activation can be divided into innate and humoral as well as classical and 
alternative ways. Both pairs of definitions for macrophage activation are somewhat overlapping. 
The innate activation of macrophages is induced by microbial stimuli such as TLR ligands or 
β-glucans and induces the upregulation of costimulatory molecules, the generation of low 
molecular weight metabolites like NO and reactive oxygen species (ROS), and the expression 
and release of cytokines like IFN-α/β, TNF, IL-6, and IL-12.  
Humoral activation of macrophages is mediated by the activation of Fc- or 
complement-receptors and mainly results in cytolytic processes.  
The classical activation of macrophages requires two distinct signals. The priming stimulus is 
IFN-ү from T cells. Consequently, the T cell milieu and activation state strongly interfere and 
regulate macrophage activation. The second signal is TNF either exogenously-derived or 
produced by the macrophage itself as a consequence of the contact with microbial triggers like 
TLR ligands (Mosser 2003). This induces the upregulation of MHCII and costimulatory 
molecules like CD80 and CD86, and, consequently, leads to an improved antigen presentation 
and CD4 T cell activation (Mosser and Zhang 2008). Furthermore, classically activated 
macrophages can be characterized by the production of NO, oxydative burst as well as the 
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expression of IL-1, IL-6, IL-12, and TNF. The effects result in microbicidal activity and cellular 
immunity, but can cause tissue damage as well.  
Alternative activation requires IL-4, IL-10, or IL-13 as extracellular signals. These cytokines are 
generally considered to originate from TH2 T cell reactions. This also leads to upregulation of 
MHCII expression and improves endocytosis as well as antigen presentation, interestingly with 
minor effects on CD4 T cell activation and proliferation. Additionally, the expression of 
intracellular Arginase 1 (Arg1), selective chemokines such as macrophage-derived chemokine 
(MDC, CCL22), thymus and activation regulated chemokine (TARC, CCL17), and mannose 
receptor is increased. The characteristic cytokines produced by alternatively activated 
macrophages are IL-10 and IL-1 receptor antagonist (IL-1ra). Alternatively activated 
macrophages are thought to be crucial for humoral immunity, allergic and anti-parasite 
responses as well as repair mechanisms (Gordon 2003).  
During the very early stages of mammalien ontogeny developmental embryonic macrophages 
are produced in the yolk sac (Cline and Moore 1972; Enzan 1986). They are necessary for the 
clearance of apoptotioc cells and, thus, play a crucial role in organogenesis. 
 
1.4.3 Interleukin 6 
The pro-inflammatory cytokine IL-6 plays an important role in immunity and links the innate with 
the adaptive immune system. IL-6 is a pleiotropic cytokine produced by many types of cells 
such as macrophages, T cells, fibroblasts, and endothelial cells. The expression of IL-6 is 
induced by stimuli such as bacteria, viruses, and other cytokines such as IL-1 and TNF. IL-6 
promotes growth, differentiation and expansion of B cells as well as the production and 
secretion of immunoglobulins. It induces the differentiation and activation of macrophages and 
T cells and initiates the production and release of acute phase proteins (Kishimoto 2006).  
 
1.4.4 Regulation of the iNOS expression and NO signaling 
The level of iNOS-derived NO is mostly regulated at the transcriptional level. Depending on the 
stimulation and cell type, different signaling pathways are activated to express transcription 
factors that are required to induce iNOS mRNA expression, i.e. activators such as activating 
protein 1 (AP-1), protein kinase C, janus kinase (JAK), tyrosine kinase, MAP kinase, and raf-1 
protein kinase or inhibitors such as protein tyrosine phosphatase and phosphoinositide-3-
kinase. Both the proximal and distal region of the iNOS promoter features binding sites for 
transcription factors NF-κB and Jun / Fos heterodimers as well as CCAAT binding enhancer 
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binding proteins (C/EBT), cyclic adenosine monophosphate (cAMP) response element-binding 
protein (CREB), and the signal transducers and activators of transcription protein (STAT) family 
(Aktan 2004). The signaling effect of NO occurs by the nitrosation of heme-iron present in the 
enzyme soluble guanylate cyclase (sGC). sGC is a heterodimeric enzyme that converts 
guanosine triphosphate to cyclic guanosine monophosphate (GMP) which mediates the 
signaling.  
 
1.4.5 Different types of myeloid cells used in this study 
Different types and sources of myeloid cells were used in this work, especially peritoneal 
exudate cells (PEC), CD11b+ spleen cells, and bone marrow-derived dendritic cells (BMDC).  
 
1.4.5.1 Peritoneal exudate cells (PEC) 
PEC were used as the source of myeloid cells representing primary macrophages. PEC migrate 
into the peritoneal cavity after injection of PBS and can easily be isolated via peritoneal lavage. 
Up to 90% of the PEC are macrophages. 
 
1.4.5.2 CD11b+ splenocytes 
About 5% of the spleen cells in healthy mice are CD11b+ myeloid cells. The cells can easily be 
isolated from the spleen of either naïve or experimentally treated mice. 
 
1.4.5.3 Bone marrow-derived dendritic cells (BMDC) 
The generation of BMDC is an advanced culture method for generating large quantities of 
relatively pure myeloid cells from mouse bone marrow (Lutz, Kukutsch et al. 1999). The cells 
are grown in a GM-CSF-containing medium and differentiate into CD11b+ CD11c+ myeloid cells 
with dendritic phenotype within 10 days. 
 
1.4.6 Myeloid-derived suppressor cells (MDSC)  
More than 20 years ago myeloid cells with suppressive properties were described in cancer 
patients (Buessow, Paul et al. 1984; Young, Newby et al. 1987). There is strong evidence that 
myeloid cells with suppressive activity contribute to the negative regulation of the immune 
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system in cancer and other diseases. Those cells were termed myeloid–derived suppressor 
cells (MDSC). They are part of the myeloid lineage and can be characterized by an immature 
state and a specific capacity to suppress T cell functions. Additionally, MDSC contribute to the 
regulation of the innate immunity as they are able to modulate the cytokine production of 
macrophages (Sinha, Clements et al. 2007).  
MDSC are a subpopulation of cells called “immature myeloid cells” (IMC) that comprise myeloid 
progenitor cells as well as immature forms of myeloid cells. IMC originate from the bone 
marrow. In healthy organisms they differentiate very quickly into mature granulocytes, 
macrophages, and dendritic cells. In pathologic conditions like cancer, infectious diseases, 
sepsis, trauma, and autoimmune diseases the differentiation of IMC is partially blocked leading 
to increased MDSC numbers and higher activation. Activated MDSC are characterized by the 
expression of the immunosuppressive factors iNOS and Arg1. iNOS requires L-arginine as 
substrate and catalyzes the generation of NO and ROS (Gabrilovich and Nagaraj 2009) and 
Arg1 depletes l-arginine. The granulocyte-differentiation epitope (GR1) is expressed early in the 
myeloid development in the bone marrow and can be detected using the RB6-8C5 antibody 
(Fleming, Fleming et al. 1993). The epitope recognized by this antibody is part of both Ly6C and 
Ly6G. These proteins are members of the Ly6 family which are phospatidylinositol-anchored 
cell surface glycoproteins with a molecular weight between 12 and 20 kDa (Gumley, McKenzie 
et al. 1995). IMC are CD11b+ GR1+ and can be subdivided into polymorphonuclear 
CD11b+ Ly6Cint Ly6G+ granulocytic cells (Ly6Cint Ly6G+ / PMN-MDSC) and MDSC with 
monocytic morphology (MO-MDSC / MDSC) characterized by the markers 
CD11b+ Ly6C+ Ly6G-. PMN-MDSC produce high amount of ROS but almost no NO. Contrary to 
this, MDSC are induced by inflammation and provide low production of ROS but high amounts 
of NO (Movahedi, Guilliams et al. 2008; Youn, Nagaraj et al. 2008). Especially MDSC are very 
potent in suppressing both CD4 and CD8 T cell proliferation (Zhu, Bando et al. 2007). 
MDSC have to be expanded and activated, in order to fully develop efficient suppressive 
properties. Granulocyte/macrophage colony-stimulating factor (GM-CSF) is a very potent 
cytokine for the MDSC development as it interacts very early with expansion, maturation, and 
differentiation of early hematopoietic progenitors (Barreda, Hanington et al. 2004). During 
inflammation high concentrations of GM-CSF are produced and released from activated T cells, 
natural killer (NK) cells, dendritic cells (DC), and, interestingly, various tumors. GM-CSF may 
lead to expansion, redistribution, and functional changes of CD11b+ GR1+ cells and may force 
the development of functional MDSC (Ribechini, Greifenberg et al. 2010). Consequently, one 
way to generate MDSC in vitro is the incubation of mouse bone marrow cells with GM-CSF. It 
has been shown that low GM-CSF conditions are sufficient to generated immature DC and 
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MDSC between day 8 and 10 of the BMDC culture whereas this can be reached within 4 days 
under high GM-CSF concentrations. Such MDSC generated in vitro from mouse bone marrow 
cells efficiently suppress both CD4 and CD8 T cell proliferation and other effector mechanisms 
(Rossner, Voigtlander et al. 2005). Besides GM-CSF, several other mediators and pathological 
conditions like vascular endothelial growth factor (VEGF), prostaglandin E2, interferon-ү (IFN-ү), 
tumors, infections, graft versus host disease, chronic inflammation, and autoimmunity are 
known to be involved in increased MDSC generation (Ribechini, Greifenberg et al. 2010). It has 
also been shown that MDSC numbers are drastically increased in polymicrobial sepsis (Delano, 
Scumpia et al. 2007). MDSC were found in bone marrow, spleen, and lymph nodes. This effect 
can be mimicked by the administration of a combination of LPS and IFN-ү resulting in activation 
and development of splenic MDSC along with a partial blockade of DC development 
(Greifenberg, Ribechini et al. 2009). Figure 4 illustrates the origin of MDSC.  
 
 
Figure 4: MDSC development 
Myelopoiesis in the bone marrow is orchestrated by several cytokines including GM-CSF, stem-cell factor 
(SCF), IL-3, and FMS-related tyrosine kinase 3 (FLT3). Hematopoietic stem cells differentiate into 
common myeloid progenitor cells and, afterwards, into immature myeloid cells. In healthy conditions 
these cells migrate to peripheral organs and differentiate into macrophages, DC, or granulocytes. In 
pathological conditions such as provided by infection, trauma, or tumor normal differentiation is abrogated 
and MDSC arise from immature myeloid cells (Gabrilovich and Nagaraj 2009).  
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The majority of studies concerning MDSC reveal that the immunosuppressive effects require 
cell-cell contact. This indicates that the suppressive effects function either via cell-surface 
receptors, through the release of short-lived mediators or by changes in the micro-environment 
of the target cells (Gabrilovich and Nagaraj 2009). One of the most prominent mechanisms of T 
cell suppression constitutes the depletion of the non-essential amoni acid L-arginine. L-arginine 
serves as a substrate for two enzymes, Arg1 and iNOS. Arg1 converts L-arginine to urea and L-
ornithine whereas iNOS generates NO and L-citrulline (Bronte and Zanovello 2005). Adequate 
L-arginine availability is crucial for proper T cell function. It is depleted by Arg1 from the 
microenvironment whereby T cell proliferation is suppressed. This is mediated by several 
mechanisms. CD3 ζ-chain expression is reduced leading to a reduction of costimulatory signals 
(Rodriguez, Zea et al. 2002). Furthermore, upregulation of cell cycle regulators cyclin D3 and 
cyclin-dependend kinase 4 is impaired (Rodriguez, Quiceno et al. 2007). iNOS contributes to 
the depletion of L-arginine as it is required as substrate for the generation of NO. NO inhibits 
JAK3 and STAT5 function in T cells and reduces the MHCII expression on antigen presenting 
cells (APC) whereby the T cell functions are constricted (Bingisser, Tilbrook et al. 1998; Harari 
and Liao 2004). Additionally, NO is known to directly induce apoptosis in T cells (Rivoltini, 
Carrabba et al. 2002). Recently, data from tumor models revealed that the suppressive activity 
of PMN-MDSC is based on Arg1 expression whereas the suppressive effects in MO-MDSC are 
based on STAT1 and iNOS expression (Movahedi, Guilliams et al. 2008). 
Another suppressive MDSC mechanism is the production of ROS, especially in tumor-bearing 
organisms. ROS production in MDSC can be initiated by treating the cells with factors 
expressed from tumors, i.e. tumor growth factor β (TGF-β), IL-3, IL-6, IL-10, platelet-derived 
growth factor and GM-CSF  (Sauer, Wartenberg et al. 2001; Youn, Nagaraj et al. 2008). 
Peroxynitrite emerges from the chemical reaction of NO with superoxide anions and is one of 
the most powerful oxidants generated in organisms. It induces the nitrosylation and nitration of 
the amino acids cystein, methionine, tryptophane, and tyrosine in T cells and, thus, deactivates 
T cell receptors and costimulatory molecules (Vickers, MacMillan-Crow et al. 1999).  
The capability of MDSC to support the de novo generation of forkhead box P3+ (FoxP3+) Treg 
in vivo has been shown (Huang, Pan et al. 2006). The different ways of MDSC generation, 
induction, activation, and their suppressive interactions and mechanisms are described in 
Figure 5. 
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Figure 5: Activation and suppressive mechanisms of MDSC 
The cationic amino acid transporter 2B (CAT-2B) transfers L-arginine into the cytoplasma of MDSC. iNOS 
is expressed in MDSC after stimulation with various mediators like TLR ligands, IFN-ү, or TNF, via the 
transcriptional control of STAT1 or NF-κB. iNOS utilizes L-arginine as substrate to generate NO. NO can 
react with superoxide anions to form peroxinitrite. Other cytokines like TGF-β, IL-4, and GM-CSF activate 
STAT6 and other transcription factors and increase the expression of Arg1. Arg1 depletes L-arginine. 
Reduced L-arginine concentrations lead to the loss of ζ-chain integrity in T cells and disable proper T cell 
activation. Peroxinitrite is responsible for the nitration and nitrosylation especially of cystein residues and 
causes impaired function of signaling proteins in T cells. NO causes defective TCR signaling, cell cycle 
arrest, and apoptosis and is responsible for the inhibition of CD8 cytotoxicity (Sica and Bronte 2007). 
 
1.5 Aim of the thesis 
The aim of this work was to investigate the role of TNFR2 on myeloid cells, in particular under 
septic conditions caused by CLP. Dr. Theo Sterns reported that TNFR2 deficient mice were 
protected from a secondary infection during the phase of sepsis that is usually characterized as 
sepsis-induced immunosuppression (Sterns, Pollak et al. 2005). One hypothesis of this work 
was that MDSC in TNFR2-/- mice are more frequent or more active compared to MDSC in 
C57BL/6 wildtype mice and, thus, are responsible for the protection of TNFR2-/- mice from 
immunoparalysis. Another hypothesis was that missing direct cellular TNFR2-signaling in 
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myeloid cells causes the beneficial course of disease in CLP-treated TNFR2-/- mice after 
secondary infection compared to wildtype mice. Therefore, it was examined how myeloid cells 
influence the impact of CLP in mice and whether this cellular phenotype could be responsible 
for the protection of TNFR2-/- mice from a secondary infection in sepsis. This included the 
investigation of the general functions of TNFR2-/- myeloid cells and macrophages with a special 
focus on myeloid-derived suppressor cells.  
Furthermore, it should be clarified whether the cellular phenotypes that were found in septic 
TNFR2-/- mice are due to the lack of direct TNFR2-signaling or due to possible side effects 
caused by the absence of TNFR2. The latter consist of missing reverse signaling via 
membrane-bound TNF and soluble TNFR2 as well as of higher soluble TNF concentrations 
leading to increased and continuous TNFR1-signaling as a consequence of the lack of soluble 
TNF being trapped by soluble TNFR2. In this context the question arose whether TNFR2-/- mice 
are TNF tolerant as they might be continuously exposed to higher levels of soluble TNF and 
whether this might cause epigenetic modifications. For the exploration of these issues different 
types of myeloid cells from naïve and CLP-treated mice were analyzed in terms of numbers, 
frequency, activation, MDSC phenotype, Arg1 and iNOS mRNA expression, and production of 
NO as well as the production profile of cytokines and soluble TNFR2. By the use of mixed 
C57Bl/6 wt and TNFR2-/- cultures and bone marrow chimeric mice it should be examined 
whether missing TNFR2-signaling or altered TNFR1 stimulation is responsible for the 
phenotypes seen in TNFR2-/- myeloid cells. 
Another attempt of this thesis was to directly activate or block the TNFR2 in vivo and in vitro. 
Therefore, monoclonal mouse anti-mouse TNFR2 antibodies were to be generated and tested 
for TNFR2-specific agonistic and antagonistic properties. Specific activation of TNFR2 could 
identify effects caused by TNFR2-signaling whereas specific TNFR2 blockade would transform 
wildtype cells into a TNFR2-/- status. With such tools, effects seen in TNFR2-/- cellular systems 
could be mimicked in wildtype cells treated with antagonistic TNFR2 mAB. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Instrumentation 
Item Manufacturer City (Country) 
Blaubrand® hemocytometer Brand GmbH + Co KG Wertheim (GER) 
Cell Safe, Incubator Integra Bioscience GmbH Fernwald (GER) 
Centrifuge Shandon Cytospin 4  ThermoScientific GmbH Karlsruhe (GER) 
Circular shaker GFL-3015  Omnilab GmbH Mettmenstetten (GER) 
Eppendorf 5417R centrifuge Eppendorf AG Hamburg (GER) 
Eppendorf 5418R centrifuge  Eppendorf AG Hamburg (GER) 
Eppendorf 5810R centrifuge Eppendorf AG Hamburg (GER) 
Eppendorf BioPhotometer  Eppendorf AG Hamburg (GER) 
Film developing device Optimax Typ TR MS Laborgeräte GmbH Heidelberg (GER) 
Gel documentation device GeneGenius Syngene Cambridge (UK) 
Gel drying device model 483 Bio-Rad Laboratories GmbH München (GER) 
Gel electrophoresis device Bio-Rad Laboratories GmbH München (GER) 
Heat incubator WTB Binder GmbH Tuttlingen (GER) 
HiTrap™ protein G HP columns GE Healthcare GmbH München (GER) 
iQ5 real-time PCR cycler  Bio-Rad Laboratories GmbH München (GER) 
Laminar flow HB2448 Thermo Fisher Scientific GmbH Bonn (GER) 
LSRII, Flow cytometer BD Biosciences GmbH Heidelberg (GER) 
MACS® MultiStand Miltenyi Biotec GmbH Bergisch Gladbach (GER)
Magnetic stirrer MR2002  Heidolph GmbH & Co. KG  Schwabach (GER) 
Microplatereader Emax Molecular Devices München (GER) 
Microscope Diaplan  Olympus GmbH Hamburg (GER) 
Microscope Olympus CK2 Olympus GmbH Hamburg (GER) 
MidiMACS™ Separator  Miltenyi Biotec GmbH Bergisch Gladbach (GER)
Mini PROTEAN electrophoresis system Bio-Rad Laboratories GmbH München (GER) 
MiniMACS™ Separator  Miltenyi Biotec GmbH Bergisch Gladbach (GER)
MS2 IKA® vortexer IKA® Staufen (GER) 
Nitrogen tank German Cryo GmbH Jüchen (GER) 
PCR device MyCycler  Bio-Rad Laboratories GmbH München (GER) 
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pH-Meter Inolab  WTW Weilheim (GER) 
Pipetting unit accujet pro  Brand GmbH Wertheim (GER) 
Power supply unit PowerPac 300 Bio-Rad Laboratories GmbH München (GER) 
Power supply unit PowerPack P25 Biometra GmbH Göttingen (GER) 
Protein isolation device Econo System  Bio-Rad Laboratories GmbH München (GER) 
Sartorius L2200S Sartorius AG  Göttingen (GER) 
Sartorius R16OP balance Sartorius AG  Göttingen (GER) 
Thermo-block Bio TDB-100  Biometra GmbH Göttingen (GER) 
Thermo-shaker TS-100  Biometra GmbH Göttingen (GER) 
Water-bath TW12  Julabo GmbH Seelbach (GER) 
Western blot device fastblot B34 Biometra GmbH Göttingen (GER) 
 
2.1.2 Consumables 
Item Manufacturer City (Country) 
Amersham Hyperfilm ECL GE Healthcare GmbH München (GER) 
Biosphere filter tips (10 µL, 20 µL, 100 µL, 
1mL) 
Sarstedt AG & Co Nümbrecht (GER) 
Biosphere filter tips nuclease-free (10 µL, 
20 µL, 100 µL, 1mL) 
Sarstedt AG & Co Nümbrecht (GER) 
Cannulas BD Plastipak BD Biosciences GmbH Heidelberg (GER) 
Cell culture flasks (25 cm², 75 cm², 175 
cm²) 
BD Biosciences GmbH Heidelberg (GER) 
Cell scraper (25 cm) Sarstedt AG & Co Nümbrecht (GER) 
Cellstrainer (40 µM) BD Biosciences GmbH Heidelberg (GER) 
Centrifugation tubes (15 mL, 50 mL) BD Biosciences GmbH Heidelberg (GER) 
Cover slides for hemocytometer  Engelbrecht GmbH Edermünde (GER) 
Cryogenic tubes  Nalge Nunc GmbH Langenselbold 
(GER) 
Dialysis membrane type 20 Biomol GmbH Hamburg (GER) 
Eppendorf cup (1.5 / 2 mL) Eppendorf AG Hamburg (GER) 
Eppendorf UVette® cuvettes Eppendorf AG Hamburg (GER) 
FACS tubes BD Falcon BD Biosciences GmbH Heidelberg (GER) 
Glas columns for protein purification (Ni-
NTA) 
Bio-Rad Laboratories GmbH München (GER) 
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MACS® Cell Separation Columns 25 
LS/MS 
Miltenyi Biotec GmbH Bergisch Gladbach 
(GER) 
Microtiter plate micro well  Nalge Nunc GmbH Langenselbold 
(GER) 
Multiwell cell culture plates (6, 12, 24, 48, 
96) 
BD Biosciences GmbH Heidelberg (GER) 
Paper filter for cytospin Labonard Mönchengladbach 
(GER) 
Parafilm® M  American National Can 
Group 
Chicago (USA) 
Petri dishes Sarstedt AG & Co Nümbrecht (GER) 
Polystyrene tubes BD Biosciences GmbH Heidelberg (GER) 
PVDF transfer membran immobilon  Millipore GmbH Schwalbach (GER)
Reaction vessels (15 mL, 50 mL) Greiner GmbH Frickenhausen 
(GER) 
Sample slide (sliced, matt-edge)  Engelbrecht GmbH Edermünde (GER) 
Serological pipettes (5mL, 10mL, 25mL) Sarstedt AG & Co Nümbrecht (GER) 
Sterile filter 0.2 µm Sartorius AG Göttingen (GER) 
Sterile filter bottletop 75 mm  Nalge Nunc GmbH Langenselbold 
(GER) 
Suture clip (7.5 x 1.75 mm) Tierärztebedarf J. Lehnecke 
GmbH  
Schortens (GER) 
Syringes (1mL, 2mL, 5mL, 10mL) BD Biosciences GmbH Heidelberg (GER) 
Whatman paper A. Hartenstein Würzburg (GER) 
96 well PCR plate (semi-skirted) PEQLAB Biotechnologie 
GMBH 
Erlangen (G) 
Microseal ‘B’ film Bio-Rad Laboratories GmbH München (GER) 
 
2.1.3 Chemicals and reagents 
Item Manufacturer City (Country) 
Acrylamide / bisacrylamide rotiphorese 
gel 30  
Roth gmbH & Co. KG Karlsruhe (GER) 
Agarose, elecrophoresis grade Bio&Sell e.K. Nürnberg (GER) 
Ampicilline Roche Diagnostics GmbH Penzberg (GER) 
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BD OptEIA Substrat Reagent A and B  BD Biosciencess GmbH Heidelberg (GER) 
Carboxyfluorescein succinimidyl ester Invitrogen GmbH Karlsruhe (GER) 
Chelating Sepharose Fast Flow GE Healthcare GmbH München (GER) 
Cytofix / Cytoperm BD Biosciencess GmbH Heidelberg (GER) 
DNA standard (100 bp and 1 kb Ladder) New England Biolabs GmbH Frankfurt / Main 
(GER) 
dNTP-Mix (10 mM) Promega GmbH Mannheim (GER) 
Ethylenediaminetetraacetic acid Promega GmbH Mannheim (GER) 
Fetale bovine serum PAN Biotech GmbH Aidenbach (GER) 
Gentamycine PAN Biotech GmbH Aidenbach (GER) 
Go-Taq  Promega GmbH Mannheim (GER) 
HAT-supplement PAN Biotech GmbH Aidenbach (GER) 
HT-supplement  PAN Biotech GmbH Aidenbach (GER) 
Hygromycine PAA Laboratories GmbH Pasching (A) 
Insect XpressTM Lonza GmbH Wuppertal (GER) 
Kanamycine PAN Biotech GmbH Aidenbach (GER) 
Ketaminehydrochloride 5% WDT eG Garbsen Garbsen (GER) 
LPS (S. abortus equi) Prof. M. Freudenberg Max-Planck-Institute 
of Immunology 
(GER) 
M-MLV RT 5 x reaction buffer Promega GmbH Mannheim (GER) 
Neomycin (G418)  PAN Biotech GmbH Aidenbach (GER) 
NOWA Solution A and B  MoBiTec GmbH Göttingen (GER) 
Nucelase-free water Promega GmbH Mannheim (GER) 
Oligo-dT Primer Promega GmbH Mannheim (GER) 
Penicillin/ Streptomycin  Invitrogen GmbH Karlsruhe (GER) 
Perm / Wash (10 x) BD Biosciencess GmbH Heidelberg (GER) 
Phosphat buffered salines PAA Laboratories GmbH Pasching (A) 
Polyethylenglycol 1500  Roche Diagnostics GmbH Penzberg (GER) 
Precision Plus Protein All Blue Standard Bio-Rad Laboratories GmbH München (GER) 
Recombinant mouse IFNү Peprotech GmbH Hamburg (GER) 
Recombinant mouse TNF Peprotech GmbH Hamburg (GER) 
RNaseZap®  Ambion GmbH Kassel (GER) 
RPMI 1640 PAA PAN Biotech GmbH Aidenbach (GER) 
Skimmed milk powder  Granovita GmbH Lüneburg (GER) 
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TMB substrate reagent set BD Biosciencess GmbH Heidelberg (GER) 
TNC-mTNF Prof. H. Wajant University of 
Würzburg (GER) 
Triton X-100 Serva Feinbiochemica GmbH Heidelberg (GER) 
Xylazinehydrochloride 2% WDT eG Garbsen Garbsen (GER) 
 
The solvents or chemicals not mentioned here were purchased either from Merck KGaA 
(Darmstadt, Germany) or Sigma-Aldrich GmbH (Taufkirchen, Germany). 
 
2.1.4 Antibodies 
Antibodies for ELISA / Western blot    
Item Modification Manifacturer City (Country) 
Donkey anti-human IgG (H+L) HRP HRP Dianova GmbH Hamburg (GER) 
Goat anti-mouse IgG (whole molecule) 
POX 
POX Sigma Aldrich GmbH Taufkirchen (GER)
Goat anti-mouse IgG (ү-chain specific) 
AP 
AP Sigma Aldrich GmbH Taufkirchen (GER)
Mouse anti-Penta-His mAB None Qiagen GmbH München (GER) 
Mouse anti-V5 mAB None Invitrogen GmbH Karslruhe (GER) 
Mouse anti-V5 mAB HRP HRP Invitrogen GmbH Karslruhe (GER) 
 
 
Antibodies for FACS and MACS    
Item Clone Modification Manifacturer City (Country) 
7-AAD viability staining 
solution 
 7-AAD BioLegend San Diego / 
California (USA) 
Alexa Fluor® 647 Annexin V  AF647 BioLegend San Diego / 
California (USA) 
anti-APC isolation micro 
beads 
  Miltenyi Biotec 
GmbH 
Bergisch 
Gladbach (GER) 
anti-BrdU  FITC BD Biosciencess Heidelberg (GER)
anti-mouse B220 RA3-6B2 PerCP BD Biosciencess Heidelberg (GER)
anti-mouse CD11b M1/70 APC eBioscience San Diego / 
California (USA) 
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anti-mouse CD11b M1/70 FITC BD Biosciences Heidelberg (GER)
anti-mouse CD11b M1/70 PE eBioscience San Diego / 
California (USA) 
anti-mouse CD11b isolation 
micro beads 
  Miltenyi Biotec 
GmbH 
Bergisch 
Gladbach (GER) 
anti-mouse CD11c N418 Biotin eBioscience San Diego / 
California (USA) 
anti-mouse CD11c N418 PE eBioscience San Diego / 
California (USA) 
anti-mouse CD11c N418 AF700 eBioscience San Diego / 
California (USA) 
anti-mouse CD11c isolation 
micro beads 
  Miltenyi Biotec 
GmbH 
Bergisch 
Gladbach (GER) 
anti-mouse CD19 6D5 PE BD Biosciences Heidelberg (GER)
anti-mouse CD4 L3T4 Pacific blue eBioscience San Diego / 
California (USA) 
anti-mouse CD4 L3T4 PE eBioscience San Diego / 
California (USA) 
anti-mouse CD4 L3T4 PerCP eBioscience San Diego / 
California (USA) 
anti-mouse CD4 isolation 
micro beads 
  Miltenyi Biotec 
GmbH 
Bergisch 
Gladbach (GER) 
anti-mouse CD45.1 A20 Biotin BD Biosciences Heidelberg (GER)
anti-mouse CD45.1 A20 PE BD Biosciences Heidelberg (GER)
anti-mouse CD45.1 A20 APC AF750 BD Biosciences Heidelberg (GER)
anti-mouse CD45.2 104 Biotin BD Biosciences Heidelberg (GER)
anti-mouse CD45.2 104 FITC BD Biosciences Heidelberg (GER)
anti-mouse CD45.2 104 PerCP-Cy5.5 BD Biosciences Heidelberg (GER)
anti-mouse CD80 60-10A1 Biotin BD Biosciences Heidelberg (GER)
anti-mouse CD86 GL-1 Biotin BD Biosciences Heidelberg (GER)
anti-mouse CD86 GL-1 FITC eBioscience San Diego / 
California (USA) 
anti-mouse CD86 GL-1 Pacific blue BioLegend San Diego / 
California (USA) 
anti-mouse CD8α 53-6.7 AF647 BD Biosciences Heidelberg (GER)
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anti-mouse CD8α 53-6.7 PE BD Biosciences Heidelberg (GER)
anti-mouse Fcγ-Rezeptor II/III  2.4G2  Own production 
anti-mouse Ly6C AL-2 Biotin BD Biosciences Heidelberg (GER)
anti-mouse Ly6C AL-2 FITC BD Biosciences Heidelberg (GER)
anti-mouse Ly6G 1A8 PE BD Biosciences Heidelberg (GER)
anti-mouse Ly6G 1A8 V450 BD Biosciences Heidelberg (GER)
anti-mouse MHCII M5/114.1
5.2 
APC Miltenyi Biotec 
GmbH 
Bergisch 
Gladbach (GER) 
anti-mouse MHCII M5/114.1
5.2 
AF700 Miltenyi Biotec 
GmbH 
Bergisch 
Gladbach (GER) 
anti-mouse MHCII M5/114.1
5.2 
FITC eBioscience San Diego / 
California (USA) 
anti-mouse TNFR1 55R-286 AF647 AbD Serotec Düsseldorf (GER) 
anti-mouse TNFR2 TR75-89 PE AbD Serotec Düsseldorf (GER) 
anti-mouse TNFR2 TR75-89 AF647 AbD Serotec Düsseldorf (GER) 
Rabbit anti-mouse Ig FITC  FITC DakoCytomation 
GmbH 
Hamburg (GER) 
Straptavidine secondary 
conjugate 
 Pacific 
orange 
Invitrogen GmbH Karlsruhe (GER) 
 
 
2.1.5 ELISA Kits 
Item Manufacturer City (Country) 
Mouse IL-6 DuoSet ELISA development kit R&D Systems GmbH Wiesbaden 
(GER) 
Mouse sTNF RII/TNFRSF1B DuoSet ELISA 
development kit 
R&D Systems GmbH Wiesbaden 
(GER) 
Mouse TNF-alpha DuoSet ELISA development kit R&D Systems GmbH Wiesbaden 
(GER) 
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2.1.6 Buffers and solutions 
Item Composition 
12.5% resolving gel  0.85 mL acrylamide / bisacrylamide rotiphorese gel 30, 
1.5 mL 0.5 M Tris pH 6.8, 3.75 mL ddH2O, 60 µL 10% 
SDS, 5 µL TEMED, 50 µL APS 
4% collection gel  6.25 mL acrylamide / bisacrylamide rotiphorese gel 30, 
3.75 mL 1.5 M Tris pH 8.8, 5 mL ddH2O,150 µL 10% SDS, 
10 µL TEMED, 100 µL APS 
AP substrate buffer (pH 9.8) 9.8% diethanolamine, 24 mM MgCl2  
BD FACS™ Lysis Solution (10x) BD Biosciences GmbH 
Blocking buffer for TNFR2ed-huIgG 
ELISA 
10% skimmed milk powder (w/v) in TBS 
Blocking buffer for Western blot 5% skimmed milk powder (w/v) in TBS-T 
Blotting buffer (10x) 2 M glycine, 250 mM Tris 
Buffer for cell sort (Sort buffer) PBS, 0.5% (w/v) BSA, 2 mM EDTA 
Buffer for magnetic cell separation 
(MACS buffer) 
PBS, 0.5% (w/v) BSA, 2 mM EDTA 
Coomassie staining buffer 10% acetic acid, 40% ethanol, 0.2% comassie brilliant 
blue R250 
Coomassie destaining buffer 10% acetic acid, 40% ethanol 
Elution buffer for chelating 
sepharose protein purification  
250 mM imidazole, 20 mM Na2HPO4, 0.5 M NaCl, pH 7.5 
Elution buffer for IgG purification 
(protein G)  
0.1 M Glycin (pH 3.1) 
Erythrocyte lysis buffer 0.17 M NH4Cl, 20 mM HEPES 
FACS-Puffer 2% FCS in PBS 
Freezing medium (2x) 20% DMSO, 80% FCS 
Griess reagent A 1% sulfanilamide (w/v), 5% H3PO4 
Griess reagent B 0.1% naphtyl-ethylenediamine dihydrochloride 
Laemmli electro-mobility buffer (5x) 120 mM Tris Base, 0.95 M Glycin, 0.5% SDS 
Laemmli loading buffer (4x) 0.5 M Tris, pH 6.8, 40% glycine, 0.04% β-
mercaptoethanol, 4% SDS, 0.005% bromephenole-blue 
Loading dye solution (6x)  0.25% bromephenole-blue, 0.25% xylencyanole, 30% 
glycerole 
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Neutralization buffer for IgG-
purification (protein G)  
1 M Tris-HCl (pH 11) 
PBS (pH 7.3)  137 mM NaCl, 6.5 mM Na2HPO4 x H2O, 1.5 mM KH2PO4, 
2.7 mM KCl 
PBS-T 0.05% Tween 20 in PBS 
Permeabilization reagent PBS, 1% BSA, 0.01% Triton-X 100 
Reagent Diluent for R&D ELISA 1% BSA (w/v) in PBS-T  
Reagent Diluent for TNFR2ed-
huIgG ELISA 
1% skimmed milk powder (w/v) in TBS 
Reagent Diluent for Western blot 1% skimmed milk powder (w/v) in TBS-T 
Standard for Griess reagent 10 mM NaNO2  
Stop solution for AP ELISA 2 M NaOH 
Stop solution for HRP ELISA 2 N H2SO4 
Substrate solution for AP ELISA  0.06% p-nitrophenylphosphate in AP substrate buffer 
TAE-buffer  40 mM Tris-acetate, 1 mM EDTA 
TBS-Puffer  8 g NaCl, 0.2 g KCl, 3 g Tris Base, H2O bidest ad 1 l 
TBS-T 0.05% Tween 20 in TBS 
Tris-buffer for SDS-PAGE 
collection gel  
1,5 M Tris-HCl (pH 8,8) 
Tris-buffer for SDS-PAGE 
separation gel  
0.5 M Tris-HCl (pH 6,8) 
Trypan blue solution (pH 7.4) 0.16% (w/v) trypan blue, 150 mM NaCl 
Wash buffer I for chelating 
sepharose protein purification  
20 mM Na2HPO4, 0.5 M NaCl, pH 7.5 
Wash buffer II for chelating 
sepharose protein purification  
10 mM imidazole, 20 mM Na2HPO4, 0.5 M NaCl, pH 7.5 
 
All buffers and solutions were prepared using ddH2O. 
 
2.1.7 Kits 
Item Manufacturer City 
BCA Protein Assay Reagent  Pierce / Thermo Fisher 
Scientific GmbH 
Bonn (GER) 
BD Pharmingen™ - FITC BrdU Flow Kit  BD Biosciences Heidelberg (GER) 
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Diff-Quick Differential Staining Set Dade Behring GmbH Eschborn (GER) 
DOTAP Liposomal Transfection Reagent Roche Diagnostics GmbH Penzberg (GER) 
IsoGold Rapid Mouse-Monoclonal 
Isotyping Kit™ 
BioAssays Ijamsville / Indiana 
(USA) 
NucleoSpin® RNA II  MACHEREY NAGEL GmbH & 
Co. KG  
Düren (GER) 
Q SYBR Green Supermix Bio-Rad Laboratories GmbH München (GER) 
Reverse Transcription System Promega GmbH Mannheim (GER) 
 
2.1.8 Oligonucleotides 
All used oligonucleotides were obtained from Metabion GmbH (Martinsried). Melting 
temperatures were either taken from the manufacturer’s recommendations or calculated 
according to the equation shown in Formula 1. The oligonucleotides employed in cloning and 
polymerase chain reaction (PCR) are listed in Table 1and Table 2. 
)(2)(4][ TAxCGxCmT +++=°  
Formula 1: Calculation of the melting temperature of oligonucleotides  
 
Table 1: Oligonucleotides for quantitative real-time PCR 
Oligonucleotides for quantitative real-time PCR 
Target Name Sequence (5' - 3' ) 
Tm 
[°C] 
Exon 
spanning 
Amplicon 
lenght [bp] 
18s FW GTAACCCGTTGAACCCCATT 58 Yes 18s 
18s RV CCATCCAATCGGTAGTAGCG 60 Yes 
180 
ARG1 FW AGTCTGGCAGTTGGAAGCAT 59.87 Yes ARG1 
ARG1 RV CATCTGGGAACTTTCCTTTC 59.16 Yes 
172 
IL-6 FW TGCAAGAGACTTCCATCCAG 58.96 Yes IL-6 
IL-6 RV TGCCATTGCACAACTCTTTT 59.32 Yes 
203 
iNOS FW GCTGTTCTCAGCCCAACAAT 60.26 Yes iNOS 
iNOS RV TGCAAGTGAAATCCGATGTG 60.67 Yes 
214 
β-Actin FW TCACCCACACTGTGCCCATCTACGA 61 No β-Actin 
β-Actin RV GGATGCCACAGGATTCCATACCCA 59.1 No 
348 
 
 
 
 
 
 
 
 
II Materials and Methods 
 
33
Table 2: Oligonucleotides for cloning 
Cloning of TNFR2ed fusion protein in DesMTA (TNFR2ed-V5His) 
Target Name Sequence (5' - 3' ) 
TNFR2 mp75ed MTA Bam H1 5' CCCGGATCCGTGCCCGCCCAGGTTGTCTTG 
TNFR2 mp75ed 3' Not1 TGGCGGCCGCCAGCCACCCTTGGTACTTTG 
   
Cloning of TNFR2ed-huIgG fusion protein in DesMTA (TNFR2ed-huIgG) 
Target Name Sequence (5' - 3' ) 
TNFR2 mp75ed MTA Spe 5'  CCCACTAGTGTGCCCGCCCAGGTTGTCTTG 
TNFR2 hIg 3' Nos CGCGGCGGCCATCATTTACCCGGAGACACG 
   
Cloning of TNFR1ed-huFasid fusion protein in pQCXIP 
Target Name Sequence (5' - 3' ) 
TNFR1 TNFR1 Bam huFas fusion 5'  GGGGGATCCATGGGTCTCCCCACCGTGCCTGG
TNFR1 TNFR1 EcoRV huFas fusion 3'  GGGGATATCCATTAAACTGATGAAGATAAAGG 
huFas 5' EcoRV huFas GGGGATATCAAGAGAAAGGAAGTACAGAAAAC 
huFas 3' Xho huFas GGGCTCGAGCTAGACCAAGCTTTGGATTTC 
   
Cloning of TNFR2ed-huFasid fusion protein in pQCXIP 
Target Name Sequence (5' - 3' ) 
TNFR2 TNFR2 Bam Fas fusion 5'  GGGGGATCCATGGCGCCCGCCGCCCTCTGGG 
TNFR2 TNFR2 EcoRV Fas fusion 3'  GGGGATATCCTTGGCATCTCTTTGTAGGCAGG 
huFas 5' EcoRV huFas GGGGATATCAAGAGAAAGGAAGTACAGAAAAC 
huFas 3' Xho huFas GGGCTCGAGCTAGACCAAGCTTTGGATTTC 
 
2.1.9 Plasmids 
Table 3 lists the vectors used for the transfection or transduction of target cells. DesMTA was 
used to express and secrete TNFR2ed constructs for protein purification and isolation in DS-2 
Drospohila Schneider cells. pQCXIP and pcDNA3 were employed to generate cell lines 
expressing membrane-bound TNFR2 constructs. 
 
Table 3: Plasmids 
Item Manufacturer City 
pcDNA3.1 Invitrogen Karslruhe (GER) 
pQCXIP Clontech, BD Biosciences Heidelberg (GER)
pMT/Bip/V5-His (DesMTA) Invitrogen Karslruhe (GER) 
 
Furthermore, a TNFR2 expression plasmid was used. In detail, mouse TNFR2 cDNA was 
inserted into the multiple cloning site of the plasmid pcDNA3.1 using BamH1 and XhoI 
restriction enzymes. All expression plasmids were verified by sequencing. 
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2.1.10 Cell culture media 
Standard medium: cultivation of primary splenocytes, PEC and mammalian cell lines (CHO, 
L-929m cells, SP2/0-Ag14, and Wirbel cells) 
RPMI 1640, 10% (v/v) FCS, 50 µM β-mercaoptoethanol, 100 U/mL penicillin, 100 U/mL 
Streptomycin 
BMDC Medium: generation of bone marrow-derived dendritic cells 
RPMI 1640, 10% (v/v) fetal calf serum (FCS), 10% (v/v) GM-CSF supernatant, 50 µM β-
mercaoptoethanol, 100 U/mL penicillin, 100 U/ml streptomycin 
HAT-medium: selection of myeloma cells 
RPMI 1640, 10% (v/v) FCS, 0.02% (v/v) hypoxanthine aminopterin thymidine (HAT) stock, 50 
µM β-mercaoptoethanol, 100 U/mL penicillin, 100 U/ml streptomycin 
HT-medium: selection of myeloma cells 
RPMI 1640, 10% (v/v) FCS, 0.02% (v/v) hypoxanthine thymidine (HT) stock, 50 µM β-
mercaptoethanol, 100 U/mL penicillin, 100 U/mL streptomycin 
Medium for the cultivation of DS-2 Schneider cells 
Insect XpressTM , 100 µg/mL kanamycine 
 
2.1.11 Mouse strains 
C57BL/6J wildtype mice (Jenvier, Le Genest, France) 
C57BL/6J Ly5.1 (CD45.1, breeding at the University of Regensburg) (Shen, Saga et al. 1985) 
C57BL/6J TNFR2-/- (breeding at the University of Regensburg) (Erickson, de Sauvage et al. 
1994) 
C57BL/6J OVA-transgenic (OTII) (breeding at the University of Regensburg) (Barnden, Allison 
et al. 1998) 
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2.1.12 Eukaryotic cell lines 
The cell lines used within this work are listed in Table 4. 
 
Table 4: Eukaryotic cell lines 
Name Description ATCC® Medium Plasmide Antibiotics  
CHO Chinese 
hamster ovary 
cell 
CCL-61™ Standard 
medium 
  
CHO TNFR2 Chinese 
hamster ovary 
cell 
 Standard 
medium 
pcDNA3.1 Neomycin 
(G418) (1.4 
mg/mL)  
DS-2 Drosophila 
Schneider cell 
CRL-
1963™  
Insect 
XpressTM 
  
DS-2 TNFR2ed 
huIgG 
Drosophila 
Schneider cell 
 Insect 
XpressTM 
pMT/Bip/V5-
His hygro 
Hygromycine 
(300 µg/mL) 
DS-2 TNFR2ed 
V5His 
Drosophila 
Schneider cell 
 Insect 
XpressTM 
pMT/Bip/V5-
His hygro 
Hygromycine 
(300 µg/mL) 
L-929m Murine 
aneuploid 
fibrosarcoma 
cell line 
CCL-1™ Standard 
medium 
  
SP2/0-Ag14  Myeloma cell CRL-
1581™ 
Standard 
medium 
  
Wirbel (TNFR1/2-/-) Mouse fibroblast 
TNFR1/2 double 
knockout 
 Standard 
medium 
  
Wirbel TNFR1ed 
huFasid 
Mouse fibroblast 
TNFR1/2 double 
knockout 
 Standard 
medium 
pQCXIP Puromycine 
(1.4 µg/mL) 
Wirbel TNFR2ed 
huFasid 
Mouse fibroblast 
TNFR1/2 double 
knockout 
 Standard 
medium 
pQCXIP Puromycine 
(1.4 µg/mL) 
X6310 (X63Ag8-
653) GM-CSF 
Myeloma cell   Standard 
medium 
    
 
II Materials and Methods 
 
36
2.1.13 Software and internet resources 
This manuscript was prepared with Microsoft Office Word 2007. Graphs and diagrams were 
prepared using either Microsoft Office Excel 2007 or Graph Pad Prism version 5.01. 
Quantitative real-time PCR raw data were obtained from IQ5TMOptical System Software 2.0. 
Flow cytometry data analyzes were done using BD FACSDiva software, BD CellQuest pro 
software or FlowJo software. The list of references was compiled using EndNote X3 software. 
Statistic analyzes were computed employing either Microsoft Office Excel 2007 or Graph Pad 
Prism version 5.01.  
Furthermore, the listed internet references were utilized: 
 
• Ensembl Genome Browser                  http://www.ensembl.org/index.html
• Pubmed                           http://www.ncbi.nlm.nih.gov/pubmed 
• EMBL-EBI                                            http://www.ebi.ac.uk/ 
• NCBI                                                    http://www.ncbi.nlm.nih.gov 
 
2.2 Molecular biology 
2.2.1 Working with DNA 
2.2.1.1 Sequencing of plasmid DNA 
Sequencing of deoxyribonucleic acid (DNA) vectors was performed by Geneart AG, 
Regensburg. 300 ng plasmid were diluted in 10 µL nuclease-free water containing 1 pmol of the 
primer used for the sequencing reaction and shipped to the company. 
 
2.2.2 Working with RNA 
Throughout the handling with cells, RNA, and cDNA contaminations with nucleases were 
avoided using RNaseZap® and nuclease free filter-tips. 
 
2.2.2.1 RNA isololation 
RNA was isolated using the NucleoSpin® RNA II isolation kit from MACHEREY NAGEL GmbH 
& Co. KG and the protocol “Total RNA purification from cultured cells and tissue with 
NucleoSpin® RNA II”. 
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Adherent cells were lysed directly after removing the medium by addition of 350 µL of RA1 
buffer supplemented with 1% (v/v) 99% β-mercaptoethanol. Remaining non-adherent cells were 
centrifuged for 5 min with 12000 g at 4°C and the supernatant was discarded. The lysate of the 
adherent cells was transferred to the pelleted cells, in order to achieve total RNA recovery from 
the sample. The cell lysates were stored at -80°C until RNA extraction. RNA was eluated in 50 
µL ddH2O. 
 
2.2.2.2 RNA concentration determination using a photometer 
RNA samples were diluted 1 to 50, in order to reach RNA concentrations within the linear 
measuring range of the photometer. The optical density value (OD-value) corresponds to the 
absorbance of an optical element for a given wavelength λ per unit distance and is calculated by 
Formula 2 and explained in Table 5. 
 
Il
T
ll
A
OD 0
I
log1log1 ∗−=∗−== λλ  
Formula 2: Optical density 
 
Table 5: Abbreviations and descriptions of Formula 2 
 
 
The maximum absorbance is 260 nm for nucleic acid and 280 nm for proteins. An OD260 nm 
value of 1 is equivalent to an RNA concentration of 40 µg/mL. The ratio of OD260 nm to OD280 nm 
indicates if there are contaminations with. Therefore, the ratio OD260 nm / OD280 nm is used as an 
indicator for the quality of the nucleic acid and should be at 2.0 for RNA. Only RNA samples 
with an OD260 nm / OD280 nm ratio between 1.7 and 2 were used. 
 
2.2.2.3 cDNA synthesis 
RNA concentrations were adjusted to 1 µg / 12 µL. 12 µL were combined with 2 µL Oligo dT 
Primer (C1101, Promega). The tube was shortly vortexed and centrifuged followed by 5 min 
denaturation of the RNA at 70°C in the heat block. After this annealing of the primers to the 
Abbreviation Description 
l Distance [cm] that light travels through the sample 
Aλ Absorbance at wavelength λ 
T Transmittance per unit 
I0 Intensity of the incident light beam 
I  Intensity of the transmitted light beam 
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poly-A tails of mRNA was achieved by incubating the sample for 5 min on ice. 11 µL of the 
homogeneously mixed MMLV master mix described in Table 6 were added and the reverse 
transcription was performed at 42°C for 60 min. 
 
Table 6: Master mix for reverse transcription reaction 
MMLV Master mix  [µL]
M-MLV RT 5x Reaction Buffer 5
Nucleotide mix (10 mM) 1.25
M-MLV Reverse Transcriptase 1
Nuclease-free water 3.75
Total 11
 
After reverse transcription the reverse transcriptase enzyme was inactivated by 5 min 
incubation at 70°C. cDNA was stored at -20°C. In the case of very low RNA yields due to limited 
numbers of cells the volume of 3.75 µL RNAse / DNAse free H2O was subtracted from the 
master mix. Instead of this, 15.75 µL of pure RNA were used as template for the reverse 
transcription reaction.  
 
2.2.2.4 Quantitative real-time PCR 
The quantitative polymerase chain reaction (qPCR) is a method to quantify a selected 
polynucleotide sequence by amplifying its initial concentration to a level at which an accurate 
detection can be made (Bustin 2000; Kubista, Andrade et al. 2006; Nolan, Hands et al. 2006). 
This level is called crossing point (CP) and it is defined as the number of PCR cycles that are 
necessary to detect the first reliable fluorescence signal from Sybr Green I added to the 
reaction. PCR amplifies the targeted nucleic acid in the sample and this amplification is 
considered to be exponentially in its most progressive phase. SYBR Green I is an asymmetrical 
cyanine dye used as a nucleic acid stain. The fluorescent dye SYBR Green I binds to the minor 
groove of the DNA double helix. In solution, the unbound dye exhibits very little fluorescence, 
however, fluorescence is greatly enhanced upon DNA-binding (Zipper, Brunner et al. 2004). 
The resulting DNA-dye-complex absorbs blue light (λmax = 488 nm) and emits green light 
(λmax = 522 nm). As SYBR Green I is not able to distinguish between target sequences and 
unspecific DNA amplification product or primer dimers, melting curve analysis were performed 
to control reliable PCR products. At the end of the 45 amplification cycles amplicons were 
melted for 1 min at 95°C following an annealing step for 1 min at 55°C. Melting curve analysis 
was performed by 0.5°C stepwise heating-up of the sample until 95°C. The fluorescence signal 
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decreases slowly until the melting temperature of the amplicon where a strong decline of the 
fluorescence signal can be detected. If more than one strong decline of fluorescence was 
detected, the results of this sample were seen as invalid. 
 
2.2.2.4.1 Primer design 
Primers were designed using the coding sequence of the target mRNA. They were to be 
between 18 and 23 base pairs long and should provide a specific melting temperature between 
58°C and 61°C. All primers used were designed by exon-spanning of at least 4 base pairs. This 
avoids amplification of contaminating genomic DNA. In addition, the sequences of all primers 
were blasted against the whole mouse transcriptome. Primers were defined as valid when the 
homology with other mRNA transcripts was lower than 70%. The length of the respective 
amplicons was to be between 100 and 350 base pairs, in order to guarantee accurate and fast 
PCR results. Primers were purchased from Metabion GmbH (Martinsried). The parameters of 
the primer pairs are listed in Table 1. 
 
2.2.2.4.2 Quantitative real-time PCR setup 
cDNA (1 µg / 25 µL) was diluted 1 to 5 with nuclease-free water. 5 µL were transferred into real-
time PCR 96-well plates. Master mix was prepared as a multiple of the reagent volumes shown 
in Table 7 with the primer pairs for the target and the housekeeper gene listed in Table 1.  
 
Table 7: Master mix for quantitative real-time PCR 
Master mix (1x) V [µL] 
Primer FW (100 µM) 0.1 
Primer RV (100 µM) 0.1 
Q SYBR Green 
Supermix 12.5 
Nuclease-free water 7.3 
Total 20 
 
20 µL of the master mix were transferred to the 5 µL cDNA provided before. Each cDNA sample 
was assayed in at least two technical replicates. 
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2.2.2.4.3 Quantitative real-time PCR program 
Quantitative real-time PCR was performed using the Bio-Rad iQ5 real-time PCR cycler. Single 
well factors collection was activated, in order to adjust the data interpretation software to the 
autofluorescence of every well. Table 8 illustrates the controlling and timing of the thermocycler. 
Table 8: Protocol for quantitative real-time PCR  
Cycle Repeats Step Dwell T [mm.ss] 
Setpoint 
[°C] 
PCR / Melt Data 
Acquisition ∆T [°C] End T [°C] 
Hot Start 1   4.00 95.0       
PCR 45 Melting 0.20 95.0       
    Amplification 1.00 59.0 Real Time     
Melting 1   1.00 95.0       
Annealing 1   1.00 55.0       
Melting Curve 81   0.30 55.0 Melting Curve 0.5 95.0 
Cooling 1   0.30 5.0       
 
2.2.2.4.4 Data interpretation 
Efficiency of the PCR reaction was determined in the up-front for every pair of primers and 
ranged between 1.95 and 2.0. The mRNA expression data were calculated assuming a PCR 
efficiency of 2 and either the delta CP method or the delta-delta CP method as described in 
Formula 3 and Table 9 (Pfaffl 2001). 
 
∆∆CP∆∆CP
sampleuntreatedtorelative
∆CP∆CP
HKtorelative
sampleuntreatedsampletreated
genereferencegenetarget
2EexpressionmRNATG
2EexpressionmRNATG
∆CP∆CP∆∆CP
CPCP∆CP
−−
−−
==
==
−=
−=
 
Formula 3: Quantitative real-time PCR data interpretation 
 
Table 9: Abbreviations and descriptions of Formula 3 
Abbreviation Description 
CP Crossing point 
TG Target gene 
HK House keeping gene 
E Efficiency 
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2.2.3 Working with proteins 
2.2.3.1 Expression of recombinant proteins in Drosophila DS-2 Cells 
DS-2 cells were transfected with pMT/Bip/V5-His (DesMTA) vectors and grown until high 
cellular density was achieved. Following protein expression induction using 0.5 mM CuSo4 
recombinant proteins tagged with a leader sequence were expressed. The leader sequence 
provides the secretion of the recombinant proteins and is cleaved from the target protein during 
this process. Thus, recombinant proteins were easily purified from the supernatant without lysis 
of the cells. Supernatants were collected 4 – 5 days after induction. 
 
2.2.3.2 Measuring of protein concentrations 
Protein concentrations were determined using BCA Protein Assay Reagent (Pierce / Thermo 
Fisher Scientific GmbH) according to the manual of the manufacturer. 
 
2.2.3.3 SDS-PAGE 
Sodium dodecyl sulfate (SDS)-PAGE separates proteins according to their molecular weight 
using electrophoretic mobility (Laemmli 1970). In this work the Mini Protein Electrophoresis 
system (Bio-Rad Laboratories GmbH) was employed. First, a 12.5% resolving gel was cast and 
overlaid with butanol. After complete polymerization butanol was removed, 4% collection gel 
was filled into the rack, and the comb generating the slots for the samples was inserted. 15 µL 
of the samples were mixed with 5 µL 4 x Laemmli loading buffer and denaturized for 5 min at 
95°C. After polymerization of the collection gel the system was inserted into the apparatus and 
the basins containing the anode and the cathode were filled with 1x Laemmli electro-mobility 
buffer. The cationic basin covered the loading area of the gel. The comb was removed and 
20 µL of the samples as well as 10 µL of the standard were transferred into the single slots of 
the gel. The separation of the proteins occurred with 35 mA and 200 V. After runs were 
completed either staining of the proteins using coomassie or blotting of the proteins to 
polyvinylidene fluoride (PDVF) membranes (Western blot) was performed. 
 
2.2.3.4 Coomassie staining 
Protein detection in polyacrylamide gels or on PVDF membranes following Western blot 
analysis was performed using coomassie-blue. Gels or membranes were incubated in 
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coomassie staining buffer for 1 h and non-bound dye was removed by incubation in coomassie 
destaining buffer over-night. The heat and vaccum gel drying device was used to dry gels, 
PVDF membranes were air-dried.  
 
2.2.3.5 Western blot 
Proteins separated with SDS-PAGE were transferred to PVDF-membranes (Towbin, Staehelin 
et al. 1979). One PVDF-membrane and 6 slides of whatman papers were tailored to the size of 
the gels. Following short incubation in methanol, the membranes were washed in ddH2O and 
transferred to 1 x blotting buffer. The whatman papers and the gel were also immersed in 
1 x blotting buffer. Three whatman papers were placed on top of each other on the anode plate 
of the western blot device Fastblot B43 (Biometra GmbH) followed by the PVDF-membrane, the 
gel, and 3 more whatman papers. Great importance was payed to bubble-free assembling. The 
cathodic lid of the apparatus was closed and proteins were transferred for 1 h using 1.0 mA per 
cm2 gel and 200 V. Following the protein transfer, the membranes were blocked at 4°C for 1 h 
or longer with blocking buffer. The purified antibodies used for the detection were diluted in 
10 mL of reagent diluent and incubated with the membranes at RT on a shaker for 1 to 2 h. 
After 3 washes with 20 mL TBS-T for 5 min the membranes were incubated with a secondary 
peroxidase-coupled antibody diluted in 10 mL TBS containing 1% skimmed milk powder (w/v) 
for 30 min. Following another washing procedure as described before, the membranes were 
developed using NOWA A and B solution. Those two solutions were mixed in equal parts and 
pipetted over the membrane. Resulting chemiluminescence was detected and visualized by 
applying a film for an exposure time between 30 s and 5 min. 
 
2.2.3.6 ELISA 
The principle of the enzyme-linked immunosorbent assay (ELISA) method is the antibody-based 
antigen detection. The antigen was either directly coated to the surface of a microtiter plate or 
captured using a capture antibody according to the sandwich-ELISA principle. Coating with both 
antigen and capture antibody required buffers free of other proteins. Thereafter, the 
supernatants were discarded. A blocking step using buffers with high concentrations of proteins 
unspecific for the employed antibodies saturated all protein binding sites of the well and avoided 
unspecific binding of antibodies in the following procedures. The supernatants were discarded. 
The antigen containing sample like cell culture supernatants or serum was diluted and 
transferred to the microtiter plate where target proteins were retained by the capture antibody. 
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Following several washes, the primary antibody was diluted in reagent diluent containing 
blocking protein and pipetted to the microtiter plate where it bound to the antigen. The 
secondary antibodies were either unlabeled or labeled with biotin or directly conjugated with a 
detection enzyme like alkaline phosphatase (AP) or peroxidase (POX). If the secondary 
antibody was not labeled, a tertiary antibody labeled with AP or POX was to be used. If the 
secondary antibody was biotinylated, it was detected using streptavidine conjugates with either 
AP or POX. The detection was based on enzymatic activity due to the incubation with proper 
substrates. Educts of those reactions were measured either at 450 nm (POX) or 405 nm (AP). 
Absolute quantification was performed employing a standard row of known antigen 
concentrations. 
 
2.2.3.6.1 ELISA for the detection of mouse serum IgG titers 
For the determination of IgG titers in the serum of mice 200 ng TNFR2 huIgG expressed in DS-
2 cells were coated in 100 µL PBS per well (96-well plate) at 4°C over night. As the mice were 
immunized with TNFR2ed V5His expressed from DS-2 cells, the detection of false-positive 
antibodies specific for V5His epitope could be avoided. The supernatants were discarded and a 
wash step of 3 washes with 300 µL TBS-T was performed. Now the wells were blocked using 
300 µL blocking solution at RT for 1 h. Following another wash step, log2 dilutions of the serum 
were prepared in PBS on an extra plate in duplicates and 100 µL per well were transferred to 
the ELISA plate. As negative control serum of naïve TNFR2-/- mice was used and analyzed 
identically. After an incubation time of 2 h at RT supernatants were removed and plates were 
washed as described above. The detection antibody anti-mouse-IgG-AP (γ-chain-specific) was 
diluted 1 to 5000 in reagent diluent and 100 µL per well were transferred to the ELISA plate. 
After an incubation time of 90 min at RT the plates were subjected to another wash step. One 
tablet 4-nitrophenyl phosphate disodium salt hexahydrate was diluted in 20 mL AP substrate 
buffer and mixed properly. 100 µL of the reagent were loaded in each well of the ELISA plate. 
The reactions were stopped by the transfer of 50 µL 2M NaOH to each well when sufficient 
yellow coloration of several wells was reached. OD values were detected at 405 nm using 
ELISA reader Emax instrument (Molecular Devices, München). 
  
 
2.2.3.6.2 ELISA for the detection of IgG from hybridoma supernatants 
ELISA was used to detect hybridoma clones that produced specific antibodies against TNFR2. 
The method used is as described in 2.2.3.6.1 with few alterations. The supernatants of the 
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hybridoma clones were taken and directly loaded onto the ELISA plate after washing off the 
blocking solution. The serum of the mouse at the day of the splenectomy was diluted 1 to 5000 
in PBS and served as positive control. Negative controls consisted of either pure medium or 
supernatants from hybridomas that were negatively tested for the respective antigen.  
 
2.2.3.6.3 ELISA for the detection of TNF, TNFR2, and IL-6 
Quantification of soluble forms of the receptor TNFR2 and the cytokines TNF and IL-6 in 
supernatants of cell cultures was performed using the respective ELISA Duo Sets from R&D 
Systems. Samples were used pure or diluted up to 1 to 25. The used ELISA kits are listed in 
2.1.5. The detection limits were 31.25 pg/mL for TNF ELISA, 15.625 pg/mL for TNFR2 ELISA, 
and 16.625 pg/mL for IL-6 ELISA. For the detection of TNF and TNFR2 in non-stimulated 
BMDC cultures during the differentiation into DC the supernatants were used pure and the 
detection limits were changed. Supernatants of stimulated cells and the respective non-
stimulated controls were diluted 1 to 5 for TNF ELISA, 1 to 10 for TNFR2 ELISA, and 1 to 25 for 
IL-6 ELISA. Consequently, the detection limits were 156.25 pg/mL for the TNF ELISA, 
156.25 pg/mL for the TNFR2 ELISA, and 390.625 pg/mL for the IL-6 ELISA. 
 
2.2.3.7 Detection of NO – Griess reagent 
Griess reagent A and B were used to detect NO concentrations in the supernatants of cells. 100 
µL of the supernatant were transferred to a 96-well plate. Standard for the Griess reagent was 
diluted 1 to 100 in medium to generate the highest standard concentration of 100 µg/mL 
followed by 7 log2 dilutions in medium. Medium was used as blank control. Standard and 
samples were measured in duplicates. Griess reagent A and B were equally mixed and 100 µL 
were transferred in each case to the 100 µL sample or standard. OD was measured at 540 nm 
employing ELISA reader Emax instrument (Molecular Devices, München). The detection limit of 
this method is 2 µM. 
 
2.2.3.8 Biological assay for TNF detection – L-929m cell kill 
L-929m cells can be used to detect very little amounts of biologically active and available soluble 
TNF as they die dose-dependent. 2 x 104 L-929m cells were seeded in 100 µL medium per 96-
well microtiter plate on day 0. On day 1 the supernatants were discarded. Soluble TNF standard 
was titrated in log2 dilutions and 100 µL were transferred to the cells in three technical 
replicates. Samples of unknown soluble TNF concentrations were loaded to the cells in the 
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same step and in three technical replicates. 100 µL 2 x actinomycin D containing medium 
(4 µg/mL) were added to the standards and samples. On day 2 the viability of the cells was 
detected via MTT-assay as described in 2.2.3.9. 
 
2.2.3.9 Viability assay using MTT 
MTT offers a method to detect the viability of cells as a value of mitochondrial activity. 
Mitochondrial reductase reduces yellow 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide to purple formazane proportionally to the mitochondrial activity. 2 x 104 cells of interest 
were seeded per well in 96-well microtiter plates and submitted to the respective biological test 
in 200 µL. On day 2 10 µL MTT stock solution (5 µg/mL) were added to every well and 
incubated for 4 h. By the addition of 70 µL of 20% SDS per well cells were lysed and formazane 
crystals were resolved within 24 h. OD values as an indicator for the viability of the cells were 
detected at 540 nm using ELISA reader Emax instrument (Molecular Devices, München). 
Biological assays were conducted with at least 2 technical replicates per sample. 
 
2.2.3.10 Purification of V5His-tagged proteins 
Proteins consisting of the extracellular domain (ed) of TNFR2 tagged with a V5His sequence for 
chromatographic purification (TNFR2ed-V5His) were expressed in DS-2 Schneider cells and 
purified using Chelating Sepharose Fast Flow (GE Healthcare GmbH). TNFR2ed-V5His 
expression in DS-2 cells was induced with 0.5 mM CuSO4 for 4 days in cell culture flasks. The 
supernatant was taken and centrifuged at 4°C and 3220 g for 10 min. The supernatants free of 
debris were filtered using sterile filters (bottletop). 50 mL aliquots of the supernatant were mixed 
with 110 µL chelating sepharose in a 50 mL reaction tube and shaked over night at 4°C. 
Following another centrifugation step (10 min, 4 °C, 3220 g), the pelleted chelating sepharose 
was recovered using Pasteur pipettes. The pellets were pooled and placed into a 
chromatographic tube. After 3 washes with wash buffer I another 3 washes with wash buffer II 
were performed. Every single wash was conducted using twice the volume of the chelating 
sepharose in the tube. After that proteins were eluated several times using 1.5 mL elution 
buffer. The fractions were collected. The single fractions were analyzed for protein content 
using SDS page, western blot analysis (mouse anti Penta-His mAB, second AB goat anti-
mouse IgG (whole molecule) POX), and coomassie staining. The fractions were dialyzed 
against PBS over night at 4°C and protein concentrations were determined according to 2.2.3.2. 
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Fractions were pooled. They were diluted to a concentration of 1 mg/mL and stored until use at 
-80°C. 
 
2.2.3.11 Purification of human IgG-tagged proteins 
Fusion proteins consisting of TNFR2ed and the Fc portion of human IgG-tagged for 
chromatographic purification (TNFR2ed-huIgG) were expressed in DS-2 Schneider cells and 
purified using HiTrap™ protein G HP columns (GE Healthcare GmbH). TNFR2ed-huIgG 
expression in DS-2 cells was induced with 0.5 mM CuSO4 for 4 days in cell culture flasks. The 
supernatants were taken and centrifuged for 10 min at 4°C and 3220 g. The sterile and debris-
free supernatants were purified by the Econo System from Bio-Rad. HiTrap™ Protein G HP 
Columns from GE Healthcare were equilibrated with PBS before the supernatants were loaded 
on the column with a flow rate of 0.8 mL / min without recirculation. Afterwards, the column was 
flushed with PBS until the OD280 nm of the UV detector reached the blank value of PBS. The 
bound proteins were eluated using elution buffer and a flow rate of 0.5 mL / min. Fractions of 1 
mL were collected and immediately neutralized using 20 - 40 µL neutralization buffer. The single 
fractions were analyzed for their protein content using SDS page, western blot analysis (Donkey 
anti-human IgG (H+L) horseradish peroxidase (HRP)), and coomassie staining. The fractions 
were dialyzed against PBS at 4°C over night and protein concentrations were determined 
according to 2.2.3.2. Fractions were pooled, diluted to a concentration of 1 mg/mL, and stored 
until use at -80°C. 
 
2.2.3.12 Purification of IgG from hybridoma supernatants 
The sterile and debris-free supernatant of the hybridoma clones were purified using the Econo 
System from Bio-Rad. HiTrap™ Protein G HP Columns from GE Healthcare were equilibrated 
with PBS before the supernatants were loaded to the column with a flow rate of 0.8 mL / min 
without recirculation. Afterwards, the column was flushed with PBS until the OD 280 nm of the UV 
detector reached the blank value of PBS. The bound proteins were eluated using elution buffer 
containing 0.1 M glycin (pH 3.1) and a flow rate of 0.5 mL / min. Fractions of 1 mL were 
collected and immediately neutralized using 20 - 40 µL neutralization buffer 1 M Tris-HCl 
(pH 11). 10 µL of the single eluates were analyzed for the antibody content using SDS page 
followed by coomassie staining. The eluates were pooled according to the size of their bands in 
high, medium, and low density antibody fractions. These pools were dialyzed against PBS at 
4°C over night before protein concentrations were determined employing BCA Protein Assay 
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Reagent from Pierce / Thermo Fisher Scientific. After sterile-filtration using a 0.2 µM filter the 
antibodies were stored at 4°C. 
 
2.3 Cell-biological methods 
2.3.1 Cell culture conditions 
The work with cell cultures was done using sterile reagents, pipettes, and vessels and 
employing the laminar flow sterile cabinet HERAsafe® KS (Thermo Fisher Scientific GmbH). 
Consumables, reagents, and cell lines are listed in 2.1.2, 2.1.3, and 2.1.6. The used cell lines 
and the specific medium are listed in 2.1.12. Mammalian cells were cultured at 37°C, 5% CO2, 
and 95% humidity. Cells were split 2 or 3 times per week at a ration of 1 to 10. DS-2 Schneider 
cells were grown at 28°C without additional CO2 supply.  
 
2.3.2 Cryo preservation of cells – freezing and thawing 
For longterm storage at -196°C 1 - 10 x 106 cells were pelleted and resuspended in 1 mL 1 x 
freezing medium. The suspension was transferred into cryotubes and subsequently gently 
deep-frozen. The cryotubes were carried over into the nitrogen tank (-196°C) for long-term 
storage after one week. 
In order to thaw those cells the cryotubes were warmed up in the water bath (37°C) until the last 
ice crystals had disappeared. The cells were gently resuspended using a 1 mL pipette and 
transferred into a 15 mL reaction tube containing 14 mL cold medium. Following a centrifugation 
step (300 g, 7 min, 4°C), the supernatant was discarded and the pellet was resuspended in 
medium. The cells were transferred into cell culture flasks and cultured under the conditions 
described in 2.3.1. 
 
2.3.3 Determination of cell numbers 
Cells in single cell suspensions were counted using a Neubauer hemocytometer. In brief, cells 
were mixed with at least 50% (v/v) trypan blue and 10 µL of the mixture were placed in the 
space between the hemocytometer and the cover slip. Cell concentrations in the sample were 
calculated according to Formula 4 . The mean value of four independent areas containing 50 to 
100 cells counted was calculated, in order to minimize the variance. 
 
II Materials and Methods 
 
48
factordilution
chambertheofvolume
chamberoneincountedcellsofnumbercellsofionConcentrat ×=  
 
Formula 4: Calculation of cell numbers using Neubauer hemocytometer 
 
2.3.4 Stimulation of cells 
Cells were stimulated by mixing the cells and the 2 x stimulation master mix in equal volumes. 
Double concentrated stimulation master mix was generated by mixing 1 µL of 1 mg/mL LPS 
(S. abortus equi), 20 µL of 20 µg/mL IFN-ү, and 4 mL medium resulting in 250 ng/mL LPS and 
100 ng/mL IFN-ү. Cells were seeded in medium and the same volume of 2 x stimulation solution 
was added to reach final concentrations of 125 ng/mL LPS and 50 ng/mL IFN-ү. Unless 
otherwise indicated, 2.5 x 105 cells were stimulated in 1 mL final volume. 
 
2.3.5 Generation of GM-CSF-containing supernatant 
X6310 (X63Ag8-653) GM-CSF cells were used as a source of a supernatant containing 
recombinant mouse GM-CSF and employed for BMDC generation as described in 2.4.6. The 
cells were split two times per week and the medium was collected from cultures that were 2 to 3 
days old. The supernatants were centrifuged (10 min, 3220 g, 4°C), filtered in order to 
guarantee sterility using a bottle top filter system, and stored at -20°C. The concentration of 
GM-CSF was determined to be 250 ng/mL (personal communication: Dr. Philip Groβ).  
 
2.3.6 Stable transfection of eukaryotic cells using DOTAP 
Dotap Liposomal Transfection Reagent was used for stable transfection of cells. Transfections 
were performed according to the protocol of the manufacturer. 
 
2.3.7 Stable retroviral transduction of eukaryotic cells 
Eukaryotic Wirbel cells deficient for both TNFR1 and TNFR2 were stably transduced with 
TNFR1ed-huFasid and TNFR2ed-huFasid constructs using retroviral vectors. The transfection 
was performed by PD Dr. W. Schneider according to the protocol employed previously 
(Schneider-Brachert, Tchikov et al. 2004). 
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2.3.8 Cytospin  
For the generation of cytospin preparations 5 x 104 cells (PEC) were resuspended in 100 µL 
medium and centrifuged at 700 rpm for 5 min using Shandon Cytospin 4 (ThermoScientific 
GmbH) onto glass slides. Those were dried for 1 h at RT before they were differentially stained 
as described in 2.3.9. 
 
2.3.9 Differential staining  
Diff-Quick Differential Staining Set was used to stain cells (PEC) coated to glass slides and air 
dried (see 2.3.8). Object slides were submerged into fixation solution (6 times), staining 
solution I (8 times), staining solution II (2 times), and finally rinsed employing ddH2O for 2 min. 
After air drying immersion oil was applied directly onto the preparation. The cellular composition 
of the PEC was determined using a transmitting light microscope. This method allowed the 
differentiation between macrophages, mast cells, lymphocytes as well as neutrophilic and 
eosinophilic granulocytes. 
 
2.3.10 Flow cytometry 
All flow cytometric analysis (fluorescence-activated cell sorting, FACS) were measured using 
BD LSR II. The employed antibodies and the respective fluorescence conjugates or 
biotinylations as well as the secondary streptavidine-fluorochrome conjugates are listed in 2.1.4. 
If not stated otherwise, all steps were conducted on ice. 1 x 106 cells were filtered through cell 
strainer and dispensed into FACS tubes. After a wash with FACS buffer and a centrifugation 
step (300 g, 7 min, 4°C) the supernatants were discarded and the tube opening was tabbed on 
paper tissue to dry drops. This procedure is called “wash step” in this work and can be 
performed with different buffers. After that cells were resuspended in 100 µL FACS buffer 
containing 10 µg/mL rat anti-mouse Fcγ-receptor II and III and incubated on ice for 20 min. 
Master mixes containing the antibodies for each staining were prepared in FACS buffer 
according to the recommended dilutions listed in 2.1.4. Cells were washed again with FACS 
buffer and pelleted as described above. Supernatants were removed and 100 µL of the master 
mix were transferred to the cells. The tubes were vortexed briefly and incubated on ice in the 
dark for 30 min. If utilizing biotinylated primary antibodies, streptavidine conjugated pacific 
orange second dye was diluted in FACS buffer as described in 2.1.4. Cells were pelleted and 
supernatants were drained. 100 µL of the second dye were given to the cells and staining took 
place for 30 min at 4°C and in the dark. After another wash and centrifugation step as described 
II Materials and Methods 
 
50
above cells were either resuspended in 200 µL FACS buffer and analyzed subsequently or 
treated with 200 µL 2% paraformaldehyde and, consequently, fixed. In the latter case samples 
were measured within 3 days. 
 
2.3.11 FACS Aria cell separation 
For FACS Aria cell separation cells were treated and stained in accordance with the protocol 
described in 2.3.10 with only a few alterations. For the staining up to 1 x 108 cells were 
incubated in 1 mL master mix containing double-concentrated antibodies or streptavidine-dye 
conjugates. Cells were kept under sterile conditions using a laminar flow cabinet. After complete 
staining cells were pelleted and resuspended to a concentration of 2 x 107 cells /mL in sort 
buffer. After sorting cells were collected in 15 mL reaction tubes containing 2 mL FCS or in 
sterile FACS tubes containing 1 mL FCS. The cell numbers per collection tube were counted by 
the instrument. Cells were washed twice with medium and used for the respective cellular 
assay. Re-analysis of the sorted cells were performed using the BD LSR II (BD Biosciences 
GmbH) instrument. Purities of the sorted cells were higher than 98%. 
 
2.3.12 MACS cell separation 
Magnetic cell separation (MACS) technology was used to purify CD11b+ cells from whole 
splenocyte preparations as described in 2.4.4. In some cases CD11c+ cells were depleted 
before using the same method. Throughout the separation procedure cells were kept on ice as 
far as possible. In brief, cells were counted, washed once in totally 50 mL with chilled MACS 
buffer (PBS, 0.5% (w/v) BSA, 2 mM EDTA) in a 50 mL reaction tube, and pelleted (300 g, 7 min, 
4°C). Supernatants were discarded and cells were resuspended in 80 µL MACS buffer per 107 
cells. 20 µL of the respective MACS micro beads coated with antibodies against CD11b or 
CD11c were added per 1 x 107 cells. The suspension was mixed and incubated at 4°C for 
15 min. Cells were washed and centrifuged once more as described before. Supernatants were 
removed and the cells were adjusted to a concentration of 2 x 108 cells / mL MACS buffer. 
Depending on the number of cells MS or LS separation columns were chosen. MS columns 
were designed to purify up to 107 labeled cells from total 2 x 108 cells, LS columns allow the 
yield of 108 cells from total 2 x 109 cells. LS columns were placed into the magnetic rack 
MidiMACS™ Separator that was arranged under the laminar flow cabinet and attached to the 
MACS® MultiStand. The columns were equilibrated by rinsing with 3 mL MACS buffer. The cell 
suspension was applied to the column and unlabeled cells passing through the matrix were 
II Materials and Methods 
 
51
collected. 3 wash steps, each comprising 3 mL MACS buffer, were performed. New buffer was 
only added when the reservoir was empty. Columns were removed and placed on a suitable 
collection tube (15 mL reaction tube). 5 mL MACS buffer were applied to the columns and cells 
were eluated by firmly pushing the plunger into the columns. When cells were used for further 
FACS cell sorting one MACS separation step reaching purities of about 70% of the target cells 
was sufficient to increase the concentration of the cells of interest. When cells were examined 
directly in a cellular assays the MACS purification was repeated. Therefore, the eluated cells 
were adjusted to 2 x 108 cells / mL MACS buffer and directly transferred to a new and already 
equilibrated MS separation column. The following steps were performed as described before for 
the first purification step. Thus, purities over 90% were reached. For the isolation of cells with 
LS separation columns adopted volumes of MACS buffer were used according to the manual of 
the manufacturer. The detailed cell separation procedures are described in the manufacturer’s 
manuals for CD11b microbeads, for CD11c microbeads, and for anti-APC microbeads. The 
latter system included staining of the cells with anti-CD11b APC as described in 2.3.11 before 
purification of the labeled cells with anti-APC microbeads. 
 
2.3.13 BrdU staining 
Bromodeoxyuridine (BrdU) uses nucleotide substitution to replace thymidine with uridine in the 
DNA structure of dividing cells both in vitro and in vivo (Gage 2000). The more proliferation 
takes place the more BrdU is integrated into the DNA and the stronger FITC fluorescence 
signals can be detected. 
BMDC differentiation cultures were supplemented with 0.01 mM BrdU (BD Biosciences GmbH) 
on day 9 and cultured for 24 h. The next day, cells were washed from the petri dish and stained 
with the respective antibodies according to the protocol described in 2.3.10 without fixation of 
the cells. BMDC were pelleted (300 g, 7 min, 4°C), supernatant was discarded, and cells were 
treated with 100 µL Cytofix / Cytoperm for 30 min at RT in the dark. Washing procedure was 
performed by the addition of 1 mL 1 x Perm / Wash solution followed by centrifugation of the 
cells (300 g, 7 min, 4°C), pouring off the supernatant, and tapping the tube opening on paper 
tissue to dry drops. In the next step, cells were resuspended in 100 µL PBS supplemented with 
1% BSA and 0.01% Triton-X 100 (Permeabilization reagent) and incubated for 10 min on ice in 
the dark. Following another washing procedure as described before cells were resuspended in 
100 µL Cytofix / Cytoperm and incubated at RT in the dark for 5 min. Washing procedure was 
performed and DNA in the cells was digested by administration of 100 µL PBS supplemented 
with 30 µg DNAse. After incubation for 1 h and after another washing procedure 2.5 µL anti-
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BrdU mAB FITC were added to the ~ 50 µL remaining buffer over the cells and mixed properly. 
Labeling of the BrdU took place at RT and in the dark within 20 min. After the last washing 
procedure cells were resuspended in 200 µL FACS buffer and either analyzed in the flow 
cytometer immediately or within 2 days.  
 
2.3.14 Combined Annexin V / 7-AAD staining 
Annexin V is a member of the annexin family of intracellular proteins that binds to 
phosphatidylserine (PS) in a calcium-dependent manner. Usually, PS is only found on the 
intracellular leaflet of the plasma membrane in healthy cells and would not be accessible for the 
staining. During early apoptosis membrane integrity is lost and PS translocates to the external 
leaflet. Thus, Alexa Fluor® 647 Annexin V allows to detect early apoptotic cells (Nurden, Bihour 
et al. 1993; Koopman, Reutelingsperger et al. 1994; Vermes, Haanen et al. 1995). 
7-AAD possesses a high DNA binding constant and is efficiently excluded by intact cells. 
Nevertheless, DNA of necrotic and dead cells is stained with this compound as cell membrane 
integrity is completely lost (Schmid, Krall et al. 1992).  
BMDC were washed from the petri dish and stained with the respective antibodies according to 
the protocol described in 2.3.10 without fixation of the cells. BMDC were pelleted (300 g, 7 min, 
4°C), supernatants were discarded, and the cells were washed once with 4 mL chilled PBS and 
a second time with 500 µL Annexin V binding buffer (BioLegend). 2.5 µL AlexaFluor® 647 
Annexin V and 5 µL 7-AAD were mixed with 9.25 µL Annexin V binding buffer. 100 µL of this 
staining solution were transferred to the cells and mixed followed by 20 min incubation time at 
RT in the dark. 200 µL Annexin V binding buffer were added to the FACS tubes and the cells 
were analyzed immediately using the flow cytometry device.  
 
2.4 Methods using mice 
Animal experimentation has been approved by the local authorities (AZ:54-2532.1-32/08 and 
AZ:54-2531.1-22/09). 
 
2.4.1 Housing of animals 
Mice were kept in a conventional barrier animal laboratory according to the german animal 
protection law. Mice were exposed to a 12 h light / dark rhythm and they were fed with species 
specific standard diet and tap water ad libitum.  
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2.4.2 Anesthesia 
Anesthetic was prepared freshly before use and under sterile conditions employing the laminar 
flow cabinet. It consisted of PBS supplemented with 0.75% ketaminehydrochloride and 0.14% 
xylazinehydrochloride. 4.62 mL PBS were mixed with 0.9 mL 5% ketaminehydrochloride and 
0.48 mL xylazinehydrochloride. The weight of the mouse to be anesthetized was measured and 
10 µL of the anesthetic were administrated i.p. per gram.  
 
2.4.3 Cecal ligation and puncture 
Sublethal CLP was used as animal model for sepsis. Mice were anesthetized with anesthetic 
and midline laparotomy was performed. The cecum was placed on a sterile pice of 
PARAFILM® M followed by ligation of the distal 30% of the appendix using lisle. After a singular 
cecum puncture with a 0.4 mm needle was performed the lesion in the abdominal wall was 
closed with metal clips. As the cecum is an endogenous source of bacterial contamination, 
perforation of the cecum results in bacterial peritonitis, which is followed by translocation of 
mixed enteric bacteria into the blood compartment causing sepsis and immunosuppression. 
Experiments were performed 48 h after surgery.  
 
2.4.4 Spleen cell preparation 
C57BL/6 mice were killed by cervical dislocation. Spleens were immediately taken and 
incubated on 900 µL chilled RPMI 1640 medium without any supplementation. The spleens 
were gently disrupted and 100 µL of collagenase D were added and mixed. After 15 min of 
incubation at 37°C in the incubator the spleen cells were isolated by pressing the organ through 
a cellular strainer (40 µm) into a 50 mL reaction tube using a syringe plunger. The strainer and 
the plunger were flushed well with medium, in order to maximize the cellular yield. Cells were 
washed in 50 mL medium and pelleted (300 g, 7 min, 4°C). The supernatant was discarded and 
the pellet was resolved in 5 mL erythrocyte lysis buffer and incubated at RT for 10 min. Cells 
were washed with 45 mL fresh medium followed by another centrifugation step as described 
above. Supernatants were removed and splenocytes were resuspended in 10 mL medium. The 
suspension was filtered using a cellular strainer (40 µm) and cell numbers were determined 
employing trypan blue solution and the protocol described in 2.3.3. Flow cytometric analysis, 
MACS or SORT purifications as well as stimulation experiments were performed in this work 
with splenocytes obtained with this method. 
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2.4.5 Peritoneal exudate cell preparation 
Immigration of peritoneal exudate cells (PEC) was induced by injecting 1 mL PBS i.p. 16 h 
before the peritoneal cavity was washed out with 10 mL of cold medium and PEC were 
transferred into 15 mL polypropylene tubes. The cells were pelleted, washed once with cold 
medium, and counted using Tuerk solution. When used as feeder cells, 2 x 104 cells per well 
(96-well plate) were seeded in 100 µL medium. For stimulation experiments 2.5 x 105 cells were 
transferred in 500 µL medium to a 48 well microtiter plate and immediately supplemented with 
500 µL medium for non-stimulated controls or 500 µL 2 x stimulation master mix. Cells were 
either used for RNA isolation after the indicated time or supernatants were collected after 48 h 
for ELISA or NO detection. 
 
2.4.6 Bone marrow-derived dendritic cell generation 
Bone marrow-derived denritic cells (BMDC) were generated according to the protocol of 
Manfred Lutz (Lutz, Kukutsch et al. 1999). In brief, mice were killed, femura and tibiae were 
dissected, and remaining tissue was removed. The following steps were done under the laminar 
airflow cabinet. The bones were sterilized by incubation in 70% EtOH for 1 min and transferred 
into PBS. After that both ends of the intact bones were cut by scissors and bone marrow was 
flushed into a 50 mL Falcon tube using 2 mL PBS and a 0.45 mm syringe. Clots within the bone 
marrow suspension were disrupted by pipetting up and down several times. The cells were 
washed once with medium, resuspended in 10 mL medium containing 10% GM-CSF 
supernatant from X6310 cells (see 2.3.5) per mouse, and filtered with a cellstrainer. Cells were 
counted using Tuerck solution. 2 x 106 cells were transferred into a 100 mm bacteriological 
petri dish and the culture vessel was filled up with 10 mL with GM-CSF-containing medium. The 
cell differentiation into BMDC took place in the incubator. 10 mL GM-CSF-containing medium 
were added on day 3. 10 mL of the medium were removed from the cultures both on day 6 and 
on day 8. The cells within this medium were pelleted at 300 g at 4°C for 10 min. After discarding 
the supernatant the pellet was resuspended in 10 mL fresh GM-CSF-containing medium and 
transferred back to the BMDC culture. For the experiment the BMDC from one petri dish were 
gently resuspended in the used medium by pipetting up and down several times. The cell 
suspension was transferred to a 50 mL Falcon tube and washed once with medium without 
GM-CSF. Cells were counted using dilutions with trypan blue solution. Flow cytometry analyses 
were performed with non-stimulated cells immediately after determining the yield. For 
stimulation experiments 2.5 x 105 cells were transferred in 500 µL medium to a 48 well microtiter 
plate and immediately supplemented with 500 µL medium for non-stimulated controls or 500 µL 
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2 x stimulation master mix. Stimulation occurred in medium without GM-CSF. Cells were either 
used for RNA isolation after the indicated time or supernatants were collected after 48 h for 
ELISA or NO detection. 
For mixed BMDC cultures aliquots of bone marrow cells from mice different in their congenic 
marker were mixed at equal parts after the preparation. 2 x 106 cells from the mixture were 
employed in the BMDC generation protocol described above. 
 
2.4.7 Generation of bone marrow chimeric mice 
The generation and analysis of cells from bone marrow chimeric mice is the means of choice to 
examine whether hematopoietic or stromal cells are causing certain phenotypes. In this work 
four different combinations of bone marrow chimeric mice were generated. Bone marrow donor 
and bone marrow recipients were C57BL/6 mice differing in their CD45 congenic marker. 
CD45.2 wt as well as CD45.2 TNFR2-/- bm were transplanted into CD45.1 wt mice. As a control 
CD45.1 wt bone marrow was transplanted into CD45.2 wt and CD45.2 TNFR2-/- recipients. Host 
mice were irradiated 2 times with 5 gray from a linear accelerator, in order to destroy their 
hematopoietic system. Bone marrow cells from donor mice were isolated. Briefly, femura and 
tibiae were dissected and remaining tissue was removed. Following steps were done under the 
laminar airflow cabinet. The bones were sterilized by incubation in 70% EtOH for 1 min and 
transferred to PBS. After that both ends of the intact bones were cut by scissors and bone 
marrow was flushed using PBS and a 0.45 mm syringe into a 50 mL Falcon tube. Clots within 
the bone marrow suspension were disrupted by pipetting up and down several times. The bone 
marrow cells are washed twice with PBS, resuspended in 10 mL PBS, and counted. After 
irradiation host mice were anesthetized and 5 x 106 bone marrow cells were injected i.v.. After 3 
weeks reconstitution was checked using venous blood samples from every mouse. 90 µL blood 
were mixed with 10µl 50 mM EDTA (pH8). Blood was washed once with FACS buffer and 
stained in 75 µL for the congenic markers CD45.1 and CD45.1 as well as for the T cell marker 
CD3 and the B cell marker B220. Erythrocytes were lysed by addition of 1mL 1 x BD FACS™ 
Lysis Solution (diluted in ddH2O), thoroughly mixed, and incubated for 10 min at RT. Remaining 
cells were washed once with FACS buffer, pelleted (300 g, 7 min, 4°C), and fixed using 2% 
paraformaldehyde before cell composition was analyzed using flow cytometry. 
After 8 weeks of reconstitution the mice with the highest degree of reconstitution were chosen 
for the experiments. PEC and BMDC were generated as described in 2.4.5 and 2.4.6. The cells 
were stimulated with LPS and IFN-ү (100ng/mL, 50ng/mL) for 48 h, in order to detect NO, 
cytokines, and soluble TNFR2. In addition, BMDC were investigated for the expression of the 
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activation markers CD80, CD86, and MHCII and PEC were checked for their composition using 
cytospin and Diff-Quick Differential Staining Set (Dade Behring GmbH). Furthermore, 
reconstitution and cell distribution were recorded using spleen cells as described in 2.4.4. 
Figure 6 illustrates the 4 groups of bm chimeric mice differing in the congenic markers of either 
the donor or the recipient bone marrow. 
 
 
Figure 6: Generation of bm chimeric mice 
 
 
2.5 Monoclonal anti-TNFR2 antibody production 
2.5.1 Species 
Three female TNFR2-/- mice were used for vaccination and termed (0), (L) and (R). 
 
2.5.2 Vaccination 
The immunization strategy is illustrated in Table 10. In brief, 100 µg TNFR2ed-V5His protein 
were administrated 3 times i.p. using the adjuvants Complete Freund’s adjuvans (CFA) or 
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Incomplete Freund’s adjuvans (IFA) and PBS. The spleen cells were isolated on day 44 about 
60 h after the last vaccination as described in 2.4.4 using medium without FCS and without 
performing the erythrocyte lysing step. Cells of spleen (R) were used in the fusion of Diana 
Minge. Splenocytes of mice (0) and (L) were divided in two equal aliquots and stored at -80°C. 
The fusion described in this work was performed using one aliquot of the splenocytes from 
mouse (0). Monoclonal antibodies obtained from both fusions were tested for their functional 
properties.  
 
Table 10: Vaccination scheme 
ime [d] Protein [1 mg/mL, PBS] V Protein [µL] Adjuvant V Adjuvant [µL] 
0 TNFR2ed-V5His  100 CFA 100 
21 TNFR2ed-V5His  100 IFA 100 
42 TNFR2ed-V5His  100 PBS 100 
 
2.5.3 Fusion 
The cell line used for the fusion with B cells from the immunized mice was the mouse myeloma 
cell line SP2/0-Ag14 which is a fusion cell line of a myeloma cell line from Balb/C spleen cells 
and the myeloma cell line P3X63AAG8 and provides reliable fusion properties using 
polyethylene glycol 1500 (PEG 1500) (Shulman, Wilde et al. 1978). Medium without FCS was 
used to wash the splenocytes prepared as described in 2.4.4 and the SP2/0-Ag14 cells before 
mixing both cell types in a ratio of 3 spleen cells to 1 myeloma cell (3.5 x 107 splenocytes and 
1.17 x 107 myeloma cells) in a 15 mL Falcon tube. The mixed cells were pelleted for 5 min with 
300 g at 4°C and the supernatant was discarded. By an additional short centrifugation step the 
cell pellet was completely dried. The cell pellet was dissolved by snipping the tube with the 
fingers. The cells were warmed up for 1 min at 37°C in the water bath before dropwise addition 
of 1 mL 37°C prewarmed PEG 1500 within 1 minute. Continuously rolling of the tube in this step 
ensured adequate interaction of PEG 1500 with the cells. After another 1 min of incubation in 
the water bath at 37°C 10 mL prewarmed HAT medium were added dropwise and within 5 min 
to the cells while continuously rolling of the Falcon tube. The cell suspension was diluted to 
200 mL with HAT medium. 100 µL were transferred to each well of 20 96-well microtiter plates 
coated with peritoneal exudate cells the day before (see 2.4.5) resulting in a total volume of 
200 µL in each well. As a control untreated Sp2/0-Ag14 cells were incubated in 200 µL HAT 
medium, in order to guarantee the exclusive survival and expansion of hybridomas from 
splenocytes and Sp2/0-Ag14 cells (Foung, Sasaki et al. 1982). The first hybridoma clones were 
detected after 1 week and the supernatants of those wells were tested for the specific antibody 
production after 10 days. After 2 weeks the cultured medium was changed stepwise from HAT 
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medium to HT medium and finally to normal medium. In parallel, the clones were expanded to 
larger cell culture vessels and finally grown in cell flasks. 
 
2.5.4 Detection of positive hybridoma clones 
In order to detect hybridoma clones that produce antibodies against TNFR2, recombinant 
TNFR2ed-huIgG protein was used. This ensured the exclusive detection of antibodies against 
TNFR2ed and not against the V5His tag of the recombinant TNFR2ed protein that was used to 
immunize the mice. ELISA plates were coated with 200 ng TNFR2ed-huIgG per 100 µL PBS 
and well at 4°C over night. The plates were washed 3 times using TBS-T and blocked with 
300 µL skimmed milk powder in TBS 10% (m/v) over night at 4°C. After 3 washes with TBS-T 
100 µL supernatants of the single hybridoma clones were transferred to the ELISA plate. As 
negative control medium was pipetted into a few wells of the ELISA plate. The serum of the 
mouse taken at the day of the splenectomy was diluted 1 to 5000 with PBS and 100 µL of this 
solution served as positive control on every ELISA plate. The samples and controls were 
incubated over night at 4°C before performing 3 more wash steps with TBS-T. Anti-mouse IgG 
ү-chain specific AP conjugated antibody was diluted 1 to 5000 in TBS containing 0.5% (m/v) 
skimmed milk powder and 100 µL were transferred to every well and incubated at room 
temperature for 2 h. The plate was washed 3 times with TBS-T before loading with 100 µL AP 
reaction solution (see 2.1.6) and incubation for 5 to 15 min. The reaction was stopped by the 
addition of 50 µL 2 M NaOH to the wells. OD was measured at 450 nm. Positivity was defined to 
generate an OD value that exceeds the OD value of the background at least 3 times the 
standard deviation of the OD value of the background. Positive clones were to be monoclonal 
and 3 times sucessfully tested for their positivity. 
 
2.5.5 Subcloning 
Hybridoma clones that produced antibodies against TNFR2ed-V5His were subcloned, in order 
to generate monoclonal cell lines. Cells were removed from the well, counted, and adjusted to a 
concentration of 10 cells per mL in medium. All 96-wells of a microtiter plate were filled with 
100 µL of the cell suspension, in order to achieve a theoretical distribution of 1 cell per well and, 
consequently, to assure monoclonality. The growing clones were checked for antibody 
production. If all clones were positive, the most potent one was chosen, expanded, and defined 
to be monoclonal. If not all clones were positive, another subcloning procedure was to be 
performed using the most potent clone of the first plate. 
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2.5.6 Generation of supernatants 
Positive clones were expanded and finally transferred into 175 cm² cell culture flasks containing 
50 mL medium. Cells were grown in high density. After 4 days the cell suspension was removed 
from the flasks, the cells were pelleted in 50 mL Falcon tubes at 4 °C and 300 g for 10 min, and 
the supernatant was sterile-filtered and stored at 4°C. The cells were resuspended in 150 mL 
fresh medium and transferred into 3 new 175 cm² cell culture flasks. The procedure was 
repeated several times until more than 1 L supernatant was collected. 
 
2.5.7 Protein G purification of monoclonal antibodies 
Isolation and purification of monoclonal antibodies were performed as described in 2.2.3.12. 
 
2.5.8 Functional characterization of monoclonal anti-TNFR2 antibody 
Mouse anti-mouse TNFR2 mAB were either tested using the supernatant of the monoclonal 
hybridoma cultures or the protein G purified mAB dialysed against PBS and sterilized by 
filtration with 0.2 µm filters. 
 
2.5.8.1 Determination of the IgG isotypes 
IsoGold Rapid Mouse-Monoclonal Isotyping Kit™ (BioAssays) was used to determine the 
isotype subclasses of the newly generated mouse anti-mouse TNFR2 mAB.  
 
2.5.8.2 ELISA for anti TNFR2 antibody characterization 
ELISA tests were performed as described in 2.5.4. 
 
2.5.8.3 Western blot for anti-TNFR2 antibody characterization 
In order to characterize the newly generated mouse anti-mouse TNFR2 mAB, Western blot 
analyzes were performed. Therefore, SDS-PAGE and Western blot were performed with 
TNFR2ed-huIgG, protein standard, and 1 µg/mL TNFR2ed-V5His as described in 2.2.3.3 and 
2.2.3.5. Several replicates of these blots were prepared and incubated with 10 mL of the 
different hybridoma cell culture supernatants. The controls were blots incubated exclusively with 
donkey anti-human IgG (H+L) HRP or mouse anti-V5 mAB HRP. As secondary antibody for the 
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hybridoma supernatants goat anti-mouse IgG (whole molecule) POX was employed. The 
experimental setup of one representative Western blot setting is illustrated in Figure 7. 
 
Figure 7: Mouse anti-mouse TNFR2 mAB Western blot test 
 
2.5.8.4 Flow cytometry for anti-TNFR2 antibody characterization 
The performances of anti-TNFR2 antibodies in FACS applications were investigated using 
transfected CHO cells overexpressing mTNFR2 (whole molecule). CHO wt and CHO TNFR2tg 
cells were trypsinized and removed from the culture flask. 1 - 5 x 105 cells were transferred into 
FACS tubes and washed once with FACS buffer. Cells were shortly vortexed with 500 µL 
supernatant from the different clones and incubated for 30 min at 4°C. After one wash step with 
FACS buffer FITC conjugated anti-mouse Ig antibody was adequately diluted and 100 µL were 
transferred to the cells. The FACS tubes were mixed and incubated at 4°C for 30 min. 
Non-stained cells and cells stained with an available anti-mouse TNFR2 mAB conjugated with 
AF647 were used as controls. After another wash step cells were fixed with 2% 
paraformaldehyde and analyzed using flow cytometry. 
 
2.5.8.5 TNFR2 activation or inhibition assay for anti-TNFR2 mAB 
In order to characterize the functional properties of the newly generated mouse anti-mouse 
TNFR2 mAB (see 2.5), fusion proteins comprising mouse TNFR2 ectracellular domain and 
human FAS intracellular domain (TNFR2ed-huFasid) were cloned and transduced into Wirbel 
wt cells using retroviral techniques (PD Dr. Wulf Schneider). In the case of agonistic antibodies 
for TNFR2, transduced cells should die due to the induction of apoptosis. Vice versa, when 
treated with possibly antagonistic antibodies for TNFR2, TNFR2ed-huFasid transduced cells 
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should be protected from apoptosis even when treated with soluble mouse TNF (Peprotech 
GmbH) or membrane-bound TNF. These methods were used before by Dr. Anja Krippner-
Heidenreich in the human system for huTNFR1 and huTNFR2 (Krippner-Heidenreich, Tubing et 
al. 2002). As TNFR1 and TNFR2 are highly homologue receptors, the mentioned tests were 
performed in parallel with TNFR1ed-huFasid transduced cells. Thus, cross-reactivity can be 
examined. Figure 8 illustrates the principle of the test. 
 
 
Figure 8: Agonistic / antagonistic mouse anti-mouse TNFR2 mAB test 
 
Wirbel cells transduced with TNFR2ed-huFasid cells were always tested with the control wt cells 
and TNFR1ed-huFasid transduced cells. 2 x 104 wt cells were seeded in 100 µL medium in the 
wells of a 96-well plate on day 0. The next day, the supernatants were removed and the tests 
for either agonistic or antagonistic function were performed. All 3 types of cells were tested in 
triplicates. In order to detect agonistic properties, the purified antibodies were adjusted to 
50 µg/mL with medium. 100 µl were transferred to the 3 types of cells. Subsequently, 100 µL of 
4 µg/mL actinomycin D containing medium were added and cells were incubated for 24 h in the 
incubator. In order to detect antagonistic properties, cells were treated with 100 µL 50 µg/mL 
purified anitibodies diluted in medium for 6 h. Afterwards, 100 µL medium containing 4 µg/mL 
actinomycin D and either supplemented with 50 ng/mL mTNF (Peprotech GmbH) or 100 ng/mL 
TNC-mTNF (Prof. H. Wajant) were added and cells were incubated for 24 h. TNC-mTNF is a 
mutant form of TNF that has been designed for exclusive activation of TNFR2. In both types of 
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assays controls were performed with cells without antibody treatment. These control cells were 
incubated either with TNF or not. MTT assays as described in 2.2.3.9 were used to calculate the 
viability of the cells 24 h after the different treatments with the antibodies. 
 
2.6 Statistical calculations 
Experimental results are shown as mean values and associated standard deviations. The 
statistical analyzes were based on Student´s t-test. p-values < 0.05 were accepted as 
statistically significant. 
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3 Results 
3.1 iNOS mRNA expression and Nitric Oxide (NO) production of 
TNFR2-/- myeloid cells 
The overproduction of NO can be harmful for septic patients. Therefore, iNOS mRNA 
expression and NO production were investigated in different myeloid cells. 
 
3.1.1 CD11b+ CD11c- splenocytes after CLP 
In order to get information about the relative proportion of NO producing cells in the spleens of 
CLP-treated mice, the frequency of CD11b+ CD11c- cells as the main source of NO was 
measured in the spleens of mice at different time points after CLP. No significant differences in 
the kinetic of CD11b+ CD11c- relative splenocyte proportions after CLP comparing wildtype and 
TNFR2-/- mice could be detected. Data are shown in Figure 9. Percentages of CD11b+ CD11c- 
cells were slightly increased starting on day 4 until day 11. 
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Figure 9: CD11b+ CD11c- splenocytes after CLP – kinetic 
Wildtype and TNFR2-/- were subjected to CLP. At the indicated time points mice were killed by cervical 
dislocation and spleen cells were isolated. The cells were analyzed for the content of CD11b+ CD11c- 
myeloid cells using flow cytometry. Shown are the mean ± SD of 4 to 5 individual animals per group and 
time point. 
 
As the absolute numbers of CD11b+ CD11c- splenocytes were not changed, the capacity of 
these cells to express iNOS mRNA and to produce NO was analyzed next. Figure 10 shows 
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that CLP was essential for iNOS mRNA expression and NO production and that both 
parameters were impaired in CD11b+ CD11c- splenocytes of TNFR2-/- mice after CLP. 
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Figure 10: CLP is required to detect significant amounts of iNOS mRNA expression and NO 
production 
Wt and TNFR2-/- mice were left untreated or subjected to CLP. After 2 days spleen cells were isolated 
and pooled. Following CD11c+ MACS depletion, CD11b+ cells were isolated using MACS technology. The 
purification process was repeated, in order to increase the purity. The cells were seeded at a 
concentration of 2.5 x 105 / 48 well microtiter plate and stimulated with 125 ng/mL LPS and 50 ng/mL 
IFN-ү in 1 mL for 6 h (mRNA expression analysis, A) or for 48 h (NO detection, B). The data originate 
from one of three representative experiments, shown are the mean ± SD of 3 technical replicates per 
group. 
 
Figure 11 shows the iNOS mRNA expression and NO production data based on 
CD11b+ CD11c- spleen cells from mice 2 days after CLP. TNFR2-/- CD11b+ CD11c- splenocytes 
showed reduced iNOS mRNA expression and NO production. Figure 11 contains data from 
several independent experiments. 
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Figure 11: iNOS mRNA expression and NO production of CD11b+ CD11c- splenocytes 2 days after 
CLP 
Wt and TNFR2-/- splenocytes from up to 3 CLP-treated mice were isolated and pooled. Following CD11c+ 
MACS depletion, CD11b+ cells were isolated using MACS technology. The purification process was 
repeated, in order to increase the purity. The cells were seeded at a concentration of 2.5 x 105 / 48 well 
microtiter plate and stimulated with 125 ng/mL LPS and 50 ng/mL IFN-ү in 1 mL for 6 h (mRNA 
expression analysis, A) or for 48 h (NO detection, B). Every pair of dots represents one independent 
experiment. 
 
3.1.2 Peritoneal exudate cells (PEC) 
As the differences between TNFR2-/- and wt CD11b+ CD11c- spleen cells only were apparent in 
CLP-treated mice, it was next examined whether myeloid cells of naïve TNFR2-/- mice show this 
phenotype, too. Therefore, wt and TNFR2-/- PEC from naïve mice were tested for the iNOS 
mRNA expression and NO production. As shown in Figure 12, TNFR2-/- PEC were 
characterized by reduced iNOS mRNA expression and significantly reduced NO production. 
 
 
 
 
 
 
 
 
 
 
 
CD11b+ CD11c- splenocytes iNOS mRNA expression
C57BL/6 CLP TNFR2-/- CLP
0.000
0.005
0.010
0.015
re
la
tiv
e 
m
RN
A 
le
ve
ls
to
β -A
ct
in
CD11b+ CD11c- splenocytes NO production
C57BL/6 CLP TNFR2-/- CLP
0
10
20
30
40
N
itr
ite
 [µ
M
]
A B
III Results 
 
66
. 
 
 
 
 
 
 
 
Figure 12: iNOS mRNA expression and NO production of PEC  
WT and TNFR2-/- PEC were isolated from the peritoneal cavities of up to 3 pooled naïve mice per group. 
The cells were seeded at a concentration of 2.5 x 105 / 48 well microtiter plate and stimulated with 125 
ng/mL LPS and 50 ng/mL IFN-ү in 1 mL for 6 h (mRNA expression analysis, A) or for 48 h (NO detection, 
B). Every pair of dots represents one independent experiment. 
 
3.1.3 Bone marrow-derived dendritic cells (BMDC) 
Another source of myeloid cells are BMDC differentiation cultures. Therefore, it was addressed 
next whether the deficient iNOS mRNA expression and NO production of cells from TNFR2-/- 
mice could also be detected in BMDC. Figure 13 shows that BMDC from TNFR2-/- mice 
expressed reduced iNOS mRNA levels and produced significantly reduced concentrations of 
NO. 
   
   
 
 
 
 
 
     
Figure 13: iNOS mRNA expression and NO production in BMDC 
Wt and TNFR2-/- BMDC were generated according to the protocol. On day 8 cells were flushed from the 
petri dishes and seeded at a concentration of 2.5 x 105 / 48 well microtiter plate. BMDC were stimulated 
with 125 ng/mL LPS and 50 ng/mL IFN-ү in 1 mL for 6 h (mRNA expression analysis, A) or for 48 h (NO 
detection, B). Every pair of dots represents one independent experiment used for iNOS mRNA 
expression analysis. Data for NO production were obtained from 3 individual mice per group. The lines 
connect the mean values of one experiment. 
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3.2 The role of MDSC for the TNFR2-/- phenotype in myeloid cells  
MDSC play a critical role in the modulation and suppression of the proliferation and effector 
functions of T cells. MDSC from TNFR2-/- mice could play an important role for the protection of 
these mice from the harmful effects of secondary infections in a phase of immunosuppression 
after CLP treatment. 
 
3.2.1 MDSC in CD11b+ splenocytes 
3.2.1.1 Relative proportion of MDSC 
In order to find out whether altered percentages of MDSC could cause the protection of 
TNFR2-/- during sepsis, the relative proportions of MDSC (CD11b+ Ly6C+ Ly6G-) were 
determined in the spleens of TNFR2-/- mice compared to wt control animals during the course of 
CLP-induced sepsis. No significant differences were seen comparing the splenocytes of 
TNFR2-/- and wt mice neither in naïve mice nor during sepsis as illustrated in Figure 14. There 
was a cell loss 6 h after CLP in both mouse strains. The initial proportion of MDSC among 
CD11b+ splenocytes was recovered after one day and strongly increased on day 11.  
MDSC content in the spleen - kinetic after CLP
0
0.5
1
1.5
2
naïve 6h 10h 1d 2d 4d 6d 11d
Time after CLP
M
D
SC
 
[%
 li
ve
 c
el
ls
] C57BL/6 
TNFR2-/- 
 
Figure 14: MDSC proportion of the live cells in the spleen – kinetic after CLP 
MDSC (CD11b+ Ly6C+ Ly6G-) contents in spleen cells from naïve or CLP-treated wt and TNFR2-/- mice 
were compared using flow cytometry. Shown are the mean ± SD from 3 to 5 animals per group and time 
point.  
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3.2.1.2 Nitric Oxide (NO) production of MDSC 
Having shown that the percentages of MDSC in the spleens of CLP-treated TNFR2-/- mice were 
not impaired during the course of CLP induced sepsis, we next addressed the question whether 
the effector functions of these cells were altered. Therefore, the NO production and iNOS 
mRNA expression were measured in sorted subpopulations of CD11b+ splenocytes from naïve 
or CLP-treated wt and TNFR2-/- mice 2 days after surgery. The sorting strategy is explained in 
Figure 15. Results are illustrated in Figure 16. The importance of CLP for proper iNOS mRNA 
expression and NO production shown in 3.1.1 could be reproduced. MDSC 
(CD11b+ Ly6C+ Ly6G-) and PMN (CD11b+ Ly6Cint Ly6G+) cells of wildtype mice express high 
amounts of iNOS mRNA and MDSC produce significant amounts of NO. 
 
 
Figure 15: Sorting strategy for MDSC and other CD11b+ populations in splenocytes 
Mice were subjected to CLP or left naïve. 2 days after CLP splenocytes were isolated and purified using 
CD11b+ MACS. Subsequently, CD11b+ cells were subdivided into CD11c+, PMN (Ly6Cint Ly6G+), MDSC 
(Ly6C+ Ly6G-) (Zhu, Bando et al. 2007), and Ly6C- Ly6G- subpopulations employing FACS Aria cell sort. 
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Figure 16: iNOS mRNA expression and NO production in Ly6G/C subpopulations of CD11b+ 
splenocytes of naïve mice and 2 days after CLP 
Mice were subjected to CLP or left naïve. 2 days after CLP splenocytes were isolated and purified using 
CD11b+ MACS. Subsequently, CD11b+ cells were subdivided into CD11c+, PMN (Ly6Cint Ly6G+), MDSC 
(Ly6C+ Ly6G-), and Ly6C- Ly6G- subpopulations employing FACS Aria cell sort. 1 x 105 cells were 
stimulated in 200 µL with 125 ng/mL LPS and 50 ng/mL IFN-ү. After 6 h cells were used for iNOS mRNA 
expression analysis (A). Shown are the mean ± SD from 3 technical replicates of one sample. After 72 h 
supernatants were used for NO detection (B). Shown are the mean ± SD from 3 to 8 different cultures. 
The data originated from one representative experiment out of two. 
 
3.2.2 MDSC population in bone marrow-derived dendritic cells (BMDC) 
3.2.3 CD11b+ cells and MDSC in bone marrow 
The next aim was to investigate the frequencies of MDSC (CD11b+ Ly6C+ Ly6G-) and PMN 
(CD11b+ Ly6Cint Ly6G+) in the bone marrow of wt and TNFR2-/- mice, in order to characterize 
this source of progenitor cells for BMDC differentiation cultures. The results are shown in Figure 
17. The relative proportion of CD11b+ cells in TNFR2-/- bone marrow was significantly increased. 
The percentages of MDSC (CD11b+ Ly6C+ Ly6G-) and PMN (CD11b+ Ly6Cint Ly6G+) in TNFR2-/- 
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bone marrow were significantly increased compared to wildtype control bone marrow. The 
relative proportions of MDSC (CD11b+ Ly6C+ Ly6G-) and PMN (CD11b+ Ly6Cint Ly6G+) in 
TNFR2-/- bone marrow were not impaired when referred to the CD11b+ bone marrow cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Expression of CD11b, Ly6C, and Ly6G in wildtype and TNFR2-/- bone marrow 
Bone marrow cells from wildtype and TNFR2-/- mice were isolated and stained for CD11b, Ly6C, and 
Ly6G. The cells were analyzed using flow cytometry. (A) shows the percentages of CD11b+ cells of live 
cells. The percentages of MDSC (CD11b+ Ly6C+ Ly6G-) and PMN (CD11b+ Ly6Cint Ly6G+) of live cells 
are illustrated in (B) and (C). The percentages of MDSC (CD11b+ Ly6C+ Ly6G-) and PMN (CD11b+ 
Ly6Cint Ly6G+) of CD11b+ cells are illustrated in (D) and (E). Shown are the single values and the mean 
(horizontal line) of four different mice per group. 
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3.2.3.1 Differentiation and development of BMDC 
In order to characterize the development of BMDC, differentiation cultures from wildtype and 
TNFR2-/- mice were examined for the expression of CD11b and CD11c at different time points. 
As shown in Figure 18, the expression of CD11c started to increase on day 6 and reached the 
plateau on day 8 with a relative proportion of 90%. The percentages of CD11b+ CD11c- BMDC 
decreased reciprocally, indicating that almost 100% of the cells in BMDC cultures express 
CD11b and belong to the myeloid cell lineage. No difference between wt and TNFR2-/- BMDC 
differentiation cultures could be detected. 
 
 
 
 
 
 
 
 
 
 
Figure 18: CD11b and CD11c distribution in BMDC – kinetics 
The percentages of BMDC expressing the markers CD11b and CD11c were analyzed employing flow 
cytometry on different time points during the differentiation into dendritic cells. The percentages of 
CD11b+ CD11c- cells are analyzed in (A) whereas the relative proportion of CD11b+ CD11c+ cells is 
visualized in (B). Shown are the single values and the mean (horizontal line) of four different BMDC 
cultures per group representing individual mice. 
 
3.2.3.2 Frequency of MDSC 
The next aim was to characterize the relative proportions of cells expressing the MDSC markers 
CD11b+, Ly6C+, and Ly6G- in BMDC cultures at different time points. Throughout the 
differentiation into BMDC TNFR2-/- cultures contained significantly reduced percentages of 
MDSC. Data are shown in Figure 19.  
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Figure 19: MDSC contents in BMDC cultures - kinetics 
The percentages of BMDC expressing the MDSC markers CD11b+, Ly6C+, and Ly6G- were analyzed 
employing flow cytometry at different time points during the differentiation into dendritic cells. Shown are 
the single values and the mean (horizontal line) of four different BMDC cultures per group representing 
individual mice. 
 
3.2.3.3 Nitric Oxide (NO) production of MDSC 
Having shown that BMDC differentiation cultures contain high amounts of MDSC on day 4, it 
was next investigated whether these cells express iNOS mRNA and produce NO and if there 
are differences between MDSC and PMN. BMDC subpopulations expressing the markers for 
MDSC (CD11b+ Ly6C+ Ly6G-) and PMN (CD11b+ Ly6Cint Ly6G+) were separated on day 4 using 
FACS aria cell sort according to the sorting strategy explained in Figure 20.  
 
Figure 20: Sorting strategy for MDSC and PMN in BMDC cultures on day 4  
BMDC were removed from the petri dish cultures on day 4 and stained for CD11b, CD11c, Ly6C, and 
Ly6G. The CD11b+ population was separated into PMN (Ly6Cint Ly6G+) and MDSC (Ly6C+ Ly6G-) 
employing FACS Aria cell sort (Zhu, Bando et al. 2007).  
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The iNOS mRNA expression and the NO production capacity of these different cell populations 
were measured. Figure 21 shows that MDSC were the main source of NO on day 4. Differences 
between TNFR2-/- and wt cultures could not be detected on the NO level but TNFR2-/- MDSC 
featured significantly reduced iNOS mRNA expression after 6 h of stimulation. 
 
 
 
 
 
 
 
 
 
 
Figure 21: iNOS mRNA expression and NO production of MDSC (CD11b+ Ly6C+ Ly6G-) and PMN 
(CD11b+ Ly6Cint Ly6G+) from BMDC cultures on day 4 
BMDC were stained on day 4 with anti-Ly6C FITC and anti-Ly6G PB. Cells were sorted into the two main 
populations (CD11b+ Ly6C+ Ly6G-) and PMN (CD11b+ Ly6Cint Ly6G+), adjusted to the same cell number 
(2.5 x 105 / mL in the 48 well plate), and stimulated in 1 mL with LPS and IFN-ү (125 ng/mL, 50 ng/mL) for 
6 h before iNOS mRNA expression was analyzed (A). After 48 h NO concentrations were determined in 
the supernatants (B). Shown are the single values and the mean (horizontal line) of three different BMDC 
cultures per group representing individual mice.  
 
3.2.4 Arg1 expression of BMDC and MDSC 
The next aim was to investigate the mRNA expression of Arg1 as the most prominent marker for 
suppressive MDSC. Arg1 mRNA expression of was measured in non-stimulated whole BMDC 
on day 6 and purified MDSC on day 4. Figure 22 shows that both TNFR2-/- BMDC and sorted 
TNFR2-/- MDSC expressed slightly decreased Arg1 mRNA levels. 
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Figure 22: Arg1 mRNA expression in BMDC and MDSC 
BMDC were stained on day 4 with anti-Ly6C-FITC and anti-Ly6G-PB. The MDSC populations 
(CD11b+ Ly6C+ Ly6G-) were isolated employing the FACS Aria sort device. Arg1 mRNA expression was 
analyzed in non-stimulated cells (A). On day 6 non-stimulated whole BMDC were analyzed for the 
expression of Arg1 mRNA expression (B). Shown are the single values and the mean (horizontal line) of 
three different MDSC cultures per group (A) and four different BMDC cultures per group (B). (A) and (B) 
represent two different experiments. 
 
3.3 Phenotypes of TNFR2-/- bone marrow-derived dendritic cells 
(BMDC) 
3.3.1 Non-stimulated BMDC   
Differences in the BMDC differentiation between the C57BL/6 wt and TNFR2-/- background were 
examined using kinetics or the time points indicated. Either expression of different markers or 
the concentrations of soluble TNF and soluble TNFR2 in the medium were measured. All BMDC 
samples were non-stimulated. 
 
3.3.1.1 Cell numbers in BMDC cultures 
First, the yields of cells in the BMDC differentiation cultures of wt and TNFR2-/- mice were 
analyzed. As illustrated in Figure 23, pure TNFR2-/- BMDC cultures provided significantly 
reduced yields of cells on day 8 and 10. 
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Figure 23: BMDC yields from BMDC cultures - kinetics 
BMDC numbers in the petri dishes were counted on different time points during the BMDC differentiation 
culture period. Shown are the single values and the mean (horizontal line) of four different BMDC cultures 
per group representing individual mice. 
 
3.3.1.2 Frequency of cells expressing activation markers 
(MHCII+ CD80+ CD86+) in BMDC cultures 
Next, the question was addressed whether the expression of activation markers is impaired in 
BMDC from TNFR2-/- mice compared to wildtype mice. TNFR2-/- BMDC contained higher relative 
proportions of cells expressing the activation markers MHCII+, CD80+, and CD86+. This finding 
is visualized in Figure 24. The data are statistically significant on day 8 and 10. 
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Figure 24: Activation markers – BMDC cultures kinetics 
The percentage of BMDC expressing the activation markers MHCII+, CD80+, and CD86+ were analyzed 
employing flow cytometry at different time points during the differentiation into dendritic cells. Shown are 
the single values and the mean (horizontal line) of four different BMDC cultures per group and time point 
representing individual mice (A). (B) illustrates the histogram of one representative culture out of four on 
day 10. 
 
3.3.1.3 Frequency of MDSC in BMDC cultures 
TNFR2-/- BMDC cultures contained lower proportions of cells expressing the MDSC markers 
CD11b+, Ly6C+, and Ly6G- throughout the BMDC differentiation culture period. This finding is 
shown in Figure 19. The data are statistically significant. 
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3.3.1.4 Proliferation in BMDC cultures 
Having shown that BMDC differentiation cultures from TNFR2-/- mice yield reduced cell numbers 
compared to wildtype mice, it was next analyzed whether this is due to decreased proliferation 
in TNFR2-/- BMDC differentiation cultures. TNFR2-/- BMDC cultures on day 10 of the 
differentiation culture period contained slightly reduced percentages of cells that incorporated 
BrdU into the DNA indicating less proliferation. This finding is shown in Figure 25. 
 
 
 
 
 
 
 
 
Figure 25: Proliferation in BMDC cultures 
The percentages of BMDC that were positive for BrdU were analyzed employing flow cytometry on day 
10. Cells were incubated with BrdU for the 24 previous hours. Shown are the single values and the mean 
(horizontal line) of three different BMDC cultures per group representing individual mice. 
 
3.3.1.5 Cell death in BMDC cultures 
The role of cell death for the decreased cellular yield of TNFR2-/- BMDC was investigated next. 
TNFR2-/- BMDC did not contain altered numbers of apoptotic and necrotic cells. Data are based 
on flow cytometry analysis of Annexin V+ and 7-AAD+ cells. This finding is shown in Figure 26. 
 
 
 
 
 
 
 
 
Figure 26: Cell death in BMDC cultures 
The percentages of BMDC positive for Annexin V and 7-AAD were analyzed employing flow cytometry on 
day 10. Shown are the single values and the mean (horizontal line) of three different BMDC cultures per 
group representing individual mice.  
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3.3.1.6 TNF concentrations in BMDC cultures 
Subsequently, the concentrations of soluble and biologically active TNF in BMDC differentiation 
cultures of wildtype and TNFR2-/-mice were analyzed, in order to get information about the 
relevance of this cytokine during the BMDC differentiation. TNFR2-/- BMDC cultures produced 
significantly higher concentrations of soluble TNF on every day of the kinetic. Figure 27 shows 
the concentrations of soluble TNF that were not blocked by soluble TNFR2 representing the 
biologically active form of the cytokine. Increased TNFR1-signaling in TNFR2-/- BMDC 
differentiation cultures might occur. 
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Figure 27: sTNF concentrations in BMDC cultures - kinetics 
At every time point of the kinetic 0.5 mL of the supernatant were removed from each petri dish of BMDC 
cultures and replaced by fresh GM-CSF-containing medium. The concentrations of soluble TNF were 
measured employing ELISA. Shown are the single values and the mean (horizontal line) of four different 
BMDC cultures per group representing individual mice. 
 
3.3.1.7 TNFR2 concentrations in BMDC cultures 
Furthermore, the concentrations of soluble TNFR2 were measured in the BMDC differentiation 
cultures, in order to acquire informations about its possible influence on the availability of 
biologically active soluble TNF. Wt BMDC cultures showed high concentrations of soluble 
TNFR2 in the supernatant after day 3 of the BMDC differentiation cultures period as 
demonstrated in Figure 28. 
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Figure 28: sTNFR2 concentrations in BMDC cultures - kinetics 
At every time point of the kinetic 0.5 mL of the supernatant were removed from each petri dish of BMDC 
cultures and replaced by fresh GM-CSF-containing medium. The concentrations of soluble TNFR2 were 
measured employing ELISA. Shown are the single values and the mean (horizontal line) of four different 
BMDC cultures per group representing individual mice. 
 
3.3.2 Stimulated BMDC cultures  
BMDC from pure cultures were isolated and seeded in defined volumes. After stimulation with 
LPS and IFN-ү NO, soluble TNFR2, and the cytokines IL-6 and soluble TNF were measured. 
 
3.3.2.1 NO production capacity in TNFR2-/- BMDC cultures 
In order to exclude that FACS Aria sort cell separation interferes with the decreased NO 
production capacity of TNFR2-/- BMDC, BMDC were sorted after 8 days of the BMDC 
differentiation period and were stimulated. NO concentrations in the supernatants of TNFR2-/- 
BMDC were again significantly reduced. Data are shown in Figure 29. Reduced NO production 
capacity of TNFR2-/- BMDC has already been shown in 3.1.3. This finding served as a control 
experiment for further investigations using FACS aria cell sort. 
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Figure 29: NO production capacity after sort in BMDC cultures 
CD45.1 C57BL/6 wt and CD45.2 TNFR2-/- mice were used. BMDC were removed from the petri dish 
culture plates on day 8 and stained according to their respective congenic markers CD45.1 (C57BL/6 wt) 
and CD45.2 (TNFR2-/-). Cells were subjected to FACS Aria cell separation procedure. 2.5 x 105 cells were 
stimulated in 1 mL medium with LPS and IFN-ү (125 ng/mL, 50 ng/mL). NO concentrations were 
measured after 48 h. Every pair of symbols represents one independent experiment and the mean values 
of more than three biological replicates. Shown are the single values and the mean (horizontal line) of 3 
independent experiments. 
 
3.3.2.2 IL-6 production capacity in BMDC cultures 
Next, it was addressed whether the capacity to produce IL-6 is impaired in BMDC from TNFR2-/- 
mice. BMDC were stimulated and IL-6 concentrations in the supernatants were measured at 
different time points during the BMDC differentiation culture period. The IL-6 production capacity 
was significantly reduced in TNFR2-/- BMDC cultures throughout the kinetic as shown in Figure 
30. 
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Figure 30: IL-6 production capacity in BMDC cultures - kinetics 
BMDC were removed from the petri dish cultures at the time points indicated. 2.5 x 105 cells were seeded 
in 1 mL and in 48 well microtiter plates and, subsequently, stimulated with LPS and IFN-ү (125 ng/mL, 
50 ng/mL). IL-6 concentrations were measured after 48 h using ELISA. Shown are the single values and 
the mean (horizontal line) of four different BMDC cultures per group representing individual mice. 
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3.3.2.3 sTNF concentrations in TNFR2-/- BMDC cultures 
Next, it was addressed whether the concentrations of soluble TNF were also impaired after 
stimulation. TNF concentrations in the supernatants of stimulated BMDC were measured at 
different time points during the differentiation. The concentrations of soluble TNF were 
significantly increased in TNFR2-/- BMDC cultures after day 4 as shown in Figure 31. 
 
 
 
 
 
 
 
 
 
Figure 31: sTNF concentrations in BMDC cultures - kinetics 
BMDC were removed from the petri dish cultures at the time points indicated. 2.5 x 105 cells were seeded 
in 1 mL and in 48 well microtiter plates and, subsequently, stimulated with LPS and IFN-ү (125 ng/mL, 
50 ng/mL). Soluble TNF concentrations were measured after 48 h using ELISA. Shown are the single 
values and the mean (horizontal line) of four different BMDC cultures per group representing individual 
mice. 
 
3.3.2.4 sTNRF2 concentrations in BMDC cultures 
In parallel, soluble TNFR2 concentrations were measured in the supernatants of stimulated 
BMDC at different time points during the differentiation. The soluble TNFR2 concentrations 
were significantly increased in TNFR2-/- BMDC cultures after day 4 as shown in Figure 32. 
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Figure 32: sTNFR2 concentrations in BMDC cultures - kinetics 
BMDC were removed from the petri dish cultures at the time points indicated. 2.5 x 105 cells were seeded 
in 1 mL and in 48 well microtiter plates and, subsequently, stimulated with LPS and IFN-ү (125 ng/mL, 
50 ng/mL). Soluble TNFR2 concentrations were measured after 48 h using ELISA. Shown are the single 
values and the mean (horizontal line) of four different BMDC cultures per group representing individual 
mice. 
 
3.3.3 Mixed and non-stimulated BMDC cultures  
In order to address whether different culture conditions in terms of soluble TNF and soluble 
TNFR2 influence the phenotypes seen in TNFR2-/- BMDC cultures, both populations were 
differentiated in the same petri dish, in order to guarantee identical conditions. Mixed BMDC 
cultures were obtained by preparing bone marrow cells from one wildype and one TNFR2-/- 
mouse and mixing equal numbers of these cells. Hence, the resulting mixed culture should 
consist of 50% wt and 50% TNFR2-/- bone marrow cells. These cultures were differentiated into 
BMDC. At the indicated time points the two populations in the mixed BMDC cultures were 
investigated using flow cytometry or FACS Aria cell sort device.  
 
3.3.3.1 Cell proportions in mixed BMDC cultures 
In order to find out, whether the reduced yield of BMDC of TNFR2-/- mice is due to missing 
intrinsic signaling or depending on altered culture conditions, the frequencies of the respective 
population in mixed BMDC differentiation cultures were analyzed at different time points. Figure 
33 illustrates that TNFR2-/- BMDC were present in an above-average frequency in mixed 
cultures on day 3. In contrast to this, the percentage of TNFR2-/- BMDC decreased steadily and 
reached significantly lower levels compared to the wt BMDC on day 8 and day 10. These 
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findings correspond to the results from BMDC generated in separated BMDC differentiation 
cultures shown in Figure 23. 
 
 
 
 
 
 
 
 
 
 
Figure 33: BMDC distribution in mixed cultures - kinetics 
Mixed BMDC were analyzed for the distribution of CD45.1 wt and CD45.2 TNFR2-/- cells at the time 
points indicated using flow cytometry. Shown are the single values and the mean (horizontal line) of four 
different mixed BMDC cultures per group representing individual mice. 
 
3.3.3.2 Frequency of cells expressing activation markers 
(MHCII+ CD80+ CD86+) in mixed BMDC cultures 
Afterwards, the influence of TNFR2-/- BMDC culture conditions on the activation of the 
developing BMDC should be figured out. Therefore the frequencies of activated cells in the two 
different populations of mixed BMDC differentiation cultures were examined at different time 
points. The relative proportions of activated cells in the TNFR2-/- BMDC population of mixed 
BMDC cultures started lower on day 4 and day 6 but were significantly increased on day 10. 
Data are interpreted in Figure 34. These findings correspond to the results from BMDC 
generated in separated BMDC differentiation cultures shown in Figure 24. 
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Figure 34: Activation markers expression in mixed BMDC cultures - kinetics 
Mixed BMDC were analyzed for the percentages of activated cells (MHCII+ CD80+ CD86+) in the two 
populations that were distinguished by their congenic markers. Measurements were done at the time 
points indicated using flow cytometry. Shown are the single values and the mean (horizontal line) of four 
different BMDC cultures per group and time point representing individual mice (A). (B) illustrates the 
histogram of one representative culture out of four on day 10. 
 
3.3.3.3 Frequency of MDSC in mixed BMDC cultures 
Moreover, the frequencies of cells expressing the markers of MDSC (CD11b+ Ly6C+ Ly6G-) in 
the two different populations of mixed BMDC differentiation cultures were examined at different 
time points. The relative proportions of MDSC in the TNFR2-/- population of mixed cultures were 
significantly decreased after day 4. Data are shown in Figure 35. These findings correspond to 
the results from BMDC generated in separated BMDC differentiation cultures shown in Figure 
19. 
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Figure 35: MDSC in mixed BMDC cultures - kinetics 
Mixed BMDC were analyzed for the percentages of MDSC (CD11b+ Ly6C+ Ly6G-) in the two BMDC 
populations that were distinguished by their congenic markers. Measurements were done at the time 
points indicated using flow cytometry. Shown are the single values and the mean (horizontal line) of four 
different mixed BMDC cultures per group representing individual mice. 
 
3.3.3.4 Proliferation of mixed BMDC cultures 
The proliferation was measured in the two populations of mixed BMDC differentiation cultures. 
The relative proportions of proliferating cells in the TNFR2-/- population of mixed cultures were 
slightly decreased on day 10. The data are shown in Figure 36. These findings correspond to 
the results from BMDC generated in separated BMDC differentiation cultures shown in Figure 
25. 
 
 
 
 
 
 
 
 
Figure 36: Proliferation in mixed BMDC cultures 
Mixed BMDC were analyzed for the percentage of proliferating cells (anti-BrdU FITC) in the two BMDC 
populations that were distinguished by their congenic markers. Measurements were performed on day 10 
using flow cytometry. Cells were incubated with BrdU for the 24 previous hours. Shown are the single 
values and the mean (horizontal line) of three different mixed BMDC cultures per group representing 
individual mice. 
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3.3.3.5 Cell death in mixed BMDC cultures 
In parallel, the frequencies of dead cells in the two populations of mixed BMDC differentiation 
cultures were analyzed. The relative proportions of dead cells in the TNFR2-/- population of 
mixed cultures were comparable to the percentages in the wt population. Data are illustrated in 
Figure 37. These findings correspond to the results from BMDC generated in separated BMDC 
differentiation cultures shown in Figure 26. 
   
 
 
 
 
 
 
 
                                                                                                                                                                  
Figure 37: Cell death in mixed BMDC cultures 
Mixed BMDC were analyzed for the percentages of apoptotic and necrotic cells (Annexin V+ 7-AAD+) in 
the two BMDC populations that were distinguished by their congenic markers. Measurements were 
performed on day 10 using flow cytometry. Shown are the single values and the mean (horizontal line) of 
three different mixed BMDC cultures per group representing individual mice. 
 
3.3.4 Mixed BMDC cultures, sorted and stimulated 
Mixed BMDC cultures were separated after 8 days of co-culture according to their congenic 
markers using FACS Aria sort device. The cells were subsequently stimulated with LPS and 
IFN-ү for 48 h before supernatants were removed and analysis were performed. 
 
3.3.4.1 NO production in mixed BMDC cultures 
First, the NO production capacities in the two separated pupulations of mixed BMDC 
differentiation cultures were analyzed. TNFR2-/- BMDC recovered from mixed cultures showed 
significantly reduced amounts of NO in the supernatants after stimulation. This is demonstrated 
in Figure 38. These findings correspond to the results from BMDC generated in separated 
BMDC differentiation cultures shown in Figure 13 and Figure 29. 
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Figure 38: NO production of sorted BMDC grown in mixed cultures 
The two BMDC populations in mixed BMDC cultures were sorted on day 8 according to their congenic 
markers using FACS Aria sort. 2.5 x 105 cells were stimulated in 1 mL medium with LPS and IFN-ү 
(125 ng/mL, 50 ng/mL). NO concentrations were measured after 48 h. Every pair of symbols represents 
one independent experiment and the mean value of more than three biological replicates. Shown are the 
single values and mean (horizontal line) of three independent experiments. 
 
3.3.4.2 IL-6 production in mixed BMDC cultures 
Additionaly, the IL-6 production capacities in the two separated pupulations of mixed BMDC 
differentiation cultures were analyzed. The TNFR2-/- BMDC recovered from mixed BMDC 
cultures showed significantly reduced amounts of IL-6 in the supernatants after stimulation. This 
is shown in Figure 39. These findings correspond to the results from BMDC generated in 
separated BMDC differentiation cultures shown in Figure 30. 
 
 
 
 
 
 
 
 
 
Figure 39: IL-6 production of sorted BMDC grown in mixed cultures 
The two BMDC populations in mixed BMDC cultures were sorted on day 8 according to their congenic 
markers using FACS Aria sort. 2.5 x 105 cells were stimulated in 1 mL medium with LPS and IFN-ү 
(125 ng/mL, 50 ng/mL). IL-6 concentrations were measured after 48 h. Shown are the single values and 
the mean (horizontal line) of three technical replicates of one experiment. 
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3.4 Bone marrow chimeric mice 
Bone marrow chimeric mice were generated to examine TNFR2-/- hematopoietic cells grown in 
wildtype hosts and and wildtype hematopoietic cells grown in TNFR2-/- hosts. 
 
3.4.1 Reconstitution 
Eight weeks after bone marrow transplantation mice were killed and the rates of reconstitution 
were checked in the spleens. As shown in Figure 40, about 80% reconstitution of the donor 
bone marrow could be achieved. The distributions of CD4 and CD8 T cells as well as B-cells 
were not changed in the 4 different groups and were similar to naïve animals. 
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Figure 40: Reconstitution of bm chimeric mice 
Spleen cell suspensions were prepared and stained according to the congenic markers CD45.1 (A) and 
CD45.2 (B) of donor and host, respectively. In order to guarantee a natural spleen cell composition, 
additional stainings for CD4 T cells, CD8 T cells and B cells (B220) were performed and analyzed using 
flow cytometry (C). Shown are the single values and the mean (horizontal line) of four individual animals 
per group (A and B) and the mean of the pecentages of the different cells of four individual mice per 
group (C). 
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3.4.2 PEC cell distribution and NO production 
First, PEC from bm chimeric mice were analyzed for the cellular composition and the NO 
production capacity. As shown in Figure 41 the cell distributions of PEC in the different 
chimeras were similar. However, no difference in the NO production could be detected anymore 
in PEC from wildtype mice that were reconstituted with TNFR2-/- bone marrow. 
 
 
 
 
 
 
 
 
 
 
Figure 41: bm chimeras – PEC distribution and NO production 
PEC were generated from bm chimeric mice and analyzed for the distribution of various cell types (A). 
Additionally, 2.5 x 105 cells were stimulated in 1 mL medium with LPS and IFN-ү (125 ng/mL, 50 ng/mL), 
in order to measure NO after 48 h (B). Shown are the mean of four individual mice per group (A) and 
single values and mean (horizontal line) of four individual mice per group (B). 
 
3.4.3 BMDC from bm chimeric mice 
BMDC were generated from bm chimeric mice according to the protocol and tested on day 8.  
 
3.4.3.1 Frequency of cells expressing activation markers (MHCII+ CD80+ 
CD86+) in BMDC cultures from bm chimeric mice 
The frequencies of activated cells in BMDC differentiation cultures of bm chimeric mice 
expressing the activation markers MHCII+, CD80+, and CD86+ on day 8 are shown in Figure 42. 
Significantly increased percentages of mature and activated cells were found in BMDC 
differentiation cultures of wildtype mice that were reconstituted with TNFR2-/- bone marrow. 
These findings correspond to the results from BMDC generated in separated BMDC 
differentiation cultures shown in Figure 24.  
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Figure 42: Activation markers of BMDC from bm chimeric mice 
The percentages of BMDC expressing the activation markers MHCII, CD80, and CD86 were analyzed 
employing flow cytometry on day 8. Shown are the single values representing individual mice and the 
mean (horizontal line) of four different BMDC cultures per group. 
 
3.4.3.2 Nitric Oxide (NO) production of BMDC from bm chimeric mice 
Besides, the NO production capacity was investigated in BMDC differentiation cultures of bm 
chimeric mice on day 8 after stimulation with LPS and IFN-ү. Figure 43 shows that BMDC from 
wildtype mice reconstituted with TNFR2-/- bone marrow produced significantly reduced amounts 
of NO. These findings correspond to the results from BMDC generated in separated BMDC 
differentiation cultures shown in Figure 13 and Figure 29. 
 
 
 
 
 
 
 
 
 
 
Figure 43: NO production of BMDC from bm chimeric mice 
BMDC were removed from the petri dish on day 8 of BMDC differentiation culture. 2.5 x 105 cells were 
seeded in 1 mL and in 48 well microtiter plates and, subsequently, stimulated with LPS and IFN-ү 
(125 ng/mL, 50 ng/mL). NO concentrations were measured after 48 h using Griess reagent. Shown are 
the single values representing individual mice and the mean (horizontal line) of four different BMDC 
cultures per group. 
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3.4.3.3 IL-6 production of BMDC cultures from bm chimeric mice  
Moreover, the IL-6 production capacity was examined in BMDC differentiation cultures of bm 
chimeric mice on day 8 after stimulation with LPS and IFN-ү. Figure 44 shows that BMDC from 
wildtype mice reconstituted with TNFR2-/- bone marrow produced significantly reduced amounts 
of IL-6. These findings correspond to the results from BMDC generated in separated BMDC 
differentiation cultures shown in Figure 30. 
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Figure 44: IL-6 production of BMDC from bm chimeric mice 
BMDC were removed from the petri dish on day 8 of the culture. 2.5 x 105 cells were seeded in 1 mL and 
in 48 well microtiter plates and, subsequently, stimulated with LPS and IFN-ү (125 ng/mL, 50 ng/mL). IL-6 
concentrations were measured after 48 h using ELISA. Shown are the single values representing 
individual mice and the mean (horizontal line) of four different BMDC cultures per group. 
 
3.4.3.4 sTNF concentrations in BMDC cultures from bm chimeric mice 
Additionally, the soluble TNF concentrations were measured in BMDC differentiation cultures of 
bm chimeric mice on day 8 after stimulation with LPS and IFN-ү. Figure 45 shows that BMDC 
from wildtype mice reconstituted with TNFR2-/- bone marrow produced slightly increased 
concentrations of soluble TNF in the supernatant. These findings correspond to the results from 
BMDC generated in separated BMDC differentiation cultures shown in Figure 31. 
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Figure 45: sTNF concentrations in the supernatants of BMDC from bm chimeric mice 
BMDC were removed from the petri dish on day 8 of the culture. 2.5 x 105 cells were seeded in 1 mL and 
in 48 well microtiter plates and, subsequently, stimulated with LPS and IFN-ү (125 ng/mL, 50 ng/mL). 
Soluble TNF concentrations were measured after 48 h using ELISA. Shown are the single values 
representing individual mice and the mean (horizontal line) of four different BMDC cultures per group. 
 
3.4.3.5 sTNFR2 concentrations in BMDC cultures from bm chimeric mice 
In parallel, the TNFR2 concentrations were measured in BMDC differentiation cultures of bm 
chimeric mice on day 8 after stimulation with LPS and IFN-ү. BMDC from wildtype mice 
reconstituted with TNFR2-/- bone marrow expressed hardly any soluble TNFR2 compared to the 
wildtype control BMDC indicating almost complete reconstitution. Data are shown in Figure 46. 
These findings correspond to the results from BMDC generated in separated BMDC 
differentiation cultures shown in Figure 32. 
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Figure 46: sTNFR2 concentrations in the supernatants of BMDC from bm chimeric mice 
BMDC were removed from the petri dish on day 8 of the culture. 2.5 x 105 cells were seeded in 1 mL and 
in 48 well microtiter plates and, subsequently, stimulated with LPS and IFN-ү (125 ng/mL, 50 ng/mL). 
Soluble TNFR2 concentrations were measured after 48 h using ELISA. Shown are the single values 
representing individual mice and the mean (horizontal line) of four different BMDC cultures per group. 
 
3.5 Generation of mouse anti-mouse TNFR2 mAB 
3.5.1 Cloning of recombinant TNFR2ed-huIgG and TNFR2ed-V5His-
tagged proteins 
First, vectors for the expression of two different recombinant TNFR2ed fusion were cloned. The 
cloning strategy for TNFR2ed proteins tagged with the Fc part of human IgG or V5His was 
based on a vector cloned by Dr. Andrea Hauser (Hauser, Hehlgans et al. 2007). pMT/Bip/V5-
His (DesMTA) hygro vector was generated by integration of the hygromycine cassette from 
pCoHygro vector via the restriction enzyme sites Accl and Sapl. TNFR2 extracellular domain 
was cloned into pMT/Bip/V5-His hygro via BamH1 Not1 using the primers shown in Table 2 
resulting in the expression of TNFR2ed-V5His. 
The sequence for TNFR2ed-huIgG was integrated via Spe and Nos restriction sites. In the latter 
case a stop codon was generated after the human Fc portion. Thus, the V5His tag was not 
attached to the protein. All vectors were verified using gene sequencing. The predicted 
molecular weight for the TNFR2ed-V5His protein was 29.11 kDa and 53.43 kDa for the 
TNFR2ed-huIgG protein.  
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3.5.2 Expression of TNFR2ed-huIgG and TNFR2ed-V5His-tagged proteins 
DS-2 cells were transfected with pMT/Bip/V5-His (DesMTA) hygro plasmids for TNFR2ed-huIgG 
or TNFR2ed-V5His. 0.3 mg/mL hygromycine was used for selection and during the expansion 
of the successfully transfected cells. Protein expression was induced, supernatants were 
collected, and proteins were isolated as described in 2.2.3.10 and 2.2.3.11. After dialysis 
against PBS protein concentrations were adjusted to 1 mg/mL and serial dilutions were 
performed followed by the analysis using SDS page and Western blot. Figure 47 shows that the 
recombinant proteins had the predicted molecular weight of ~ 53.5 kDa for TNFR2ed-huIgG and 
~ 30 kDa for TNFR2ed-V5His (A, B) and were successfully modified with the respective 
tag (C and D). Cross-reactivity of the used antibodies for huIgG and V5His was excluded. 
 
 
Figure 47: SDS page and Western blot of TNFR2ed proteins tagged with huIgG or V5His 
SDS-PAGE was performed using 10, 5, 2.5, and 1.25 µg of recombinant TNFR2ed-huIgG and TNFR2ed-
V5His per lane. A and B show the coomassie stained SDS gels used for Western blot (C, D). 
huIgG-tagged TNFR2ed was selectively detected in a Western blot with donkey anti-human IgG (H+L) 
HRP (C). V5His-tagged TNFR2 was exclusively detected when incubating the Western blot with the 
primary antibody anti-V5 mAB (mouse) and the secondary antibody goat anti-mouse IgG (whole 
molecule) POX. 
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3.5.3 Test for biological activity of TNFR2ed-huIgG / V5His constructs  
Next, it was examined whether recombinant TNFR2ed proteins were functionally active. In this 
case preincubation of both TNFR2 constructs with TNF should reduce the biologically active 
TNF concentrations available for L-929m cell kill as described in 2.2.3.8 and 2.2.3.9. Figure 48 
shows that both TNFR2ed-huIgG and TNFR2ed-V5His were able to bind soluble TNF and 
effected protection in TNF dependent L-929m cell cytotoxicity assay. 
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Figure 48: Test for biological activity of recombinant TNFR2ed proteins tagged with huIgG or 
V5His 
Different fractions of sterile recombinant TNFR2ed-huIgG (fractions 3 and 4) (A) and TNFR2ed-V5His 
(fractions 1, 2, and 3) (B) eluates were diluted to the indicated concentrations in medium containing 
0.05 ng/mL TNF and 2 µg/mL actinomycin D. After 2 h of incubation at 37 °C 200 µL of the respective 
solutions were transferred to L-929m cells seeded for the TNF cytotoxicity assay the day before. After 
24 h the viability of the differentially treated cells was measured using MTT assay. Cells treated with 
neither TNFR2ed nor TNF were used as 100% alive controls as well as cells treated only with TNF for 
TNF-induced kill. Shown are single values 
A 
B 
III Results 
 
96
3.5.4 Immunization of TNFR2-/- mice and test of serum titer 
TNFR2-/- mice (0, L, R) were immunized with TNFR2ed-V5His according to the protocol listed in 
2.5.2. The immunized mice developed considerable levels of anti-TNFR2ed IgG titers as shown 
in Figure 49.   
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Figure 49: Serum levels of mouse anti-mouse TNFR2 antibodies after the first boost 
Three days after the first boost blood was taken from the immunized mice and serum was prepared. 
Serum levels of mouse anti-mouse TNFR2 antibodies IgG (γ-chain specific) were determined using 
ELISA. Shown are the mean ± SD of three technical replicates. 
 
3.5.5 Fusion and characterization of mouse anti-mouse TNFR2 mAB 
3.5.5.1 Fusion 
Two days after the second boost spleen cells were fused with SP2/0-Ag14 cells as described in 
2.5.3. Ten days after the fusion about 90% of the wells contained viable hybridoma clones. The 
supernatants of all wells from 20 96-well microtiter plates were checked for binding 
TNFR2ed-huIgG using ELISA. 14 clones were defined as positive as OD values exceeded the 
background OD more than 3-fold the standard deviation of the background. By the following 
intense testing and subcloning 5 hybridoma clones expressing monoclonal antibodies were 
identified and expanded for the generation of large amounts of supernatant. Antibodies were 
either tested using the supernatants or protein G purified fractions. 
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3.5.5.2 ELISA 
Supernatants of five hybridoma cultures were identified to bind to TNFR2ed-huIgG and 
hybridomas were named II D12, II G11, XIII A4, XVIII A9, XIX H10. In addition, in some test 
systems clone DJ2008 generated in cooperation with Diana Minge was tested, too. Figure 50 
shows that supernatants of the hybridomas contained high amounts of mouse anti-mouse 
TNFR2 mAB IgG. After purification on protein G columns high OD values could be reached only 
by application of high concentrations of the respective antibody and, hence, titers were low. This 
is illustrated in Figure 50. 
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Figure 50: Titer test of mouse anti-mouse TNFR2 mAB – hybridoma supernatants and Protein G 
purified mAB 
A titer test was performed employing ELISA and log2 dilutions of the hybridoma supernatants (A) or of 
protein G purified antibodies starting with 100 µg/mL (B). Detection was performed using goat anti-mouse 
IgG (ү-chain specific) AP. Shown are the mean ± SD of three technical replicates (A) and single values 
(B). 
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3.5.5.3 Isotype test 
As the ELISA detection system for mouse anti-mouse TNFR2 clones was ү-chain specific, only 
IgG antibodies were detected. The isotypes of the 6 generated mouse anti-mouse TNFR2 mAB 
were tested using IsoGold rapid mouse-monoclonal isotyping kit™ and either supernatant or 
eluate as substrate. All clones were found to be of the IgG1 isotype. 
 
3.5.5.4 SDS-PAGE 
Mouse anti-mouse TNFR2 mAB were purified from about 1 L supernatant of the monoclonal 
hybridoma cultures using protein G as described in 2.2.3.12. Eluate fractions were analyzed in 
SDS-PAGE, in order to evaluate the content of protein. Figure 51 exemplarily shows the SDS-
gel of the hybridoma clone XIII A4. According to the strength of the antibody bands, different 
eluate fractions were pooled followed by dialysis against PBS and determination of the protein 
content using the BCA-kit. 
 
 
Figure 51: SDS-PAGE analysis of the antibody content in different fractions of protein G eluates 
10 µL of the eluate fractions (1 – 16) were analyzed by SDS-PAGE for their protein content and combined 
in three pools for dialysis against PBS and determination of the absolute protein concentration. 
 
3.5.5.5  Western blot 
The protein G purified mouse anti-mouse TNFR2 mAB were tested for staining in Western blot 
analysis. Figure 52 shows that all newly generated mAB detected both TNFR2ed-huIgG and 
TNFR2ed-V5His. Thus, cross-reactivity with the V5His tag used for immunization of the mice 
could be excluded.  
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Figure 52: Performance of mouse anti-mouse TNFR2 mAB in Western blot analysis 
1 µg of TNFR2ed-huIgG and TNFR2ed-V5His were loaded on several SDS gels and run on SDS-PAGE. 
One SDS gel was directly stained with coomassie whereas the other gels were used for Western blot. 
Western blot membranes were incubated with 10 mL 5 µg/mL mouse anti-mouse mAB in TBS containing 
1% skimmed milk powder each over night. Several washes were performed followed by the incubation 
step with the secondary antibody anti-mouse IgG POX. Following several wash steps bound antibodies 
were analyzed using chemiluminescence. As control one membrane was incubated with anti-human IgG 
POX. Another control membrane was incubated with anti-V5 antibody (mouse) followed by the secondary 
antibody anti-mouse IgG POX.  
 
3.5.5.6 Flow cytometry 
CHO cells were transfected with pcDNA3.1 plasmid designed for the expression of mouse 
TNFR2 as described in 2.1.9. Performance of mouse anti-mouse TNFR2 mAB in flow cytometry 
was examined using wt CHO cells and CHO cells expressing mouse TNFR2 (TNFR2tg). As 
shown in Figure 53, 44.7% of the transfected cells were positive for commercially available 
TNFR2 staining mAB AF647. 
The cells were incubated with the supernatants of the mouse anti-mouse TNFR2 mAB 
hybridomas followed by incubation with FITC labeled anti-mouse IgG AB. Clone XVIII A9 
showed weak binding to the receptor expressed on the cell membrane (2.2%). Clone XIX H10 
detected 10.1% of the cells as positive for TNFR2. Cross-reactivity or unspecific binding of the 
supernatants to the cells could be excluded as CHO wt cells exhibited almost no signal neither 
III Results 
 
100
using commercially available anti-TNFR2 AF647 mAB nor the supernatants of the mouse anti-
mouse TNFR2 mAB hybridomas. 
 
Figure 53: Performance of mouse anti-mouse TNFR2 mAB in flow cytometry 
Both CHO wt and CHO cells tranfected with mouse TNFR2 were used. Cells were removed from the 
tissue flasks. 5 x 105 cells were stained with the commercially available anti-TNFR2 AF647 mAB as 
control for successful binding to the recombinant protein. Cells were stained with 2 mL supernatant of the 
newly generated mouse anti-mouse TNFR2 mAB hybridomas for 30 min. Cells were washed with FACS 
buffer and stained with the secondary antibody anti-mouse IgG FITC for 30 min. After another wash with 
FACS buffer the cells were analyzed using flow cytometry. 
 
3.5.5.7 Transduction of Wirbel cells with TNFR1/2ed-huFasid 
Wirbel cells were retrovirally transduced with pQCXIP plasmids expressing TNFR1ed-huFasid 
and TNFR2ed-huFasid obtained from Dr. Wulf Schneider. In brief, TNFR1ed and TNFR2ed, 
respectively, were cloned into the vector using the Bam and EcoRV restriction enzymes. The 
intracellular portion of human Fas was inserted using EcoRV and Xho restriction sites. Cells 
were grown in medium supplemented with 1.5 µg/mL puromycine for the selection. Transfection 
efficiencies were determined using flow cytometry as shown in Figure 54. 13.1% of TNFR1ed-
huFasid and 71.4% of TNFR2ed-huFasid transduced cells were positive for the respective 
receptor. 
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Figure 54: Expression analysis of TNFR1ed and TNFR2ed fused to human Fasid in retrovirally 
transduced Wirbel cells 
Wirbel wt cells and TNFR1ed-huFasid as well as TNFR2ed-huFasid cells were grown and stained with 
anti-TNFR1 APC or anti-TNFR2 PE, respectively. The expressions of the recombinant proteins were 
analyzed using flow cytometry. 
 
The sensibilities of TNFR1ed-huFasid and TNFR2ed-huFasid transduced cells for mouse and 
human TNF were examined. Results are shown in Figure 55. Wt Wirbel cells were not 
influenced by human and mouse TNF. TNFR1ed-huFasid expressing cells were highly 
susceptible to both types of TNF. TNFR2ed-huFasid expressing could only be killed by mouse 
TNF. The induction of apoptosis was less pronounced and only apparent in the presence of 
high concentrations of mouse TNF. 
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Figure 55: Cytotoxicity assay on TNFR1ed- and TNFR2ed-huFasid transduced Wirbel cells – 
mouse and human TNF 
Wirbel cells (2 x 104) were seeded in 100 µL per well of 96-well plates. After 24 h supernatants were 
discarded and cells were treated with serial dilutions of mouse and human TNF starting with 100 µg/mL in 
200 µL medium containing 2 µg/mL actinomycin D. After 24 h MTT assays were performed for viability 
analysis. Viabilities of Wirbel wt (A), TNFR1ed-huFasid expressing cells (B), and TNFR2ed-huFasid 
expressing cells (C) are shown. Dots represent single values. 
 
B 
C 
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3.5.5.8 Test for agonistic properties 
Wirbel cells expressing TNFR2ed-huFasid were used to test for agonistic properties of the 
newly generated mouse anti-mouse TNFR2 mAB. In brief, mAB dependent induction of 
apoptosis was examined as shown in Figure 56. Apoptosis could neither be induced in 
TNFR2ed-huFasid expressing Wirbel cells nor in the control experiments using Wirbel wt and 
Wirbel cells transduced with TNFR1ed-huFasid. 
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Figure 56: Mouse anti-mouse TNFR2 mAB test for agonistic activity 
Wt Wirbel cells (A) and Wirbel cells transduced with TNFR1ed-huFasid (B) or TNFR2ed-huFasid (C) were 
seeded in medium (2 x 104 cells / 96-well) and treated after 24 h with 200 µL 25 µg/mL mouse anti-mouse 
mAB in medium supplemented with 2 µg/mL actinomycin D. Cells were incubated for 24 h before 
assessment of the cell viability employing MTT. Control cells were not treated with mAB and either 
incubated in pure medium (live control) or in medium containing 25 ng/mL mouse TNF (kill control). 
Shown are the mean values ± SD of three technical replicates per group. 
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3.5.5.9 Test for antagonistic properties 
Wirbel cells expressing TNFR2ed-huFasid were used to test for antagonistic properties of the 
newly generated mouse anti-mouse TNFR2 mAB. In brief, cells were preincubated with TNFR2 
mAB before TNF challenge. Data are shown in Figure 57.  
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Figure 57: Mouse anti-mouse TNFR2 mAB test for antagonistic activity 
Wirbel cells (2 x 104) both wt (A), transduced with TNFR1ed-huFasid (B), or TNFR2ed-huFasid (C) were 
seeded in medium and pretreated after 24 h with 100 µL 50 µg/mL mouse anti-mouse TNFR2 mAB in 
medium. 6 h later cells were challenged with 100 µL 50 ng/mL mouse TNF in medium supplemented with 
4 µg/mL actinomycin D. Cells were incubated in the resulting 200 µL medium containing 25 µg/mL mAB 
and 25 ng/mL mouse TNF and 2 µg/mL actinomycin D for 24 h before assessment of the cell viability 
employing MTT. Control cells were not treated with mAB and either incubated in pure medium (live 
control) or in medium containing TNF (kill control). Shown are the mean values ± SD of three technical 
replicates per group. 
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As expected, Wirbel wt control cells could not be killed. Antagonistic cross-reactivity with 
TNFR1ed-huFasid could be excluded as well. Marginal protection from TNF-induced apoptosis 
could be reached by the treatment of TNFR2ed-huFasid transduced Wirbel cells with the mouse 
anti-mouse TNFR2 mAB clones II G11, XIII A4, XVIII A9, and XIX H10. However, the grade of 
induced apoptosis using mouse TNF was very faint for TNFR2ed-huFasid transduced cells and, 
thus, significant evidence for TNFR2 blocking properties of the six candidate mAB could not be 
achieved. Therefore, TNC-mTNF mutant TNF (Prof Wajant) was used as positive control. Figure 
58 shows that this recombinant TNF mutant induces a strong kill in TNFR2ed-huFasid 
expressing cells indicating high affinity to TNFR2. Pretreatment of the TNFR2ed-huFasid 
transduced cells with mouse anti-mouse TNFR2 mAB did not reduce the induced kill indicating 
no antagonistic properties of these mAB. 
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Wirbel wt control - anti-mouse TNFR2 mAB blocking assay
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Figure 58: Mouse anti-mouse TNFR2 mAB test for antagonistic activity using TNC-mTNF  
Wirbel cells (2 x 104) both wt (A), transduced with TNFR1ed-huFasid (B), or TNFR2ed-huFasid (C) were 
testet according to the experimental setup described in the legend of Figure 57. The kill was induced with 
50 ng/mL TNC-mTNF mutant. Shown are the mean values ± SD of three technical replicates per group.  
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4 Discussion 
Severe sepsis, septic shock, and immunosuppression represent some of the most serious 
pathologies causing morbidity and mortality in intensive care. During the last few years the trend 
of their incidences has increased as a consequence of the rising life expectancy of the 
population, especially in the western civilization (Angus, Linde-Zwirble et al. 2001; Martin, 
Mannino et al. 2003). 
Therefore, great efforts are being made in basic sepsis research aiming at the development of 
new drugs and therapeutical strategies, in order to reduce multi-organ failure and to make the 
immune system more apt to react adequately to secondary infections.  
This thesis is based on the findings of Dr. Theo Sterns that TNFR2-/- mice are protected from 
lethal effects of secondary infections in the phase of immunoparalysis after CLP (Sterns, Pollak 
et al. 2005). Therefore, either the TNFR2-signaling on specific cells, reverse signaling of TNFR2 
to membrane-bound TNF, or the TNF-neutralizing functions of soluble TNFR2 leading to 
diminished TNFR1-signaling must be the reasons for the severe pathology of secondary 
infections in CLP-treated wildtype mice. It has to be taken into consideration that either direct 
signaling during sepsis could be causal for the protection of TNFR2-/- mice or that this effect 
could be caused by changes in the immune system that occurred earlier in the life of the 
animals. The latter comprises epigenetic changes caused by the three possible modes of 
TNFR2 action discussed above as well as continuous low dose TNF-signaling via TNFR1 in 
TNFR2-/- mice due to the lack of antagonizing soluble TNFR2. The lack of TNF-neutralizing 
soluble TNFR2 could lead to TNF tolerance and could be the reason for the findings of Dr. Theo 
Sterns. These hypothetical causes are discussed in the following chapters based on the novel 
findings of this work. 
 
4.1 Characterization of CD11b+ cells of TNFR2-/- mice  
4.1.1 Splenocytes in the animal model of CLP 
Initially, the phenotypcial and functional status of splenocytes, especially CD11b+ CD11c- cells 
and MDSC, was investigated after CLP and compared between wildtype and TNFR2-/- mice. It is 
known that numbers and percentages of mature DC and CD4 T cells are reduced one day after 
CLP (Hotchkiss and Karl 2003; Ding, Chung et al. 2004). The total numbers of splenocytes that 
could be recovered were slightly reduced in mice on day 1 and 2 after CLP. This effect was 
overcome on day 4 as splenomegaly started to develop. On day 11 after CLP the weight of the 
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spleens and the yield of cells exceeded the naïve levels up to 10-fold (data not shown). Figure 9 
and Figure 14 show that the percentages of CD11b+ CD11c- cells were not drastically 
influenced by CLP within the first 2 days and, starting on day 4, went up to 5% on day 11. The 
content of MDSC within the CD11c+ splenocyte population was drastically reduced 6 h, 10 h, 
and 1 day after CLP. This loss was compensated on day 2. From then on, MDSC proportions in 
the spleen rose until day 11 after CLP. This phenomenon has already been published earlier 
(Delano, Scumpia et al. 2007). The loss of cells in the CD11b+ CD11c- population is comparable 
to the the loss in absolute numbers of splenocytes while the contribution of CD11b+ cells to the 
splenomegaly is slightly increased. MDSC, however, are more than proportionally affected by 
cell loss immediately after CLP and contribute overproportionally to the splenomegaly in 
particular. Differences between wildtype and TNFR2-/- mice could not be revealed. As shown in 
Figure 16, MDSC were the source of NO in LPS and IFN-ү stimulated CD11b+ splenocytes from 
CLP-treated mice. TNFR2-/- splenic MDSC produced significantly reduced levels of NO. These 
data, in combination with Figure 10, demonstrate that a previous CLP is required for NO 
production upon stimulation with LPS and IFN-ү 
 
4.1.2 Functional characterization of MDSC 
As already described, the relative proportion of MDSC in the splenocytes of TNFR2-/- mice was 
not impaired compared to wt mice but the capacity to express iNOS mRNA and to produce NO 
was reduced (Figure 11). In BMDC differentiation cultures on day 4 it was the MDSC population 
as well that produced the majority of NO upon stimulation with LPS and IFN-ү. While differences 
in the absolute NO concentration in the supernatants after 48 h were not detected, significantly 
reduced iNOS mRNA expression after stimulation for 6 h was found (Figure 21). As shown in 
Figure 19, almost no MDSC were found in BMDC cultures on day 10 when almost all cells were 
DC as they expressed CD11c. The questions, which cell type produces NO in BMDC upon 
stimulation on day 10, could not be answered in this work. Both Ly6C and Ly6G were 
downregulated during BMDC differentiation. The two distinct populations of MDSC 
(Ly6C+ Ly6G-) and PMN (Ly6Cint Ly6G+) merged in the FACS profile. Nevertheless, as shown in 
Figure 19, the percentages of MDSC in TNFR2-/- BMDC on day 10 were still significantly 
decreased. Assuming this population being the most potent source of NO, the differences 
between TNFR2-/- and wt BMDC in terms of NO production could be explained by the cell 
numbers of MDSC. However, it is unlikely that the few cells of the not well defined MDSC 
population on day 10 exclusively produced NO thereby contributing to the difference between 
wildtype and TNFR2-/- BMDC. 
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On day 6 TNFR2-/- BMDC expressed slightly decreased Arg1 mRNA (Figure 22). This effect 
was not due to the different proportion of MDSC in the cultures as purified and cell number 
adjusted MDSC on day 4 also expressed slightly reduced Arg1 mRNA levels. Since Arg1 
expression is the most prominent marker for the activity of MDSC, a decreased capacity for 
Arg1 expression of TNFR2-/- MDSC can be assumed. 
 
4.1.3 iNOS mRNA expression and NO production 
As shown in chapter 3.1.1, iNOS mRNA expression and NO production were impaired in 
CD11b+ CD11c- splenocytes of TNFR2-/- mice 2 days after CLP compared to wildtype mice. 
CLP was required for iNOS mRNA expression and NO production. The differences between 
wildtype and TNFR2-/- splenocytes can be assigned to the MDSC population (see 3.2.1.2) in 
terms of iNOS mRNA expression and NO production. The fact that only MDSC of CLP-treated 
mice were able to express iNOS mRNA and to produce NO leads to two different possibilities: 
either new cells immigrate to the spleen or other cells differentiate in situ into the MDSC 
phenotype as a consequence of the CLP treatment.  
Myeloid cells derived from other sources were examined for these parameters, too. As shown in 
Figure 12 and Figure 13, PEC and BMDC of TNFR2-/- mice featured exactly the same 
phenotype of reduced iNOS mRNA expression and NO production even in naïve mice. As a 
result of this finding BMDC were used for further investigation of the underlying causes for this 
phenotype and its physiological role. 
NO is thought to be one of the main mediators in severe sepsis. There are several functions of 
NO inducing both systemic and cellular reactions. Three different nitric oxide synthetases are 
known: neuronal NOS (nNOS) derived NO acts as a neurotransmitter and a hormone and is 
expressed in 2% of cerebral cortical neurons as well as in dendrites and axons (Snyder and 
Bredt 1991). Epithelial NOS (eNOS) derived NO regulates the vascular tone and plays a critical 
role in the regulation of blood pressure and supply (Kirkeboen, Naess et al. 1992). iNOS derived 
NO mediates the non-specific cytotoxicity against bacteria, protozoa, and tumor cells. iNOS 
mRNA expression and NO production are increased in smooth muscle cells, in macrophages as 
well as parenchymal cells during septic shock as a consequence of high concentrations of 
bacterial components like LPS or cytokines such as IL-1β, IL-2, IL-6, TNF, and IFN-ү (Kirkeboen 
and Strand 1999). NO concentrations in the plasma of septic mice are drastically increased 
(Nathan and Xie 1994; Lush, Cepinskas et al. 2001). Anti-inflammatory cytokines like IL-4, IL-8, 
IL-10, and TGF-β, which are produced among others by TH2 cells, are known to diminish the 
NO production capacity of certain cells (Nussler and Billiar 1993). 
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As TNFR2-/- myeloid cells produce less NO, these reduced levels could protect the mice from 
vasodilation as well as tissue and organ damage. A less hazardous effect on the organism 
caused by NO could be the reason for the protection of TNFR2-/- mice from a secondary 
infection. In this case CLP would not affect the vital functions to the extent compared to wildtype 
mice. However, in contrast to this, TNFR2-/- mice do not exhibit improved survival after CLP 
(Ebach, Riehl et al. 2005). 
When iNOS mRNA is expressed in myeloid cells, they persistently produce large amounts of 
NO (Morris and Billiar 1994). More recently, it was discovered that parenchymal cells are 
responsible for large amounts of systemic NO during sepsis, too (Bultinck, Sips et al. 2006). 
This occurs particularly in the intestines of CLP-treated mice. Under hypoxic and acidic 
conditions nitrite can be reduced to the vasodilating NO and serves as an important vascular 
storage compound for NO (Lundberg and Weitzberg 2005). The various origins of NO question 
the influence of iNOS-derived NO in animal models of septic shock. Specific iNOS inhibition in 
CLP-treated mice generated divergent outcomes. Contrary to non-specific NO inhibition, 
specific iNOS inhibitors did not cause hazardous effects and sometimes even protected the 
animals from multi-organ failure or death. Contrary to this, iNOS-deficient mice were not 
protected against endotoxemia, sepsis, or TNF-induced shock but showed increased mortality 
(Cobb, Hotchkiss et al. 1999). Anti-apoptotic and anti-oxidative properties of iNOS-derived NO 
could be causal for this protective effect (Li and Wogan 2005; Cauwels and Brouckaert 2007) as 
it has been reported that NO protects from lipid peroxidation (Rubbo, Radi et al. 1994).  
All these data suggest a very complex system of NO functions causing both deleterious and 
protective effects. The consequences of NO exposure depend on the concentration, the 
physiological conditions of the organism, and the timing. However, TNFR2-/- systems do not 
exhibit absolute abrogation of iNOS induced NO and this reduced NO production could be the 
reason for protection in secondary infections. There could be levels of NO sufficient to induce 
the positive effects of this low molecular weight mediator but not high enough to cause severe 
multi-organ damage or extreme vasodilation. Besides, reduced NO production saves the 
L-arginine amounts and, hence, could protect T cells from shortage of this important amoni acid. 
This reduced NO production of TNFR2-/- mice could balance the effects of MDSC and, as a 
result, could save TNFR2-/- mice from unresponsiveness to secondary infections during CLP-
induced immunosuppression.  
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4.1.4 Characterization of BMDC  
Bone marrow is the source of precursor cells for BMDC. Therefore, bone marrow cells from 
wildtype and TNFR2-/- mice were analyzed directly after preparation for the expression of 
CD11b, Ly6C, and Ly6G. As shown in Figure 17, the percentages of CD11b+ cells in TNFR2-/- 
bone marrow were significantly increased. MDSC (CD11b+ Ly6C+ Ly6G-) and PMN (CD11b+ 
Ly6Cint Ly6G+) bone marrow cells of TNFR2-/- mice were statistically increased compared to 
wildtype controls, too. Interestingly, the relative proportions of MDSC and PMN bone marrow 
cells of TNFR2-/- mice were not impaired in the CD11b+ cell population. 
BMDC were used as a cellular model for the TNFR2-/- CD11b+ cellular phenotype that has been 
seen in different myeloid cells and especially in splenic MDSC after CLP. Additionally to the NO 
deficit upon stimulation with LPS and IFN-ү, other parameters were also analyzed. Non-
stimulated naïve BMDC featured four main phenotypes.  
First: TNFR2-/- BMDC cultures yield reduced cell numbers compared to the wildtype control 
cultures on day 8 and 10 suggesting either reduced proliferation or increased apoptosis (Figure 
23). Kinetics revealed that early in the differentiation towards BMDC, the TNFR2-/- cultures 
contained even more cells compared to the wildtype control. Staining for apoptosis (Annexin V) 
and necrosis (7-AAD) (Figure 26) indicated that the percentages of dying cells ranged between 
3.5% and 4.5% on day 10 equally in both cultures. Interestingly, TNFR2-/- BMDC showed 
reduced proliferation (Figure 25). 24 h of incubation with BrdU from day 9 until day 10 revealed 
a proliferation of 10% in TNFR2-/- BMDC cultures compared to 15% in the wildtype control. In 
order to reach statistical significance, further experiments need to be performed. Another hint 
for the hypothesis that TNFR2 is delivering proliferation signals is the finding that TNFR1-/- 
BMDC showed significantly increased proliferation as only TNFR2 is available for TNF-signaling 
in these cultures (data not shown). There are several reports that support this conclusion 
besides the finding that total cell yields in TNFR2-/- BMDC cultures are reduced. TNFR1-/- BMDC 
have been shown to be long-living (Funk, Walczak et al. 2000). The conclusion would be that 
TNFR2-signaling is necessary for proliferation and delivers a survival signal. There are several 
reports on this phenomenon for cytotoxic T cell proliferation, too (Brown and Thiele 2000; 
Brown, Lee et al. 2002). This fact might be confirmed by the finding that TNFR2-/- mice had 
reduced spleen weights and reduced total numbers of splenocytes (unpublished data). This 
phenomenon could not be ascribed to a certain cell type as it equally affected CD4 and CD8 T 
cells, B cells, macrophages, and dendritic cells. Another possible reason for the reduced cell 
yields in TNFR2-/- BMDC cultures could be induction of apoptosis via increased levels of 
biologically active TNF in TNFR2-/- BMDC cultures as the TNF antagonist soluble TNFR2 is 
missing (Figure 27 and Figure 28). Whether missing TNFR2-signaling, reverse signaling, or 
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higher concentrations of biologically active TNF is causal for the reduced BMDC yield in 
TNFR2-/- cultures, will be elucidated later. 
Second: the percentages of mature DC expressing CD80, CD86, and MHCII were significantly 
increased in TNFR2-/- BMDC cultures as shown in Figure 24. This effect became visible during 
the GM-CSF driven differentiation on day 8. On day 10 it was enhanced and about 25% of 
TNFR2-/- BMDC cultures exhibited an activated state compared to 10% in wildtype controls. It 
has been shown with TNFR2-deficient cells that TNFR2-signaling is required for the processing 
of p100 (Rauert, Wicovsky et al. 2010). In support of this, it has been reported that BMDC and 
splenic DC from mice lacking p100 contain higher percentages of cells expressing MHCII, 
CD80, and CD86 (Speirs, Lieberman et al. 2004). p100, a member of the NF-κB family, is 
processed upon stimulation of the NF-κB pathyway into the transcription factor p52. 
Consequently, the missing TNFR2-signaling could lead to decreased processing of the NF-κB 
member p100 and impaired processing into p52. This would reduce immunomodulatory effects 
of p52 leading to higher activation and maturation in terms of expression of MHCII and 
costimulatory molecules CD80 and CD86. Activated BMDC express more costimulatory 
molecules like CD80 and CD86. In combination with the upregulation of MHCII, both antigen 
presentation and CD4 T cell proliferation should be improved. When TNFR2-/- BMDC loaded 
with ovalbumine (OVA) were incubated together with CFSE-labeled OVA-specific T cells from 
OTII mice, the proliferation was slightly enhanced compared to wildtype control BMDC as 
antigen-presenting cells (data not shown). This has also been shown with splenic DC of 
TNFR2-/- mice (personal communication: Dr. Elisabeth Martin).  
Interestingly, these results can be interpreted as defective p100-processing in cells devoid of 
TNFR2 intrinsic signaling. OVA incubated BMDC of mice lacking p100 were reported to induce 
significantly increased OTII T cell proliferation (Speirs, Lieberman et al. 2004). 
Mature BMDC do not proliferate any further (data not shown). The higher percentages of 
activated BMDC could be explained by assuming an equal capacity for the generation of 
activated BMDC and by taking the reduced proliferation of non-activated cells into 
consideration. Another possible reason for the higher grade of activation in TNFR2-/- BMDC 
could be the concentration and availability of biologically active TNF during the generation of 
BMDC. As shown in Figure 27, TNFR2-/- BMDC cultures express about 1 ng/mL TNF in the late 
phase of differentiation into mature BMDC. TNF induces the maturation and activation of BMDC 
(Brunner, Seiderer et al. 2000). 
Third: the levels of biologically active TNF were significantly increased in TNFR2-/- BMDC 
cultures during the whole differentiation process and started to rise drastically on day 6 (Figure 
27). On day 10 the concentrations of biologically active TNF present in the cultures amounted to 
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1 ng/mL compared to 0.2 ng/mL in the wildtype control cultures. This is due to high amounts of 
soluble TNFR2 present in the cultures of wildtype BMDC as shown in Figure 28. The 
concentrations of this TNF antagonist rose on day 3 and reached a plateau on day 7 with about 
1.2 ng/mL. It has been shown by several other groups that altered TNF concentrations influence 
the percentages of activated mature BMDC (Brunner, Seiderer et al. 2000; Ritter, Meissner et 
al. 2003). Whether this is the only reason for the altered maturation in TNFR2-/- BMDC cultures 
or whether missing TNFR2-signaling, forward or reverse, contributes to this finding, will be 
discussed later.  
Fourth: the percentages of cells expressing surface markers for MDSC (CD11b+ Ly6C+ Ly6G-) 
were examined throughout the GM-CSF-induced differentiation into BMDC. As shown in Figure 
19, the proportion of MDSC on day 3 was about 60%. Until day 10 the population steadily 
decreased and almost disappeared. TNFR2-/- BMDC cultures contained significantly reduced 
percentages of MDSC at all times during the BMDC differentiation culture. This effect could be 
caused by the reduced proliferation of this cellular population. Additionally, naïve TNFR2-/- 
BMDC on day 6 expressed significantly reduced Arg1 mRNA compared to wildtype BMDC 
(Figure 22). Whether missing TNFR2-signaling, reverse signaling, or higher concentrations of 
biologically active TNF is causal for the reduced MDSC proportion in TNFR2-/- cultures, will be 
discussed later. 
BMDC of wildtype and TNFR2-/- mice stimulated with LPS and IFN-ү were investigated, too. The 
cell type responsible for the reduced NO production in BMDC cultures on day 4 was found to be 
MDSC since MDSC were responsible for the complete NO production (Figure 21). Interestingly, 
there was no difference in the NO production of TNFR2-/- and wildtype control BMDC whereas 
the concentrations of NO after 48 h stimulation of stimulation were comparable to the values 
that can be found in mature BMDC cultures stimulated for 48 h on day 10. On day 10 of BMDC 
differentiation culture the NO production capacity of TNFR2-/- BMDC was significantly reduced 
(Figure 13). This finding indicates that the reduced capacity to produce NO in TNFR2-/- BMDC 
on day 10 could be due to the reduced proportions of MDSC as MDSC are the only source of 
NO on day 4 and in the spleen of mice 2 days after CLP (Figure 16 and Figure 21). The sorting 
procedure of BMDC did not interfere with the impaired NO production of BMDC from TNFR2-/- 
mice (Figure 29).  
The concentrations of IL-6 were also significantly reduced in TNFR2-/- BMDC cultures after 
stimulation (Figure 30) as already seen in TNFR2-/- PEC (data not shown). IL-6 is a pleitropic 
cytokine which has been reported to be involved in the differentiation and maturation of DC and 
BMDC. IL-6 blocks the maturation of BMDC and keeps them in an immature state. Besides, 
IL-6-mediated STAT3 activation is required for the suppression of LPS-induced DC maturation 
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(Park, Nakagawa et al. 2004) possibly explaining the higher grade of activated BMDC in 
TNFR2-/- cultures. However, no significant IL-6 concentrations can be found in the supernatants 
of non-stimulated BMDC (data not shown) but is found after TLR signaling. The relevance of 
IL-6 could be more important in the context of sepsis as a consequence of high dose bacterial 
components. 
Furthermore, there are indications that IL-6 switches the monocyte differentiation and 
maturation to the direction of macrophages rather than to DC thereby being an essential factor 
in the molecular control of antigen-presenting cell development (Chomarat, Banchereau et al. 
2000). IL-6 concentrations have been shown to correlate with the severity of CLP-induced 
sepsis. However, IL-6-/- mice are not protected from CLP-induced mortality (Remick, Bolgos et 
al. 2005). IL-6 induces the expression and release of acute phase proteins from the liver. When 
the harmful role of the complement activation product C5a in the early phase of CLP-caused 
severe sepsis or after in vivo LPS treatment was investigated intensively, IL-6 was found to be 
responsible for the strong upregulation of C5a receptor (C5aR) in multiple organs of septic 
mice. The blockade of C5aR considerably increased the survival of these mice (Riedemann, 
Guo et al. 2002). Protective effects of the antibody-based blockade of IL-6 in mice during CLP-
induced sepsis have also been reported and were linked with decreased C5aR expression 
(Riedemann, Neff et al. 2003). The protection of CLP-treated TNFR2-/- mice from 
immunoparalysis after a secondary infection could be based on this decreased IL-6 production. 
This would lead to a reduced release of acute phase proteins like C5a and to a reduced 
expression of C5aR. This mechanism could contribute to the protection of the TNFR2-/- 
organism from multi-organ failure. IL-6 expression is regulated by the NF-κB signaling pathway 
(Libermann and Baltimore 1990; Baeuerle and Henkel 1994). As it is possible for both TNFR1 
and TNFR2 to activate the NF-κB pathway, an influence of the concentrations of biologically 
active TNF could be relevant. Nevertheless, neither in TNFR2-/- BMDC nor in the wildtype 
control BMDC detectable concentrations of IL-6 protein could be found in the supernatants 
without stimulation (data not shown). This implicates that either TNF tolerance due to the 
persistent exposure to high concentrations of biologically active TNF or the influence of the 
stimulation with LPS and IFN-ү could be required to make the difference in IL-6 production 
obvious. In both cases, missing TNFR2-signaling or increased TNFR1-signaling in TNFR2-/- 
BMDC might be the reason. As TNFR1-/- BMDC produce significantly increased levels of IL-6 
compared to wildtype controls (data not shown), the conclusion would be that TNFR2-signaling 
is essential for adequate IL-6 production. Whether direct TNFR2-signaling or reverse signaling 
is the crucial signaling pathway, will be discussed later.  
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The differentiation of CD4 T cells into TH17 cells in vivo requires the presence of IL-23 which 
consists of a p19 and a p40 subunit. The latter is also part of IL-12 and its production is 
significantly decreased in various myeloid cells of TNFR2-/- mice (personal communication: Dr. 
Elisabeth Martin). In vitro differentiation into TH17 cannot be induced by IL-23 but only by using 
a combination of IL-6 and TGF-β. Therefore, the combination of both cytokines supports the 
in vivo development of TH17 cells (Zhou, Ivanov et al. 2007). As TNFR2-/- cells express 
decreased amounts of IL-6 and IL-12, the number of TH17 cells is to be expected to be reduced. 
Preliminary experiments support this notion (data not shown). 
 
4.1.4.1 BM chimeric mice 
In order to elucidate whether the described phenotypical characteristics of TNFR2-/- myeloid 
cells are due to missing intrinsic TNFR2-signaling or caused by increased TNFR1-signaling as a 
consequence of the missing TNF antagonist soluble TNFR2, bone marrow chimeric mice were 
generated. Wildtype host environmental conditions were generated for a TNFR2-/- hematopoietic 
system and vice versa. On the one hand, TNFR2-/- myeloid cells develop, differentiate, and 
mature in a wildtype host organism with soluble TNFR2 which can reduce the amounts of 
biologically active TNF in the system. On the other hand, wildtype hematopoietic cells 
reconstitute the immune system in TNFR2-/- mice free of TNFR2 except for the indigenious 
production by the transferred hematopoietic cells. In order to discriminate between donor and 
host cells, the CD45 congenic system was used. CD45.1 wildtype mice were reconstituted with 
CD45.2 TNFR2-/- bone marrow and vice versa. Control experiments with CD45.1 wildtype mice 
that were reconstituted with CD45.2 wildtype bone marrow were performed as well as the 
reciprocal combinations. The reconstitution efficiencies were checked at the day of the 
experiment and ranged between 80% and 90% (Figure 40). 
BMDC from CD45.1 wildtype mice that were reconstituted with CD45.1 TNFR2-/- bone marrow 
maintained the known phenotypes of TNFR2-/- BMDC that were described and discussed above 
in this work. BMDC of wildtype mice carrying a TNFR2-/- hematopoietic system contained 
significantly higher proportions of activated cells expressing CD80, CD86, and MHCII (Figure 
38). The NO and IL-6 concentrations in the supernatants of these cells after stimulation with 
LPS and IFN-ү were significantly decreased (Figure 43 and Figure 44) and contained significant 
higher amounts of soluble TNF whereas soluble TNFR2 concentrations were negligible 
compared to the control BMDC cultures (Figure 45 and Figure 46). In summary, BMDC cultures 
from a TNFR2-/- donor and a wildtype host featuring a TNFR2-/- hematopoietic system generated 
similar results as BMDC cultures of TNFR2-/- mice. These data strongly indicate that the 
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expression of TNFR2 on hematopoietic cells is required for the observed phenotypes of 
TNFR2-/- myeloid cells described above which points to a TNFR2-signaling effect. BMDC from 
wildtype mice that were reconstituted with TNFR2-/- bone marrow miss the antagonizing effects 
of soluble TNFR2 produced from the hematopoietic cells. As a consequence, high biologically 
available concentrations of TNF could lead to increased TNFR1-signaling. This would argue for 
an environmental TNF effect. Moreover, the possible influence of reverse signaling in this 
context cannot be excluded, either. Consequently, the data from bm chimeric mice are no 
absolute proof of the relevance of missing intrinsic signals via TNFR2 as a reason for the 
phenotypes described for TNFR2-/- myeloid cells.  
PEC from wildtype mice that were reconstituted with TNFR2-/- bone marrow only showed a 
slight and not significant reduction of NO production after stimulation with LPS and IFN-ү 
(Figure 41) which is in contrast to the NO production of PEC from TNFR2-/- mice. This points to 
a TNF effect via TNFR1 in TNFR2-/- mice as a consequence of enhanced TNF levels due to the 
missing antagonist soluble TNFR2. This result supports other findings of our working group: 
when stimulated with the TLR9 ligand CpG, the IL-12 production capacity was impaired in 
splenic DC from TNFR2-/- mice. IL-12 is a prominent cytokine that is induced in TH1 reactions 
and stabilizes this type of immune response. It has been reported that the IL-12 production 
capacity, induced by TLR ligands, is drastically decreased in DC of mice 2 days after CLP 
(Flohe, Agrawal et al. 2006). Thus, the reduced IL-12 production capacity of post-septic wildtype 
and naïve TNFR2-/- splenic DC were similar. This phenotype, however, was not seen in DC from 
wildtype mice reconstituted with TNFR2-/- bone marrow (personal communication: Dr. Elisabeth 
Martin) indicating an environmental rather than cell-intrinsic effect of TNFR2. In addition, TNF 
pretreatment of macrophages has been shown to reduce the expression of IL-12 (IL12p40) 
drastically upon stimulation with LPS and IFN-ү (Zakharova and Ziegler 2005). These effects 
were mainly due to TNFR1-signaling. Eight hours pretreatment with TNF were sufficient to 
induce this reduction of IL-12 production. Mice subjected to CLP treatment produce high 
amounts of TNF. As a consequence of TNFR1-signaling, the capacity to express IL-12p40 is 
drastically decreased. TNFR2-/- mice lack the antagonizing soluble TNFR2, hence, higher TNF 
levels diminish the IL-12p40 production capacity in splenic DC of both naïve and CLP-treated 
animals. In cells of naïve TNFR2-/- mice this phenomenon could be caused either by 
endogenous TNF production during the stimulation with CpG or by the chronic or repetitive 
exposure to relatively high TNF levels during the life of the experimental mice. However, these 
considerations, as well as the methods discussed until now, do not exclude the possibility of 
reverse signaling. TNFR2-/- splenic DC and PEC could be triggered in a wildtype environment by 
membrane-bound or soluble TNFR2. As soluble TNFR2 is able to bind to membrane TNF, 
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TNFR2-/- cells could be coated with soluble TNFR2 from naïve hosts that were reconstituted 
with TNFR2-/- bone marrow. Consequently, soluble TNFR2 could be transferred into the 
experimental culture systems including the stimulation with TLR ligands. This could lead to both 
reverse signaling and interference with the concentrations of biologically active soluble TNF in 
these cultures. 
 
4.1.4.2 BMDC from mixed cultures 
To directly approach the question whether missing intrinsic TNFR2-signaling, increased TNFR1 
concentrations caused by the lack of the TNF-antagonizing TNFR2, or missing reverse 
signaling is the reason for the phenotypes seen in TNFR2-/- myeloid cells, mixed BMDC cultures 
were used. Wildtype and TNFR2-/- bone marrow cells were isolated and differentiated into 
BMDC either in cultures derived from the respective mice or in cultures which contained bone 
marrow cells from both mouse lines mixed in equal parts. BMDC cultures consisting of 50% 
wildtype and 50% TNFR2-/- bone marrow cells feature identical conditions for cells derived from 
both types of mice, especially in terms of soluble TNF and soluble TNFR2 concentrations. 
Additionally, the possible requirement of membrane-bound or soluble TNFR2 for reverse 
signaling with membrane-bound TNF is also provided for TNFR2-/- and wildtype BMDC in mixed 
cultures. Hence, the probability of cellular contact with another cell expressing TNFR2 should 
be the same for all cells.  
First, naïve cells from such mixed cultures were analyzed for the expression of surface markers 
and the development of congenic markers for wildtype and TNFR2-/- BMDC, respectively. As 
shown in Figure 33, the ratio of TNFR2-/- BMDC on day 3 was significantly increased compared 
to wildtype cells. This phenomenon was reverted and, finaly, the ratio of TNFR2-/- BMDC in 
mixed BMDC cultures was significantly reduced on day 10. The TNFR2-/- population in mixed 
cultures showed an equal degree of apoptotic cells but slightly decreased proliferation on day 
10 (Figure 36 and Figure 37). Interestingly, BMDC cultures consisting of mixed cells of TNFR1-/- 
and wildtype mice showed equal proliferation of the two populations while pure TNFR1-/- BMDC 
showed significantly increased proliferation as discussed before. This leads to the conclusion 
that it is the TNFR2-signaling that promotes the proliferation of BMDC. In TNFR1-/- BMDC higher 
TNF levels are to be assumed compared to wildtype cultures as antagonizing membrane-bound 
or soluble TNFR1 is not available and only TNFR2 is present in these cultures. Contrary to this, 
in mixed TNFR1 and wildtype cultures TNFR2 molecules on both wildtype and TNFR1-/- cells 
are activated equally and, consequently, the proliferation rate is equal. 
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The percentages of CD80+ CD86+ MHCII+ activated cells in mixed BMDC cultures were 
significantly higher in the TNFR2-/- BMDC fractions (Figure 34). In contrast, the percentages of 
cells expressing the MDSC marker CD11b+, Ly6C+ , and Ly6G- were significantly reduced in the 
TNFR2-/- BMDC populations (Figure 35). These phenotypes were seen in pure TNFR2-/- BMDC 
as well and remained stable in mixed BMDC cultures. This represents a very strong indication 
for a missing intrinsic TNFR2 signal responsible for the phenotype seen in TNFR2-/- BMDC. 
Moreover, wildtype and TNFR2-/- BMDC from pure and mixed BMDC cultures were separated 
according to their congenic markers. Independent of the culture system, TNFR2-/- BMDC 
produced significantly reduced NO and IL-6 levels (Figure 38 and Figure 39) compared to the 
wildtype BMDC. Clearly, TNFR2-/- BMDC, sorted from mixed cultures, expressed higher 
amounts of TNF compared with wildtype BMDC. Thus, it cannot be entirely excluded that TNF, 
produced in the sorted BMDC cultures, could influence the outcome of NO and IL-6 production 
via TNFR1 signaling. This demonstrates the limitations of this experimental setup which is 
based on the separation of cells grown in mixed cultures followed by stimulation of the 
separated cells, in order to analyze the concentrations of produced mediators. It could partly be 
overcome by the determination of intracellular TNF, IL-6, and NO production upon stimulation of 
mixed cultures, but even then it cannot be entirely excluded. 
However, these data from mixed cultures together with the flow cytometry-based data show that 
neither TNFR1-signaling due to the lack of the TNF antagonist TNFR2 and enhanced TNF 
levels in the cultures nor missing reverse signaling activating membrane TNF via TNFR2 are the 
reasons for the TNFR2-/- phenotype of myeloid cells described in this work. 
Nevertheless, the results from mixed BMDC cultures with bone marrow cells from wildtype as 
well as TNFR2-/- mice provide very strong evidence against an influence of the milieu on the 
CD11b+ phenotypic and functional characteristics shown for TNFR2-/- cells. 
Another hypothesis that epigenetic modifications as a consequence of chronic exposure to high 
amounts of TNF in TNFR2-/- mice could be the reason for the above-mentioned observations in 
TNFR2-/- myeloid cells also exists. As TNF is usually not detectable in healthy organisms, the 
overexposure to TNF in naïve TNFR2-/- mice has not been shown yet. However, it has been 
shown that LPS pretreatment of wildtype mice switches splenic DC into a tolerant state in 
respect to IL-12 production following ex vivo restimulation with CpG (preliminary data from our 
working group). LPS pretreatment induces TNF production and, consequently, TNF tolerance. 
As LPS is a very potent endotoxin with several side effects besides TNF induction, the 
experiment needs to be repeated with TNF pretreatment. However, epigenetic modifications 
cannot be excluded as the underlying reason for the observed phenotypes described in this 
work. In order to elucidate this question, methylation studies on the histone architecture in the 
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promoter regions of iNOS, IL-6, and IL-12 are planned. Furthermore, TNFR2 could be 
downregulated in hematopoietic cells using siRNA approaches or blocked using antagonistic 
mediators such as mAB. When the shown cellular phenotypes for TNFR2-/- myeloid cells could 
be induced in these cells immediately after the knock-down or blockade of TNFR2, this would 
be another indication that the phenotypes that were seen are caused by missing intrinsic 
TNFR2-signaling. 
 
4.2 Mouse anti-mouse TNFR2 mAB with agonistic or antagonistic 
properties 
In order to clarify whether the effects seen in TNFR2-/- mice are due to the loss of TNFR2-
signaling or caused by higher TNF levels resulting from the absence of soluble TNFR2 as 
inhibitor for biologically functional TNF, specific activation or blockade of TNFR2 can be used as 
another approach. There is no specific agonistic or antagonistic ligand known for mouse 
TNFR2, so far. Monoclonal antibodies with special functional properties have been used for 
many years to selectively activate or block cytokine activation via their receptors. Furthermore, 
in vivo treatment with monoclonal antibodies can be used to eliminate the cells expressing the 
respective receptor that is recognized by the antibody. The use of mouse anti-mouse antibodies 
would enable the in vivo application as intraspecies-antibodies are not immunogenic.  
Mouse anti-mouse TNFR2 mAB were generated. In order to guarantee adequate immunity 
against the antigen, TNFR2-/- mice were immunized with the extracellular domain of TNFR2. 
These mice lack TNFR2 and, therefore, T and B cells with TNFR2-specific T and B cell 
receptors are not negatively selected during the differentiation in the thymus and the bone 
marrow.  
An immunization protocol was used aiming at the class switch from primarily IgM to high titers of 
IgG. TNFR2-/- mice were immunized and the splenocytes were fused with SP2/0-Ag14 cells. 
Five monoclonal hybridoma cell lines producing mouse anti-mouse TNFR2 mAB were identified 
in this work and tested together with the antibodies of another positive hybridoma for TNFR2 
generated earlier. The mAB were positive in binding TNFR2 in ELISA and Western blot 
analysis. Only one mAB stained TNFR2-expressing cells in FACS analysis (Figure 53). All 
mouse anti-mouse TNFR2 mAB are IgG1-type immunoglobulins. 
Thus, 6 different mAB were available for agonistic and antagonistic tests in a TNFR2-signaling 
assay. As TNFR1 and TNFR2 show high similarity in their extracellular domains, agonistic and 
antagonistic tests had to be performed in parallel with a TNFR1 and TNFR2 specific system, in 
order to detect cross-reactivity. Therefore, a test system that was described by Dr. A. Krippner-
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Heidenreich in the human system was adapted to the mouse system. Fusion proteins of TNFR1 
or TNFR2 extracellular domain and huFas intracellular domains were cloned and retrovirally 
transduced into TNFR-free cells.  
Both types of transduced cells died when incubated with mouse TNF due to the Fas-induced 
apoptosis upon binding TNF to the extracellular domains of the two TNF receptor constructs. 
Cells transduced with the TNFR2 construct were less sensible to mouse TNF compared to cells 
expressing the TNFR1 construct (Figure 55). This can be explained by the finding that TNFR2 is 
primarily activated by membrane-bound TNF. Therefore, the recombinant mouse TNF does not 
provide the optimal spatial density and aggregation conditions needed for efficient activation of 
TNFR2. As expected, human TNF only activated the TNFR1 construct leading to apoptosis of 
these cells. Nevertheless, apoptosis in neither TNFR1 construct-transduced nor in TNFR2 
construct-carrying cells could be induced by incubation with the 6 newly generated monoclonal 
mouse anti-mouse TNFR2 antibodies (Figure 56) indictaing no agonistic properties. The 
positive control mouse TNF induced sufficient apoptosis in TNFR1 construct transduced cells 
whereas it was less efficient in TNFR2 construct expressing cells. Consequently, the TNFR2 
extracellular huFas intracellular system is perhaps not sensitive enough to detect agonistic mAB 
properties (Figure 55). 
Preincubation of TNFR1 construct transduced cells with mouse anti-mouse TNFR2 mAB did not 
affect the apoptosis that was induced by the addition of TNF indicating that the antibodies do 
not cross-react with TNFR1 (Figure 57). TNFR2 construct-expressing cells were not protected 
by preincubation with the mouse anti-mouse TNFR2 mAB from TNF-induced apoptosis. 
Sufficient apoptosis in TNFR2 construct expressing cells was only achieved by the use of TNC-
mTNF (Prof. H. Wajant) as the TNC motif induces the polymerization of the TNF molecules and, 
thus, better activation of TNFR2. However, Figure 58 shows that no blocking function of the 6 
mouse anti-mouse TNFR2 mAB was detectable.   
Interestingly, the group of Prof. H. Wajant (University of Würzburg) has recently produced TNF 
mutants that selectively activate mouse TNFR2 (personal communication, data not shown). As 
human TNF selectively activates TNFR1, the specific activation of both mouse TNF receptors 
in vivo and in vitro would be possible. Nevertheless, there is no reagent available to block 
TNFR2 as the most important tool to understand the mechanism behind the cellular phenotypes 
described in this work.    
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5 Conclusion 
The results shown and discussed in this work reveal several cellular phenotypes of TNFR2-/- 
myeloid cells and allow to draw conclusions about the function of TNFR2 in general and 
especially in sepsis. It was shown that CLP is required to induce iNOS mRNA expression and 
NO production in CD11b+ CD11c- cells upon stimulation with LPS and IFN-ү and that the lack of 
TNFR2 results in a reduction of both iNOS mRNA expression and NO production. This cellular 
phenotype was also found in other myeloid cells such as PEC and BMDC from naïve mice. 
BMDC were used as a cellular model for further investigations. TNFR2-/- BMDC produce 
reduced concentrations of IL-6 upon stimulation with LPS and IFN-ү. These findings indicate 
that TNFR2-signaling is required for adequate NO and IL-6 production. 
It turned out that missing TNFR2 decreased the proliferation in these cells leading to reduced 
cell yields at day 10 of the BMDC differentiation culture. In combination with data from TNFR1-/- 
BMDC TNFR2 expression was shown to be required for adequate proliferation. TNFR2-/- BMDC 
cultures showed reduced proportions of MDSC throughout the cultivation period. TNFR2-/- 
BMDC as well as TNFR2-/- BMDC sorted for the MDSC marker Ly6C+ Ly6G- showed reduced 
Arg1 mRNA expression indicating an important role of TNFR2 in the generation and function of 
MDSC. TNFR2 signaling seems to be essential for adequate generation of MDSC and could 
contribute to the suppressive functions of these cells in dampening inflammation in vivo. The 
hypothesis that TNFR2-/- cells ex vivo or in vitro contain a higher percentage or more activated 
MDSC could not be proven. 
TNFR2-/- BMDC cultures contained increased proportions of activated (MHCII+ CD80+ CD86+) 
cells at day 8 and day 10 indicating less suppression of T cell proliferation and, simultaneously, 
improved antigen presentation and, thus, better activation of T cells. These are strong 
indications for a dampening function of TNFR2 in the immune system as its presence seems to 
be required for the downregulation of activation molecules.  
Whether direct TNFR2-signaling or indirect effects via enhanced TNFR1-signaling as a 
consequence of the missing TNF antagonist soluble TNFR2 are responsible for the phenotypes 
of TNFR2-/- myeloid cells has been investigated using bone marrow chimeric mice and mixed 
BMDC cultures. It has been shown that the phenotypes of TNFR2-/- myeloid cells remain stable 
in BMDC from wildtype host mice that were reconstituted with TNFR2-/- bone marrow and, thus, 
generating wildtype conditions for a TNFR2-/- hematopoietic system. These phenotypes also 
persisted in TNFR2-/- BMDC in mixed BMDC differentiation cultures initially containing wildtype 
and TNFR2-/- bone marrow in equal proportions. This culture method generates equal 
environmental conditions for both types of BMDC. As TNFR2-/- BMDC of both bone marrow 
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chimeric mice and mixed BMDC differentiation cultures maintained the phenotypes found for 
TNFR2-/- BMDC, this is a very strong indication for a missing intrinsic signaling via TNFR2 and, 
thus, confirms the hypothesis of an important role of direct TNFR2-signaling in the immune 
system. Additionally, these results reveal that reverse signaling via soluble or membrane-bound 
TNFR2 as ligand and membrane-bound TNF as receptor can be excluded as the reason for 
these phenotypes as the conditions are equal for TNFR2-/- and wildtype BMDC in mixed BMDC 
differentiation cultures. 
However, epigenetic promoter or histone modifications could also be the cause for the TNFR2-/- 
phenotypes described in this work since altered TNFR1-signaling in TNFR2-/- mice cannot be 
excluded completely as the TNF antagonist soluble TNFR2 is missing in these mice.  
Mouse anti-mouse TNFR2 mAB were generated and tested for binding as well as agonistic and 
antagonistic properties. The antibodies performed positive in ELISA and Western blot and one 
clone also stained TNFR2-expressing cells in FACS analysis. However, neither agonistic nor 
antagonistic functions could be detected in a cytotoxicity assay established to detect specific 
TNFR2 activation by using cells expressing the extracellular domain of TNFR2 fused to the 
intracellular domains of human Fas. 
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